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GENERAL INTRODUCTION AND 
OUTLINE OF THIS THESIS 
 
Inborn errors of metabolism are rare inheritable disorders with an estimated frequency of 
51:100,000 [1]. In the inborn errors of metabolism different groups of metabolic disorders can 
be distinguished. One of these groups is the intoxication type metabolic disorders. Intoxication 
type metabolic disorders are characterized by disturbances in glucose metabolism, protein 
metabolism, or fatty acid metabolism. The research in this thesis will focus on protein 
metabolism and specifically on the amino and organic acid related disorders (AOA). 
The building blocks of proteins are amino acids, which are essential for human growth and 
development. Amino acid metabolism results in ammonia production which is processed by 
the urea cycle and excreted as urea. The AOA compromise the branched chain amino acid 
(BCAA) disorders and urea-cycle disorders (UCD). The BCAA disorders include classical organic 
acidemias (OAD) and maple syrup urine disease (MSUD) (figure 1). BCAA disorders are 
characterized by enzymes deficiencies in specific pathways of the degradation of certain 
branched chain amino acids. Within the BCAA disorders isovaleric acidemia (IVA) 
(OMIM#243500), methylmalonic aciduria (MMA) (mutase deficiency OMIM #251000, CblA 
#251100, CblB #251110), and propionic aciduria (PA) (OMIM #606054) are considered the 
classical OAD (figure 1). UCD are caused by deficiencies of the enzymes and transporter 
needed for the urea-cycle (figure 1). While all AOA disorders affect protein metabolism, the 
disease presentations, diagnostic characteristics and prognosis may differ considerably 
between and within the subcategories and even between patients with the same disease.  
With the currently applied treatment several classical OAD and UCD patients have a poor 
prognosis. In both disease groups overall mortality risk is high, mainly in those patients 
presenting in the neonatal period with an acute metabolic decompensation [2]. In classical 
OAD the majority of patients is symptomatic and a high proportion of the patients develop 1) 
metabolic decompensations requiring hospital visits, 2) long-term complications, such as 
cardiomyopathy, renal failure, liver failure, and neurological symptoms, including cerebral 
palsy and seizures, and 3) intellectual disability [2, 3]. In classical OAD, IVA has been 
implemented in the newborn screening in 2007 and MMA and PA have been included in the 
newborn screening in the Netherlands since October 2019. In UCD, numerous patients have 
recurrent metabolic decompensations, liver failure, failure to thrive, neurological symptoms, 
including cerebral palsy and seizures, and intellectual disability. Furthermore, psychiatric 
symptoms such as hyperactivity are observed. In both classical OAD and UCD the quality of 
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life has been reported to be decreased in some [4, 5], and to be normal in others [6]. 
Considering the unsatisfactory outcome of classical OAD and UCD patients we need to 
improve patient care. Since new treatment strategies are still ahead of us, it is essential to 
evaluate current applied treatment strategies with the aim to improve these in order to 
ameliorate patient care and outcome.  
 
We hypothesized that with optimizing current available treatment patient outcome can be 
improved. In order to confirm or decline this hypothesis two main steps were necessary. Firstly,  
evaluation of current practice needed to be performed (and compared to guideline advices) 
and secondly it needed to be defined how current practices influences patient outcome. 
Previous attempts to determine the current practice in classical OAD and UCD patients have 
been performed. Patient´s height in a Dutch OAD sub-cohort had been evaluated (D. Wensink, 
unpublished results) and a national cohort study in the Netherlands on UCD patients (n=58) 
described patient characteristics (D. Salkovic [7]). In the Netherlands, considering the low 
incidence of these disorders national expertise centers have been installed in some of the 
academic centers. The Erasmus Medical Center is the center of expertise and approved by the 
ministry of health for classical OAD and UCD.  On an international level, organizations have 
been set up in Europe specifically addressing AOA, such as the European registry and network 
for intoxication type metabolic diseases (E-IMD) and the European Reference Network for 
Hereditary Metabolic disorders (Metab-ERN), which includes a subnetwork for amino acid and 
organ acids-related disorders (AOA). Regarding OAD and UCD, the E-IMD has set up a registry 
including 452 classical OAD and 417 UCD patients [8]. Based on the data collected in these 
registries the disease presentation at disease onset and emerging clinical phenotype has been 
described [2, 3]. Furthermore, guidelines have been developed, which may help in clinical 
decision making [9-11]. However, it is not known if guideline advices are followed-up in clinical 
practice.  
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1 | Epidemiology of classical OAD and UCD 
For OAD the estimated incidence in newborn ranges between 1:48,000-1:61,000 for MMA [12, 
13] and between 1:50,000-1:500,000 for PA [13] and has been calculated to be 1:67,000 for 
IVA[14]. In the Netherlands the incidence of MMA is 1:121,765, of PA 1:188,182 and of IVA 
1:180,000 [15]. The estimated incidence of UCD is 1:35,000 births, with a broad variation 
between the incidence of the different diseases within the UCD subgroups [16, 17].  
 
2 | Pathogenesis and pathophysiology in classical OAD and UCD 
In MMA and PA (classical OAD) the degradation of the BCAA isoleucine and valine is affected. 
PA is caused by propionyl-CoA carboxylase deficiency (encoded by PCAA and PCCB) which is 
needed for the degradation of propionyl-CoA (formed by degradation of isoleucine and valine) 
(figure 2). This degradation step performed by propionyl-CoA carboxylase is biotin-dependent 
(figure 2) [9]. MMA deficiency is either due to a methylmalonyl-CoA mutase deficiency 
(MCM/Mut) or due to a defect of mitochondrial adenosylcobalamin (CblA and CblB). The MCM 
types of MMA can be either caused by complete enzyme deficiency (Mut0) or partial enzyme 
deficiency (Mut-). In these four types of MMA the degradation of l-methylmalonyl-CoA (a 
product of the degradation of propionyl-CoA) to succinyl-CoA is affected (figure 2). They can 
be referred to as isolated MMA, and they do cause methylmalonic aciduria with normal 
homocysteine levels. Other disorders can cause  methylmalonic aciduria with 
hyperhomocystinemia and include the adenosylcobalamine and methylcobalamine defects 
(CblC and CblD defects) and the lysosomal cobalamin release disorder (CblF) [12]. These last 
disorders will not be further described in this thesis. Since vitamin B12 (adenosylcobalamin) is 
a cofactor of MCM, vitamin B12 responsive and unresponsive types of MMA exist (figure 2). It 
is necessary to notice that the end product (namely succinyl-CoA) is an important substance 
for the tricyclic acid cycle (figure 3), which is essential for energy production. Besides the 
degradation of the branched chain amino acids, the degradation of methionine, threonine [18] 
and carbohydrate and fatty acid oxidation are also affected in MMA and PA [19]. Furthermore 
the enzymes deficient in these disorders are involved in the catabolism of propionyl-CoA, 
1
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which can be formed in the gut by bacteria and by the degradation of fatty acids and 
cholesterol side chains. In IVA (classical OAD) the degradation of leucine is affected. The latter 
disease is caused by a deficiency of isovaleryl-CoA dehydrogenase [20].  
In classical OAD, pathophysiology leading to disease manifestation consists of three main 
principles: 1) the accumulation of toxic metabolites, 2) deficiencies of certain end-products, 
and 3) mitochondrial dysfunction and oxidative stress. Toxic metabolites are formed due to 
insufficient degradation of the BCAA and will be discussed further on this thesis. With the 
degradation of isoleucine and valine normally succinyl-CoA is formed, which is an important 
product for the TCA cycle and thereby for energy production. The observed mitochondrial 
dysfunction is likely mainly due to toxicity of metabolites on mitochondria. Furthermore, it is 
observed that both propionic acid and 2-methylcitric acid can negatively affect the citric acid 
cycle and respiratory chain complexes.                    
  
The urea cycle plays a key role in the detoxification of ammonia, which takes place almost 
entirely within the hepatocytes [21]. Ammonia detoxification occurs in different steps. First 
ammonia is converted by carbamylphosphate synthetase 1 (CPS1) to carbamylphosphate. This 
step needs N-acetylglutamate (NAG), which is produced from glutamate by N-acetylglutamate 
synthase (NAGS). Carbamylphosphate enters the urea cycle and is then converted to urea, 
which can be excreted. In the urea cycle, three enzymes are active in the mitochondria, one is 
active at the mitochondrial membrane and three are active extra-mitochondrial or cytosolic 
(figure 3). The UCD comprise the inherited deficiency of ornithine transcarbamylase deficiency 
(OTC-D) (EC 2.1.3.3; OMIM #311250), argininosuccinate synthetase deficiency (ASS-D) (EC 
6.3.4.5; OMIM #215700), argininosuccinate lyase deficiency (ASL-D) (EC 4.3.2.1; OMIM 
#207900), arginase 1 deficiency (OMIM #207800) and hyperornithinemia-hyperammonemia-
homocitrullinuria (HHH) syndrome (OMIM #238970). NAGS (OMIM #237310) and CPS1-D (EC 
6.3.4.16; OMIM #237300) are also considered to be part of the UCD, however the deficient 
enzymes are not involved in the urea cycle itself, but rather in the degradation of products 
that become available for the urea cycle. The urea cycle is regulated mainly by the CSP1 
reaction. This reaction is highly dependent on NAG and thereby regulated by glutamate levels. 
Deficiencies in any of the above mentioned enzymes can cause hyperammonemia. The high 
ammonia levels that can occur in UCD can cause severe neurological damage. When ammonia 
12
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enters the brain it is converted to glutamine by reacting with glutamate. Glutamate can be 
produced from glutamine and glutamate can also be converted to glutamine. Importantly, the 
brain cells do not have a urea cycle and glutamine-glutamine cycle is essential for 
detoxification of ammonia in the brain. Glutamate is an important excitatory neurotransmitter. 
High glutamate levels can cause hypoxic damage, and even stroke and epilepsy. Due to the 
buffering of ammonia in UCD, glutamine levels are elevated in UCD and they can cause brain 
edema by astrocyte swelling [22].  
 
1
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3 | Disease presentation in classical OAD and UCD: signs and symptoms 
3.1 | First presentation 
The majority of classical OAD and UCD patients become symptomatic. They either present with 
a metabolic decompensation or with long-term complications. In classical OAD 60% of the 
patients and in UCD 45% of the patients present with a metabolic decompensation in the 
newborn period [2]. Symptoms of patients presenting in neonatal period are vomiting, 
dehydration, weight loss, hypotonia or hypertonia, lethargy, seizures and coma [9]. The 
presentation in the newborn period is often similar to and may be mistaken by a severe 
neonatal sepsis, which can cause a diagnostic delay. Making a diagnosis in time is essential to 
optimize patient’s outcome. Patients presenting at a later age often present with non-specific 
symptoms such as feeding problems, mental retardation, epilepsy, movement disorders and 
for classical OAD also with cardiomyopathy or renal failure [9] and within the UCD spectrum 
also with psychiatric disorders [2]. MMA and PA patients often have a more severe disease 
presentation than IVA patients [18]. 
 
3.2 | The diagnosis  
Patients with classical OAD typically present with metabolic acidosis (although this can be 
absent) with either normal ammonia levels or hyperammonemia (depending on the degree of 
metabolic decompensation). Hyperammonemia can be due to the fact that propionyl CoA can 
block the urea cycle by inhibiting N-acetylglutamate synthesis. Furthermore, in classical OAD, 
elevated anion gap, ketosis, elevated lactate, leukopenia, thrombocytopenia, and anemia can 
be observed [9]. Diagnostics include determination of plasma amino acid concentrations and 
plasma or blood spot acylcarnitin levels and urinary organic acid and orotic acid levels. The 
toxic metabolites in both MMA and PA are propionyl-CoA, propionic acid, hydroxypropionic 
acid, propionylcarnitine, propionylglycine, and 2-methylcitrate. Disease specific toxic 
metabolites in MMA are increased methylmalonic acid and methylmalonylcarnitine (which are 
not increased in PA). Glycine and lysine levels are often elevated and determination of total 
plasma homocysteine can be helpful in differentiating between different MMA subtypes [9]. 
1
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In IVA plasma acylcarnitines show an increased C5 and in urine isovalerylglycine is elevated 
[23]. Enzyme diagnostics and genetic analyses are needed to confirm the diagnosis.    
 
In the neonatal period patients with UCD typically present with hyperammonemia and 
sometimes metabolic acidosis. Timely diagnosis is essential since hyperammonemia can cause 
brain damage and even death [21]. Plasma amino acid concentrations (arginine, alanine, 
citrulline, glutamine) and carnitines, liver enzymes and coagulation factors should be 
determined as well as urinary organic acid, amino acid and orotic acid levels [24]. The location 
of the enzymatic defect within the urea cycle determines which amino acid will accumulate, 
for example arginine accumulates in case of arginase 1 deficiency (Arg1) (figure 2). Figure 3 
presents the typical laboratory characteristics in the different UCD (depending on the 
enzymatic defect within the urea cycle), which helps making the diagnosis of a particular 
diseases. Hereafter enzyme diagnosis and genetics should be performed. 
16
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3.3 | Acute management 
For classical OAD and UCD, the goal of treatment in patients presenting in the neonatal period 
is to stabilize the metabolic derangement/acidosis. In patients with both disorders protein 
intake should be stopped and high kilocaloric intake needs to be established. In case of 
hyperammonemia dialysis is necessary when ammonia levels exceed 500umol/L [9, 10, 24]. 
The acidosis can be corrected with intravenous bicarbonate. However, this should be done 
with caution. If hyperammonemia is present in OAD patients, a combination of L-carnitine, 
sodiumbenzoate and phenylbutyrate as well as arginine, carbamylglutamate, vitamin B12 and 
biotine should be given depending on the severity of the hyperammonemia. It should be noted 
that the use of sodiumphenylbutyrate or phenylacetate can decrease the levels of glutamine 
and therefore prescription of these medications should be done after careful consideration [9]. 
In UCD, nitrogen excretion should be improved by medical treatment with N-scavengers such 
as nitrogen sodiumbenzoate, sodiumphenylbutyrate/ glycerolphenyl-butyrate, L-arginine or 
L-citrulline [24]. While sodiumphenylbutyrate can be giving intravenously, 
glycerolphenylbutyrate can only be administered orally.  
 
3.4 | Metabolic decompensations 
In both classical OAD and UCD, metabolic decompensations can occur at any age and they 
can cause severe morbidity and mortality. The metabolic decompensations can be triggered 
by catabolic stress due to infections, increased protein intake as well as fasting, surgical 
procedures and specific medications [9, 24]. However in many patients metabolic 
decompensations may also occur without a clear trigger and often a combination of more 
than one trigger is causative [25]. Over-restriction of dietary protein intake can also induce 
catabolism and thereby trigger a metabolic decompensation [25].  
 
3.5 | Long-term complications 
In classical OAD, long-term complications affect the following organ systems: neurological, 
optical, cardiac, renal, ear, gastro-intestinal (liver, pancreas, gut), skeletal, bone and bone 
18
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marrow (joints), fertile (ovaries) and endocrine (growth).  Importantly, long-term complications 
may also occur in metabolic stable patients [3]. Symptoms arising from the neurological system 
are spasticity/dystonia, movement disorders, epilepsy, hearing or visual field defects and 
developmental delay – the latter will be discussed in a separate paragraph –. Movement 
disorders were observed in 7%-27% in OAD patients [3]. Seizures were mainly observed in PA 
patients (13%) [3]. Metabolic decompensations as well as chronic toxicity can cause brain 
damage, often observed as basal ganglia hyperintensity on brain imaging, but other 
abnormalities such as white matter leasions can be found as well [26]. Psychiatric symptoms 
that can occur are autism, psychosis, and attention deficit hyperactivity disorder (ADHD).  
Cardiomyopathy (mainly in PA), renal failure (mainly in MMA)[9],  optic nerve atrophy 
eventually leading to blindness and hepatomegaly are long-term complications likely induced 
by mitochondrial dysfunction in MMA and PA. Furthermore, it is plausible that prolonged QTc 
interval (mainly PA), exercise intolerance and muscular hypotonia, epilepsy, pancreatitis 
(MMA>PA), sensineural hearing loss and bone marrow dysfunction can be caused by 
mitochondrial dysfunction. Other long-term complications without a clear role of 
mitochondrial dysfunction are decreased bone mineral density, joint hypermobility, pes 
planus, growth retardation, skin problems, and enamel defects [26].     
 
In UCD, long-term complications include neurological symptoms, psychiatric symptoms and 
liver and sometimes renal involvement. Neurological symptoms include movement disorders 
(such as cerebral palsy), and seizures, as well as developmental delay. Those patients with 
severe hyperammonemia and neonatal onset have the highest risk of neurological impairment 
[27]. Movement disorders were observed in 7-25% of the UCD patients [3]. Arg1 and HHH 
syndrome patients can have diplegia and in Arg1 also tremor, ataxia, choreathetosis can be 
observed [21]. Seizures were mainly observed in OTC-D male patients (14%) and ASL-D 
patients (19%) [3]. Psychiatric symptoms such as ADHD, autism, and mood disorders may also 
be observed. Renal failure is observed in ASL-D and chronic liver disease occurs mainly in OTC-
D females and ASL-D [3]. Furthermore, some of the patients may have visual or hearing 
impairment [28]. 
 
1
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3.6 | Cognitive and motor development 
In OAD, developmental delay was observed in approximately a quarter (25-65%) of the MMA 
patients, 59-100% of the PA and 10% IVA patients (identified by selective screening) [9, 29]. 
Cognitive impairment with an IQ below 70, based on standardized IQ test, was observed in 
31% of the OAD patients [6]. MMA vitamin B12 unresponsive patients appeared to have an 
increased risk of severe impaired cognitive function if they had an early onset 
hyperammonemia and/or seizures [9]. In PA no clear risk factors could be identified. Abnormal 
gross motor development was observed in approximately 1/3 of the MMA and PA patients, in 
only 4% of the IVA patients and fine motor development was abnormal in approximately 40% 
of the MMA and PA patients. 
In UCD, cognitive impairment (IQ<70) was observed in 43% [6] of the patients in the European 
cohort and intellectual and developmental disabilities in 39% of the cohort described for the 
USA [28]. [30] Gross motor development was abnormal in 3-50% and fine motor development 
was abnormal in 9-58% of the patients. The percentage was dependent on the type of disease 
[3].  
 
 
3.7 | Quality of life 
Classical OAD and UCD patients have shown to be at risk of a decreased health related quality 
of life [6, 31]. Several factors play a role in the quality of life of OAD and UCD patients and 
families. The most important ones are caused by the disease itself and are dietary restriction, 
hospitalizations due to metabolic decompensations, and the occurrence of severe organ 
related complications that affect long-term outcome.  
 
3.8 | Mortality 
While in OAD survival has increased in recent decreased, this is not true for UCD [32]. The 
survival rate in MMA and PA patients ranges from 70-90% [33-35]. UCD patients presenting in 
20
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neonatal period had a survival of only 35%, while those presenting thereafter had a survival of 
87% [36].  
 
4 | Long-term treatment in classical OAD and UCD 
For both classical OAD and UCD patients, the goal of the dietary management is to reduce the 
amount of toxic metabolites in order to prevent metabolic decompensations 
(OAD)/hyperammonemia (UCD) and long-term complications [9, 10]. This can be achieved by 
reducing the intake of specific amino acids (in classical OAD) and total protein (in classical 
OAD and UCD). In both disorders a high caloric diet is prescribed to prevent catabolism, since 
catabolism is associated with endogenous protein breakdown [10] and thereby induces 
potential toxic metabolites. Besides the dietary treatment some supportive medication is 
available. Lastly, solid organ transplantation of the kidney and/or liver are increasingly 
performed.  
 
4.1 | Dietary treatment 
4.1.1 | Dietary intake in general population 
Appropriate protein incorporation and protein tolerance is essential for normal growth, body 
weight and physiological, metabolic and psychological functions [24, 37, 38]. Dietary protein 
intake stimulates growth through the secretion of insulin-like growth factor 1 [39, 40]. To 
achieve an adequate nitrogen balance, individual metabolic demands, protein quality of the 
consumed protein, and protein utilization play a role. The metabolic demand of amino acids 
can be delivered by 1) degradation of proteins by tissues, 2) the novo synthesis of proteins 
and 3) by protein intake through the diet. The overflow of amino acids can be broken down 
via other pathways and through oxidation into nitrogen, which can then be excreted [38]. 
Considering dietary protein intake, the protein energy interaction is important (the protein: 
energy ratio or P:E ratio). Increased energy intake can improve nitrogen balance by decreasing 
protein loss [38].  
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Advice on protein intake as well as on caloric intake are well described in the WHO/FAO/UNU 
2007 reports [41] (table 1). For each age category for both females and males advised protein 
intake in gram/kg/day and kilocalorie in calories/kg/day are given. Advice on protein intake 
can be based on three main study types. First nitrogen balance studies are based on the 
principle that the majority of the nitrogen in the body is derives from protein. Hereby nitrogen 
gain seems to be equal to protein gain. These studies determine the nitrogen intake and 
output. The second study type concern carbon balance studies and third the indicator amino 
acid method. In the WHO/FAO/UNU 2007 reports recommendations are based on nitrogen 
balance studies.  
Table 1. WHO guidelines for protein and energy intake.  (table from the guideline by Baumgartner 
et al. [9]) 
 
4.1.2 | Dietary management in classical OAD and UCD 
For both classical OAD and UCD, guidelines providing recommendations on long-term 
treatment are available. In both guidelines the before mentioned recommendations by the 
WHO are used [9]. Long-term treatment recommendations imply of a restriction of the so 
called natural protein, which is derived from protein present in natural/normal dietary sources. 
Furthermore, classical OAD and UCD patients often receive amino acid mixtures (AAM), which 
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in case of classical OAD contain amino acids without the specific amino acids that cannot be 
metabolized by the patient which that specific disorder and in case of UCD contain essential 
amino acids (EAA). 
In classical OAD, the guideline notifies that the ultimate treatment goal is to achieve a natural 
protein intake of 100% of the recommended daily allowances (RDA) (FAO/WHO/UNU (2007)), 
and that amino acid mixtures (AAM) should be applied when the recommended natural 
protein intake of 100%RDA is not obtained [9]. In UCD, the guidelines states that ‘the 
FAO/WHO/UNU 2007 can be used as guide’ for protein and energy intake. The authors also 
mention that protein intake below the recommended quantity can still be adequate but that 
supplementation of EAA may become necessary. Both guidelines states that frequent 
monitoring of these patients is essential since not only decompensation and long-term 
complications should be prevented, but also growth and development should be optimized. 
Vitamin and minerals should be supplied when there are deficiencies induced by the diet. 
 
4.2 | Medical treatment 
In OAD, the goal of medical treatment is 1) to stimulate propionyl-CoA elimination, 2) to 
reduce production of propionyl-CoA in the gut and 3) to increase activity of the deficient 
enzyme by providing co-enzymes. Propionyl-CoA elimination can be stimulated by providing 
L-carnitine by conversion to nontoxic propionylcarnitine. L-carnitine can reduce the toxic 
metabolites by transforming them and by urinary excretion [9]. Propionyl-CoA production can 
be reduced by providing antibiotics, mainly metronidazole, through reducing the intestinal 
bacterial flora that produce propionyl-CoA. In MMA, vitamin B12 responsive forms exist and 
treatment with vitamin B12 clearly improves the prognosis of these patients. In PA it is not yet 
clear if biotin responsive forms of PA do exist [9].  Besides these treatment options, treatment 
regarding improving supplementation to the TCA cycle has been studied in PA patients, since 
in PA (and MMA) the supply of succinyl-COA is deficient. Citrate has shown to improve TCA 
cycle function in PA patients [42], but is not recommended as standard treatment. In OAD 
steroids should be avoided since they can induce catabolism. Furthermore, sodium valproate, 
drugs with propionate, pivalic acid, nephrotoxic drugs, and chemotherapy should be avoided 
1
23
GENERAL INTRODUCTION AND OUTLINE OF THIS THESIS 
[9]. Growth hormone has been used in some patients and has shown positive effects, however 
no clear guidelines on its use have been given [9]. 
 
In UCD, medical treatment can 1) replenish deficient substrates, 2) scavenge ammonia, and 3) 
refill the Krebs cycle by using antioxidants and anaplerotic agents. To replenish deficient 
substrates L-arginine and L-citrulline can be used. In CPS1-D, OTC-D and HHH syndrome either 
L-arginine or L-citrulline can be prescribed, while in ASS-D and ASL-D L-citrulline is prescribed. 
Carbamylglutamate is an effective drug in NAGS-D. Medical treatments that can scavenge 
ammonia and which are used for this purpose in UCD are sodium benzoate and sodium 
phenylbutyrate. A known side effect of sodium phenylbutyrate is that it can decrease plasma 
levels of branched chain amino acids [43]. In UCD patients with a carnitine deficiency L-
carnitine should be prescribed.  
 
4.3 | Solid organ transplantation 
For OAD, solid organ transplantation of the liver in PA and the liver and/or kidney in MMA has 
been performed. Liver transplantation can at least partially correct the enzyme deficiency in 
MMA and PA patients. However, it is not clear when and who to transplant and whether this 
is a safe treatment option. For UCD, solid liver transplantation is considered curative and has 
been reported for all UCD except NAGS-D and HHH syndrome. For many classical OAD and 
UCD patients neurological sequelae have been reported, which were not reversed by the 
transplantation. Furthermore, for decision making risks related to the transplantation 
procedure and the use of immunosuppressive medications required after the transplantation 
need to be taken into account. 
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5 | Aims and outlines of this thesis 
This thesis comprises a total of seven studies supporting the hypothesis that patient’s outcome 
can be improved by optimization of the currently available treatment. To answer this 
hypothesis we established four study goals. 
1. To explore the natural history of classical OAD and UCD patients and the treatments 
applied, to provide insight in the outcome/prognosis obtained with the currently 
applied therapies.  
2. To determine the most optimal dietary treatment advice.  
3. To improve monitoring of classical OAD and UCD patients. 
4. To determine the outcome (mortality, complications, quality of life (QOL) and cognitive 
development) of AOA patients who received solid organ transplantations.  
Chapter 2 provides a study in classical OAD and UCD patients on compliance with the current 
guidelines in daily clinical practice and the outcome of patients achieved with the applied 
treatment. Chapter 3 provides insights on how to improve growth in classical OAD and UCD 
patients. Chapter 4 describes the effect of dietary treatment on outcome of patients and 
provides recommendations for improvement of current dietary treatment strategies in MMA 
and PA patients. Chapter 5 focuses on the potential role of a biomarker as a predictor of the 
development of long-term complications in patients and Chapter 6 provides a study on the 
potential expected effect of newborn screening in MMA and PA on outcome. Chapter 7 shows 
the current practice of solid organ transplantation in patients with AOA in Europe and the 
neurological risks after transplantation caused by calcineurin inhibitors. In Chapter 8 the 
results of the various studies are discussed and conclusions, recommendations and future 
perspectives are provided.   
1
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CURRENT TREATMENT APPLIED IN 
UCD AND CLASSICAL OAD PATIENTS
Evaluation of dietary treatment and amino acid 
supplementation in organic acidurias and urea-cycle  
disorders. On the basis of information from a European 
multicenter registry (E-IMD) 
 Abstract 
Introduction: Organic acidurias (OAD) and urea-cycle disorders (UCD) are rare inherited 
disorders affecting amino acid and protein metabolism. As dietary practice varies widely, we 
assessed their long-term prescribed dietary treatment against published guideline and 
studied plasma amino acids levels.  
Method: We analyzed data from the first visit recorded in the European registry and network 
for intoxication type metabolic diseases (E-IMD, Chafea no. 2010 12 01).  
Results: In total, 271 methylmalonic aciduria (MMA) and propionic aciduria (PA) and 361 
UCD patients were included. Median natural protein prescription was consistent with the 
recommended daily allowance (RDA), plasma L-valine (57%) and L-isoleucine (55%) levels in 
MMA and PA lay below reference ranges. Plasma levels were particularly low in patients who 
received amino acid mixtures (AAMs-OAD) and L-isoleucine: L-leucine: L-valine (BCAA) ratio 
was 1.0:3.0:3.2. In UCD patients, plasma L-valine, L-isoleucine and L-leucine levels lay below 
reference ranges in 18%, 30% and 31%, respectively. In symptomatic UCD patients who 
received AAM-UCD, the median natural protein prescription lay below RDA, while their L-
valine and L-isoleucine levels and plasma BCAA ratios were comparable to those in patients 
who did not receive AAM-UCD. Notably, in patients with ornithine transcarbamylase 
syndrome (OTC-D), carbamylphosphate synthetase 1 syndrome (CPS1-D) and 
hyperammonemia-hyperornithinemia-homocitrullinemia (HHH) syndrome selective L-
citrulline supplementation resulted in higher plasma L-arginine levels than selective L-
arginine supplementation. 
Conclusion: While MMA and PA patients who received AAMs-OAD had very low BCAA levels 
and disturbed plasma BCAA ratios, AAMs-UCD seemed to help UCD patients obtain normal 
BCAA levels. In patients with OTC-D, CPS1-D and HHH syndrome, selective L-citrulline 
seemed preferable to selective L-arginine supplementation.  
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 1 | Introduction 
Organic acidurias (OAD) and urea-cycle disorders (UCD) are rare inherited disorders affecting 
amino acid and protein metabolism. Their estimated incidence is 1 in 1,000,000–50,000 
newborns per individual disease [1, 2]. OAD (methylmalonic aciduria (MMA) (mutase 
deficiency OMIM #251000, CblA #251100, CblB #251110) and propionic aciduria (PA) (OMIM 
#606054)) are caused by deficiencies of the enzymes needed for the breakdown of 
branched-chain amino acids (BCAA), L-valine and L-isoleucine in MMA and PA. UCD, i.e. 
inherited deficiency of N-acetylglutamate synthase (OMIM #237310), carbamylphosphate 
synthetase 1 deficiency (CPS1-D) (EC 6.3.4.16; OMIM #237300), ornithine transcarbamylase 
deficiency (OTC-D) (EC 2.1.3.3; OMIM #311250), argininosuccinate synthetase deficiency 
(ASS-D) (EC 6.3.4.5; OMIM #215700), argininosuccinate lyase deficiency (ASL-D) (EC 4.3.2.1; 
OMIM #207900), arginase 1 deficiency (OMIM #207800) and hyperornithinemia-
hyperammonemia-homocitrullinuria (HHH) syndrome (OMIM #238970), are caused by 
deficiencies of the enzymes and transporter needed for the urea-cycle. If left untreated, 
ammonium and other toxic metabolites accumulate. 
In OAD patients long-term treatment consists of reducing natural protein intake to prevent 
intoxication while allowing normal growth [3]. Although, when necessary, precursor-free 
amino acid mixtures (AAM) (AAMs-OAD: amino acid mixtures in OAD)  can be supplemented 
without inducing intoxication, there has recently been some debate on their use with respect 
to the relative high L-leucine content influencing other plasma BCAA levels [3-6]. In MMA 
and PA, AAMs-OAD lack L-valine and L-isoleucine. In some patients, single amino acids (SAA) 
can be supplied to fine-tune dietary treatment, though there is no international consensus 
on the use of either AAMs-OAD or SAA [7]. In UCD patients, the purpose of dietary 
treatment is to reduce the nitrogen load. In the most severe cases, treatment consists of a 
protein-restricted diet (either with or without the use of AAM-UCD (amino acid mixture in 
UCD)), supplemented with L-arginine and/or L-citrulline to support the urea-cycle [8]. Most 
patients also receive nitrogen scavengers. In patients with mild phenotypes, treatment can 
be less strict, ranging from a self-initiated vegetarian diet to a natural protein restriction 
without nitrogen scavengers and other supplements. In both OAD and UCD, additional 
caloric intake to maintain anabolism is necessary [9].  
2
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 In daily practice, dietary treatment is currently very diverse [4, 10]. If long-term outcome in 
these patients is to be improved, it is essential that treatment is optimized. The guideline 
proposed by Baumgartner et al for the dietary treatment of patients with MMA and PA [11] 
suggest that “the FAO/WHO/UNU (2007) safe levels of protein intake are a useful guide for 
protein prescription”. The guideline suggests that “synthetic protein should form part of the 
total protein intake if natural protein tolerance is below FAO/WHO/UNU (2007) safe levels” 
[11], and the Genetic Metabolic Dietitian International guideline on PA recommends that 
AAMs-OAD (which lack L-isoleucine and L-valine) should be added to achieve 100-120% of 
recommended daily allowance (RDA) in those patients who tolerate a natural protein intake 
less than 100% RDA [12]. However, there is no guideline available on the amount of synthetic 
protein intake as percentage of total protein intake in those patients requiring supplemental 
amino acids. The guideline for UCD proposed by Häberle et al [13] likewise suggests that the 
FAO/WHO/UNU requirements are used for protein intake. The guideline provides 
recommendations on the amount of synthetic protein intake as a percentage of the total 
protein intake for patients who require supplemental amino acids (recommendation: 20-
30%). The same guideline also propose recommendations on dosages of L-citrulline and/or 
L-arginine treatment (L-arginine dose: <20kg body weight: 100-200mg/kg/day, >20kg body 
weight: 2.5-5g/m2/day and L-citrulline dose: 100-200mg/kg/day). However, these dietary and 
supplemental recommendations are based on expert opinion. There are neither outcome 
data with respect to recommendations on appropriate plasma amino acid levels, nor are 
there clear recommendations on whether L-citrulline or L-arginine treatment is preferred in 
any of the following: CPS1-D, OTC-D and HHH syndrome.  
If optimized treatment is feasible, it is likely to improve outcome in OAD and UCD patients. 
To establish whether or not treatment is sufficient, it is very important to evaluate dietary 
and supplemental treatment in a large cohort of OAD and UCD patients. As the first step in 
this evaluation, we evaluated data from the first visit recorded in the registry from OAD and 
UCD patients in the European registry and network for Intoxication type Metabolic Diseases 
(E-IMD) 1) to compare their current long-term dietary and supplemental treatment with the 
existing guideline; and 2) to study the plasma amino acids levels in patients with this 
prescribed treatment.  
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 2 | Methods 
2.1 | Patient registry and inclusion/exclusion criteria 
The European registry and network for Intoxication type Metabolic Diseases (E-IMD; URLs: 
http://www.e-imd.org (website); https://www.eimd-registry.org (registry)) is a European 
project that was initiated in 2011 and now includes a web-based patient registry containing 
comprehensive follow-up data on more than 1,200 individuals with OAD and UCD. A detailed 
overview of the E-IMD was published previously [14]. The data in the E-IMD registry were 
entered by clinicians and dieticians. The dietary information in this registry was the diet 
prescribed, which does not necessarily equal the consumed diet. The study was approved by 
the local ethics committee of the coordinating center (University Hospital Heidelberg) and by 
all clinical partners. The current publication project was evaluated by the scientific board and 
approved by the executive board of the E-IMD consortium.  
In this cross-sectional study, we included all data from the first visits recorded in the registry 
and all visits included were during stable metabolic period. We included MMA (mut-, mut0, 
cblA, and cblB), PA, OTC-D females and males, CPS1-D, HHH syndrome, ASS-D and ASL-D 
patients. CblA and CblB patients were included as the majority of them were symptomatic 
and they were also treated with a natural protein restriction. We excluded patients with other 
inherited metabolic diseases, those with an unconfirmed suspicion of an OAD or UCD, those 
with MMA CblC and CblD subtypes and unclassified type, and those who had received a 
kidney or liver transplantation or had other serious unrelated comorbidities, such as Down 
syndrome, kernicterus, or fetal alcohol syndrome. We furthermore excluded those without 
information on the prescribed dietary treatment and those without information on clinical 
symptoms (symptomatic or not). Clinically symptomatic patients were defined as presenting 
with a metabolic crisis or long-term complications. 
 
2.2 | Data analysis 
Synthetic protein was defined as a protein-equivalent of specialized AAM-OAD/UCD and 
SAA. L-valine and/or L-isoleucine were supplied independently or in combination as SAA. 
Total protein prescription was calculated by adding natural protein and synthetic protein 
2
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 prescription. Protein prescription (natural, synthetic and total) data from the first visit 
recorded in the registry  was compared with the WHO RDA [15]. Synthetic versus total 
protein prescription (ratio) was calculated by dividing the amount of synthetic protein % RDA 
by total protein % RDA. Information on the amino-acid content of AAMs-OAD/UCD was 
obtained from the manufacturers. Supplementation with L-arginine and/or L-citrulline and 
the provision of sodium phenylbutyrate were both compared with current recommendations 
[13].  Plasma amino acid levels were compared with the amino acid reference values 
provided in table 2.1.5 of the “Laboratory Guide to the Methods in Biochemical Genetics” by 
Duran et al. 2008 [16].  
 
On the basis of their common metabolic amino acid disturbances, we combined the 
following disorders in several analyses: 1) MMA and PA; 2) inherited deficiency of ASS-D, 
ASL-D; 3) OTC-D males, CPS1-D and HHH syndrome and 4) as a separate group OTC-D 
females.  
 
2.3| Statistical analysis 
 
SPSS (IBM SPSS Statistics 22.0) was used for descriptive statistics (percentages, mean, 
standard deviation, median and range). Normality was examined using the Kolmogorov-
Smirnov test and quantile-quantile (Q-Q) plots. We corrected the p-values per outcome for 
the subgroup analyses by using the Holm method. Student’s t-test was performed to 
compare means if distribution was Gaussian and Wilcoxon rank sum test (Ws) if distribution 
was non-normal. If there were dichotomous parameters in a small sample size Fisher’s exact 
test was performed to determine statistical significance between groups and if there were 
dichotomous parameters in a large sample size chi square test was performed. One-way 
ANOVA was performed to compare more than two groups. To compare L-citrulline and L-
arginine prescription against the guideline, body-surface area was calculated with the 
Mosteller formula. To identify variables that had significant associations with plasma amino 
acid levels, we used backward stepwise linear regression analysis to explain the relationship 
between five independent variables on plasma amino acids. As forward methods produce 
suppressor effects, we performed backward linear regression [17]. Five independent variables 
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 were used in the multiple regression analysis: protein prescription (natural (% RDA) and 
synthetic); use of single branched-chain amino acids (yes/no); age at visit; clinically 
symptomatic (yes/no); and, in UCD, use of sodium phenylbutyrate (yes/no). On the basis of 
the amount of L-arginine/L-citrulline prescription and of selective L-citrulline versus L-
arginine supplementation, we also used backward stepwise linear regression to identify 
factors that had an association with plasma L-arginine levels in OTC-D and CPS1-D and HHH 
syndrome.  
 
3 | Results  
3.1 | Description of the study population 
Two hundred and seventy-one MMA and PA patients and 361 UCD patients had been 
registered between 1 February 2011 and 20 May 2016 (supplementary table 1, 4). In patients 
with MMA and PA as well as in patients with UCD, OTC-D females excluded, 82% was 
symptomatic. A total of 67% of females with OTC-D were symptomatic. In total, 73% of 
patients with OAD and UCD were diagnosed by selective metabolic testing, 13% by newborn 
screening, 13% by high-risk family or population screening, and 1% by prenatal testing. Most 
patients were from Europe (95%), the remainder from Taiwan (2%), the USA (2%), India 
(0.8%) and Japan (0.2%). Median age at first visit recorded in the registry was 9.3 years (5-
95% percentile: 0.4 – 35.6). The median time from diagnosis until the first visit recorded in 
the registry was 6.6 years (5-95% percentile: 0.2 – 23.4). Information on participating 
countries and disease groups is provided in supplementary table 2. 
 
3.2 | MMA and PA 
3.2.1 | MMA, PA and protein prescription 
A total of 92% (250/271) MMA, PA patients received a protein restricted diet (supplementary 
figure 1). Natural protein prescription was according to and above the RDA in 62%. 
Symptomatic MMA, PA patients received a lower natural and total protein prescription % 
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 RDA than asymptomatic patients (supplementary table 3a, figure 1a). A few patients were 
prescribed a natural protein intake <50% or >200% RDA (figure 1a). Various (29) AAMs-OAD 
were provided by a total of six companies and used for a majority of MMA and PA patients 
(supplementary figure 1). AAMs-OAD were free of L-valine and L-isoleucine, while the rest of 
their content varied (supplementary table 4). Median protein prescription through AAMs-
OAD was 0.50 g/kg/d (5-95% percentile: 0.18- 1.20). SAA were supplied in only 17% of those 
with MMA (24/144) and 20% of those with PA (25/127). Ninety percent of those who 
received SAA (44/49) were also prescribed AAM-OAD. Natural protein prescription was 
according to and above the RDA in the majority (58%, 96/166) of patients who received 
synthetic protein (figure 2, supplementary table 3a). The mean amounts of synthetic protein 
as a percentage of total protein prescription was 40% (SD ±15.2). In patients with MMA, 
those with the Mut0 subtype were prescribed the lowest natural protein % RDA. AAMs-OAD 
were most frequently used in Mut0 and CblB patients (supplementary table 5). 
Protein prescription within the different countries varied, with a median natural protein 
prescription of 112% RDA, a total protein prescription of 159% RDA and a synthetic versus 
total protein prescription of 40% (supplementary table 2). A high natural protein prescription 
was seen in the Austria (n=12), Taiwan (n=7) and Romania (n=2) and the highest total 
protein prescription in Czech Republic (n=10), Spain (n=20), Romania (n=2), the USA (n=10) 
and Japan (n=1). The synthetic versus total protein prescription was highest in UK (n=1), 
Japan (n=1), Denmark (n=4), Spain (n=13) and Portugal (n=2) (supplementary table 2). 
Compared to the other countries, AAM-OAD was not applied in Serbia and Taiwan.  
 
3.2.2 | Impact of dietary management on plasma amino acids in MMA, PA   
Plasma BCAA levels were reported in 66% (180/271) of the MMA and PA patients 
(supplementary table 1). In individuals with MMA and PA plasma L-valine and L-isoleucine 
levels both lay below the lowest reference ranges in 57% and 55% of the patients 
respectively (figure 3a). Symptomatic MMA and PA patients who were prescribed AAM-OAD 
had lower plasma L-valine and L-isoleucine levels than those without (figure 4, 
supplementary table 3a). Linear regression analysis showed that the plasma L-valine was 
positively associated with the amount of natural protein prescription % RDA and negatively 
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 associated with the amount of L-leucine prescription derived from AAM-OAD 
(supplementary table 3c). Plasma amino acid levels of L-isoleucine, L-valine and L-leucine 
were the lowest in patients with Mut0 and cblB phenotype (supplementary table 5). In MMA 
and PA median plasma L-isoleucine: L-leucine: L-valine ratio was 1: 2.5: 2.9 (reference value: 
1: 2: 4). Patients with AAM-OAD had ratio of 1: 3.0: 3.2, while those without AAM-OAD had 
ratio of 1: 1.9: 3.3. The ratio of L-leucine versus L-isoleucine plasma levels (Ws=4088.0, Z=-
4.590, p<0.001) as well as the ratio of L-leucine versus L-valine plasma levels (Ws=3569.5, 
Z=-6.084, p<0.001) were significantly higher in patients who received AAM-OAD compared 
to those without.  
 
3.3 | Urea-cycle disorders 
3.3.1 | UCD and protein prescription 
A total of 80% (289/361) of the UCD patients received a protein restricted diet 
(supplementary figure 1). Median natural protein prescription in symptomatic and 
asymptomatic patients was close to or above the RDA; in the majority of UCD subgroups, 
total protein prescription was above the RDA (figure 1a-d). Several patients were prescribed 
a natural protein intake protein <50% or >200% RDA (figure 1b-d). For UCD 21 different 
AAMs-UCD were provided by a total of 5 companies. AAMs-UCD were supplemented with 
BCAA (L-valine, L-isoleucine and L-leucine) (supplementary table 4). AAMs-UCD were used 
for 32% (114/361) of the patients (supplementary figure 1) and median protein prescription 
through AAM-UCD was 0.28 g/kg/d (range: 0.04-1.17 g/kg/d).  
Symptomatic patients who received AAM-UCD had a lower natural protein % RDA 
prescribed than those who did not receive AAM-UCD in the CPS1-D, OTC-D male and HHH-
syndrome subgroup (supplementary table 3b). In the ASS-D, ASL-D and CPS1-D, OTC-D male 
and HHH-syndrome subgroups, natural protein prescription in symptomatic patients taking 
AAM-UCD lay below the RDA (figure 2). SAA of BCAA were supplied in only 3% (11/361); 
3/11 of those who received SAA were also prescribed AAM-UCD. The mean amounts of 
synthetic protein as a percentage of total protein prescription were as follows in the 
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 following groups: 31% in the ASS-D and ASL-D subgroup (SD ±18.2), 32% in the CPS1-D, 
OTCD-male and HHH subgroup (SD ±11.7) and 28% (SD ±14.2) in OTC-D females.  
Protein prescription within the different countries varied, there was a high median natural 
protein prescription in Poland (n=9), Denmark (n=10) and India (n=4), while a low median 
natural protein prescription in Austria (n=3), Italy (n=39) and UK (n=8). Austria and the UK 
had a relatively high synthetic versus total protein prescription and thereby a total protein 
prescription according to recommendations, while Italy had a low total protein prescription. 
AAMs-UCD were prescribed in the majority of patients in the Netherlands, Austria and 
Greece, Czech Republic, while in the minority in all other countries (supplementary table 2).  
  
38
Chapter 2
 FIGURE 1. Protein prescription in patients with MMA and PA (A); patients with ASS-D or ASL-D 
(B); patients with CPS1-D, males with OTC-D or patients with HHH syndrome (C); and in 
females with OTC-D (D). 
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Gray boxes indicate symptomatic patients and black boxes indicate asymptomatic patients. Synthetic 
protein indicates the amounts only for patients receiving synthetic protein. Circles: outliers; whiskers: 
5-95 percentile; horizontal line: median; * p<0.05 
 
3.3.2 | Sodium phenylbutyrate in UCD  
Sodium phenylbutyrate was provided in 37% of the UCD patients (134/361). In the CPS1-D, 
OTC-D male and HHH-syndrome subgroup, prescribed natural protein and total protein % 
RDA was lower in those prescribed sodium phenylbutyrate treatment than in those who were 
not (supplementary table 3b). Sodium phenylbutyrate was applied in the majority of patients 
in Germany, Netherlands, Croatia, Czech Republic and Taiwan (supplementary table 2d). 
 
3.3.3 | Impact of dietary management and sodium phenylbutyrate on branched chain 
amino acids in UCD  
In 76% of UCD patients (277/361) BCAA levels were reported (supplementary table 1). In 
total UCD, plasma L-valine, L-isoleucine and L-leucine levels lay below the levels of reference 
values in 18%, 30% and 31% of the patients, respectively (figure 3b-d). Supplementary table 
3b shows plasma BCAA levels of the ASS-D, ASL-D subgroup, OTC-D male, CPS1-D, HHH 
syndrome subgroup and OTC-D female subgroup in symptomatic versus asymptomatic 
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 patients and in those with a natural protein restricted diet versus those without. In these UCD 
subgroups, plasma BCAA levels in patients who received AAM-UCD did not differ from those 
who did not receive AAM-UCD (supplementary table 3b). In total UCD patients, linear 
regression analysis showed that plasma L-valine, L-isoleucine and L-leucine were associated 
with sodium phenylbutyrate treatment and age at visit (supplementary table 3d).  The UCD 
patients had a plasma L-isoleucine: L-leucine: L-valine ratio of 1: 1.7: 3.7 (reference value: 1: 2: 
4). Patients who received AAM-UCD had a ratio of 1: 1.7: 3.7 and those who did not receive 
AAM-UCD had ratio of 1: 1.9: 3.7.  
 
3.3.4 | L-arginine and/or L-citrulline treatment in UCD  
L-arginine was provided in most ASS-D and ASL-D patients, i.e., in 95% of the symptomatic 
patients (90/95) and 86% of the asymptomatic patients (18/21). In 31% of ASS-D (18/58) and 
31% of the ASL-D patients (14/45), L-arginine-supplemented doses were above the 
maximum recommended guideline (6 g/day [13]). Individuals who received L-arginine in the 
ASS-D and ASL-D subgroup had lower natural protein % RDA and total protein % RDA 
prescription than those who did not receive L-arginine treatment (supplementary table 3b).  
In the CPS1-D, OTC-D male and HHH-syndrome subgroup, 86% of the symptomatic patients 
(82/95) and 59% of the asymptomatic patients (13/22) were prescribed L-citrulline and/or L-
arginine. One or both of these amino acids were also prescribed in 79% of the symptomatic 
females with OTC-D (68/86) and in 21% of the asymptomatic females (9/42). In those who 
received L-citrulline and/or L-arginine, selective supplementation with L-citrulline was 
provided in 44% (76/172); a combination of L-citrulline and L-arginine was provided in 20% 
(34/172); and selective L-arginine supplementation was provided in 36% (62/172). Many 
patients were prescribed L-citrulline (44% (48/109)) and L-arginine (24% (22/92)) above 
recommended dose [13].  
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 3.3.5 | UCD and levels of plasma L-arginine and L-citrulline 
In the subgroup of patients with CPS1-D, OTC-D (male and female) and HHH syndrome,  
patients who were prescribed selective L-citrulline supplementation had higher plasma L-
arginine levels than those who were prescribed only L-arginine (Ws=2745.5, Z= -3.066, 
p=0.002) and they had higher plasma L-arginine levels than those without supplementation 
(Ws=1406.0, Z=-5.109, p<0.001) (supplementary figure 2). Plasma L-arginine levels in 
patients who received L-citrulline only did not differ from those in patients who received a 
combination of L-citrulline and L-arginine (supplementary figure 2). The difference in plasma 
L-arginine levels between symptomatic and asymptomatic patients can be found in 
supplementary table 3b. Plasma L-arginine levels did not differ between OTC-D males and 
females. The ratio of OTC-D male versus female did not differ within patients receiving either 
L-citrulline or L-arginine or a combination of these two. Patients (CPS1-D, OTC-D (male and 
female) and HHH syndrome) who received either L-citrulline, L-arginine or a combination of 
both did not differ with regard to the age at visit, prescription of natural protein % RDA and 
prescription of protein derived from AAM-UCD. However, the mean L-arginine prescription 
(mg/kg/day) in patients who received L-arginine was lower than the mean L-citrulline 
prescription (mg/kg/day) in patients who received L-citrulline (Ws=3397.0, Z=-2.518, 
p=0.012). Regression analysis showed that plasma L-arginine levels were associated with 
selective L-citrulline therapy versus L-arginine monotherapy (β-coefficient =0.250, p=0.007) 
(R2 =0.062, R2Adjusted= 0.054), while the dose of either L-arginine or L-citrulline was not 
significantly associated with plasma L-arginine levels in the regression analysis. 
 
  
2
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 FIGURE 4. Plasma L-valine, L-isoleucine and L-leucine levels in patients with MMA and PA. 
 
 
 
Grey boxes indicate symptomatic patients and black boxes indicate asymptomatic patients. Diagonally 
striped boxes indicate patients in whom AAM was prescribed, and boxes without stripes indicate 
patients without AAM. Reference values are age dependent and can been found in figure 3 (A). 
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 4 | Discussion 
The purpose of this cross-sectional study was to evaluate current prescribed long-term 
dietary and supplemental treatment in OAD and UCD. We used the E-IMD registry to survey 
dietary management approaches of 271 OAD and 361 UCD patients to compare their current 
long-term dietary and supplemental treatment with the existing guideline; and to study the 
plasma amino acids levels in a total of 457 patients with this prescribed treatment. It is 
essential to evaluate this treatment, not only because long-term outcome in OAD and UCD 
continues to be disappointing, but also because newborn screening for these diseases is 
upcoming in an increasing number of countries.  
We have three main findings. First, plasma L-valine and L-isoleucine levels were very low in 
most patients with MMA and PA, mainly in symptomatic patients who received AAM-OAD 
(which lack L-valine and L-isoleucine), while median daily natural protein prescription was 
consistent with the current RDA. The high L-leucine content in AAM-OAD seemed to affect 
the plasma L-valine levels and lead to abnormal ratios of plasma L-leucine: L-isoleucine and 
L-leucine: L-valine. 
Second, of patients with UCD plasma BCAA levels lay below reference ranges in 
approximately 20-30%. While natural protein prescription lay below the RDA in most 
symptomatic patients who received AAM-UCD, plasma L-valine and L-isoleucine levels and 
L-isoleucine: L-leucine: L-valine ratio were similar to those in patients who did not receive 
AAM-UCD (which contain essential amino acids). Sodium phenylbutyrate was correlated with 
low BCAA levels as previously reported [18, 19]. Third, plasma L-arginine levels were 
significantly higher in patients with CPS1-D, OTC-D and HHH syndrome who were prescribed 
selective L-citrulline supplementation than in patients who were prescribed no 
supplementation or selective L-arginine supplementation. 
 
Some limitations of this study and of the registry should be addressed. First, as no diary-
based data was available on protein intake and there was no data on the patients’ adherence 
to dietary treatment, we were unable to analyze actual dietary intake and neither total 
branched chain amino acid intake. Furthermore, quality of protein consumed was not known. 
2
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 In this study we assumed that the patients took all the prescribed amounts. The large 
number of patients included in this study can give general information. As a next step actual 
dietary intake and intake of branched chain amino acids and its effect should be evaluated. 
Second, in this study kilocalorie intake was not incorporated and should be further studied in 
upcoming studies. Third, there was a high variability in the AAMs-OAD/UCD prescribed and 
they should be studied in more detail to specifically determine their effects. Fourth, the 
quantitative amino acid analyses were only a single measurement and not all patients 
included had BCAA levels measured. Our cross-sectional approach did not allow easy 
identification of predictors of plasma amino acid levels, it is difficult to assign a cause-effect 
relationship. Fifth, due to the high number of participating centers plasma amino acids levels 
are determined by various methods and different reference values are used, which can have 
impact on the conclusions drawn. No quality checks were in place to ensure the accuracy of 
data collected at each site. We did not assess the correctness of measurements and the 
differences between contributing laboratories. However, most laboratories participate 
regularly in external quality assessment (ERNDIM). Furthermore, the registry does not record 
the interval between the last intake and sampling of amino-acid plasma levels. However, as 
compartmentalization of plasma amino acids can affect the interpretation of plasma amino 
acid levels, samples should be taken accurately between 3.5 and 4 hours after the last meal 
[20]. Last, there can be a bias in the patients included, since some countries have high 
numbers of OAD and UCD, but this is not reflected in the E-IMD registry. All the limitations 
specified here require attention in future studies. 
 
4.1 | MMA, PA: protein prescription, AAM-OAD and plasma amino acid levels 
Our results show that while natural protein prescription was often close to the RDA and total 
protein prescription was even above the RDA, with current dietary prescription the majority 
of patients had plasma BCAA concentrations below the reference ranges. The low BCAA 
levels in MMA and PA were previously reported by others [4, 5, 21, 22] as well as the 
observation that daily natural protein prescription was according to the current RDA in MMA 
and PA [23, 24]. Towards improving patient care, it thus seems necessary to fine-tune plasma 
BCAA levels in individual patients. BCAAs are essential for keeping up anabolism and a 
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 decrease in plasma BCAA concentrations can herald an acute metabolic crisis [18]. 
Furthermore, BCAAs are essential for supporting normal growth and development [25-27]. 
Since a low natural protein intake can be potentially harmful, i.e. low BCAA levels, one should 
ensure that each patient achieves a higher natural protein intake in a way that does not 
cause metabolic instability. Protein prescription is currently based on the recommendations 
provided by the WHO 2007 [15]. While these recommendations are based on individuals 
consuming protein of a high biological value, the proteins commonly used by OAD patients 
are not only of low biological value, but are also poorly digestible [24]. Consequently, the 
WHO 2007 recommendation does not seem applicable to these patients, an appropriate 
guideline for their protein prescription is necessary. However, due to interpatient variability 
this may be hard to achieve. 
In OAD, AAM products are free of L-isoleucine, L-methionine, L-threonine, and L-valine, since 
these amino acids are precursors of toxic metabolites. While the guideline suggests 
prescribing AAM-OAD in those patients with a natural protein prescription below the RDA, 
we observed that the majority of those who received AAM-OAD had natural protein 
prescription that was according to and above the RDA. Nevertheless, our results show 
significantly lower plasma L-valine and L-isoleucine levels in symptomatic patients who 
received AAM-OAD. Those who received AAM-OAD are; in view of the very low L-valine and 
L-isoleucine levels, likely to be at risk of decompensations and growth retardation, and 
potentially of long-term complications. It is noteworthy that, in a small cohort of MMA 
patients, a high intake of L-leucine derived from AAM-OAD was associated with lower L-
valine and L-isoleucine plasma levels [5]. This could possibly be explained by means of the 
competitive interaction of BCAA on the same receptors (such as the large neutral amino acid 
transporter, LAT1[28]). We confirm this inverse relationship between L-leucine intake derived 
from AAM-OAD and plasma L-valine levels in our large patient cohort (of MMA and PA 
patients) with correction for covariates such as natural protein prescription. We furthermore 
showed that L-leucine: L-isoleucine as well as L-leucine: L-valine ratios were higher in those 
who received AAM-OAD versus those who did not, which is in line with a study by Myles et 
al. [6]. In patients whose natural protein intake cannot be raised, L-valine and L-isoleucine 
plasma levels may be optimized by reducing the L-leucine content of AAM-OAD. However, 
as the coefficients of the negative correlation between L-leucine derived from AAM-OAD and 
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 plasma L-valine and L-isoleucine levels were small, it is possible that such a reduction will be 
effective only in a small number of patients. It may also be hazardous: although our data do 
not confirm this, further reducing the daily L-leucine intake might lead to even lower L-
leucine plasma levels than found (low plasma L-leucine levels were previously reported [21, 
23, 29]), and thereby increase the risk of catabolism. In conclusion, AAMs-OAD for MMA and 
PA patients should be prescribed with care and with full awareness of their potentially 
harmful consequences [6]. 
In MMA and PA patients supplementation with SAA can play a role in dietary treatment [7].  
In the overall group of MMA, PA patients, the L-isoleucine: L-leucine: L-valine ratio was 1: 2.5: 
3.0 and in those patients without AAM-OAD ratio was 1: 1.9: 3.3, which indicates low L-valine 
levels (normal L-isoleucine: L-leucine: L-valine ratio is 1: 2: 4 [16, 28]). The disturbed BCAA 
ratios in patients without AAM-OAD could be due to the low biological value of protein 
consumed. In patients where maximal protein tolerance has been reached, SAA might be an 
option. In our opinion, calculating BCAA ratios can give an indication whether or not to 
increase natural protein or to supply SAA.   
The first step towards better monitoring of OAD patients was provided by the guideline that 
recommend monitoring quantitative amino acids every 3-6 months [11]. As it is very difficult 
to obtain optimal plasma BCAA levels that stimulate growth and development without 
inducing toxicity, we suggest that individualized patient care might be optimized by more 
frequent monitoring of BCAAs plasma levels.  
 
4.2 | UCD: protein prescription, AAM-UCD and plasma amino acid levels 
Natural protein prescription was often close to the RDA and total protein prescription was 
even above the RDA in UCD patients. This could be due to the fact that in this study we 
looked into protein prescription, which is not necessarily equal to the intake. Interestingly, 
several patients were prescribed high natural protein intake and total protein intake (>200% 
RDA), which is highly important to be aware of since this puts the patients at risk for 
hyperammonemia and renal disease. The risk for low plasma BCAA levels is highest in those 
who received sodium phenylbutyrate [18, 19, 30, 31]. In UCD patients, AAMs-UCD are 
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 supplemented with L-valine, L-isoleucine and L-leucine. We found that the natural protein 
prescribed in symptomatic UCD patients who received AAM-UCD was lower than 
recommended, and significantly lower than that in patients without AAM-UCD. Due to AAM-
UCD (median dose 0.28 g/kg/day) total protein prescription was consistent with 
recommendations. We observed that UCD patients who received AAM-UCD —and thus a 
lower natural protein prescription — achieved plasma L-isoleucine and L-valine levels and L-
isoleucine: L-leucine: L-valine ratios similar to patients without AAM-UCD. This suggests that 
AAMs-UCD have a beneficial effect in UCD in stable disease period.  
 
4.3 | UCD: L-arginine and/or L-citrulline 
To date there has been no clear-cut evidence that the efficacy of L-citrulline is greater than 
that of L-arginine for OTC-D, CPS1-D and HHH syndrome [13]. Now, for the first time, we 
show that patients who received L-citrulline had higher plasma L-arginine levels than those 
who received L-arginine alone. Plasma L-arginine levels depend on the amount of L-citrulline 
and/or L-arginine prescription. The bioavailability of L-citrulline is greater than that of L-
arginine [32, 33], and supplementation with L-citrulline leads to higher plasma L-arginine 
concentrations than supplementation with L-arginine. This supports the notion that it is 
preferable to use L-citrulline for patients with CPS1-D, OTC-D and HHH syndrome. 
Importantly, L-citrulline is more expensive than L-arginine [13]. 
In this study we surveyed long-term prescribed dietary treatment and amino acid 
supplementation in OAD and UCD patients in the E-IMD registry, taking the limitations of 
this study into consideration, with the aim to improve treatment. In future studies the 
possible harmful consequences (i.e., the number of decompensations, growth, long-term 
complications and mortality) of the very low plasma BCAA levels in MMA, PA and UCD 
patients must be evaluated. Recommendations on adequate plasma levels in OAD and UCD 
should be formulated and the efficacy of adjusted treatment (including AAM and/or SAA), 
without inducing toxicity, needs to be followed.  
 
 
2
51
CURRENT TREATMENT APPLIED IN UCD AND CLASSICAL OAD PATIENTS
 5 | Conclusion 
Current dietary practice in OAD and UCD patients differ widely. Natural protein prescription 
was close to the RDA, but very low BCAA levels and abnormal BCAA plasma ratios in patients 
with MMA and PA who were prescribed AAMs-OAD were observed. UCD patients with a risk 
of low plasma BCAA levels seemed to benefit from BCAA-supplemented AAMs-UCD. 
Patients with OTC-D, CPS1-D and HHH syndrome who received selective L-citrulline 
supplementation had significantly higher L-arginine plasma levels than patients who received 
no supplementation or selective L-arginine. These results make it possible to further improve 
recent treatment recommendations for OAD and UCD.  
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Supplementary Figure 1. Dietary treatment in OAD and UCD symptomatic and asymptomatic 
patients.  
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 Supplementary Figure 2. Plasma arginine levels under the various treatment regimens.  
 
 
 
Patients receiving either no L-arginine or no L-citrulline; patients receiving selective L-citrulline; 
patients receiving both L-arginine and L-citrulline; and patients receiving selective L-arginine. Circles: 
outliers; whiskers: 5-95 percentile; horizontal line: median; * p<0.05 
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 Supplementary table 4. Overview of prescribed AAM supplements in MMA, PA and UCD.  
Disease 
group 
n= Product name AAM 
Company 
L-valine 
(mg/100g 
AAM) 
 
L-
isoleucine 
(mg/100g 
AAM) 
 
L-leucine 
(mg/100g 
AAM) 
 
Total 
protein 
intake 
from AAM 
(g/kg/d) 
median ± 
range 
MMA, 
PA 
1 Asadon XMTVI Nutricia 0.0 0.3 12.8 1.00 
11 OS 2 Secunda Milupa 0.0 0.0 9.5 0.36 ± 0.38 
2 OS 3 Advanta Milupa 0.0 0.0 9.5 0.41 ± 0.28 
5 MMA/PA 
express 
Vitaflo 0.0 0.2 9.4 0.29 ± 0.22 
3 IMTV AM1 Nutricia 0.0 0.0 9.3 0.70 ± 0.40 
15 IMTV AM2 SHS 0.0 0.0 9.0 0.48 ± 0.53 
4 IMTV AM3 SHS 0.0     0.0 9.0 0.41 ± 0.02 
2 IMTV AM2 Nutricia 0.0 0.0 9.0 0.67 ± 0.13 
5 OS 2 Prima Milupa 0.0 0.0 8.1 0.40 ± 0.15 
17 OS 2 Milupa 0.0 0.0 7.6 0.40 ± 0.49 
9 MMA/PA Gel Vitaflo 0.0 0.2 6.6 0.50 ± 0.40 
11 XMTV 1 
Maxamum 
SHS 0.0 0.1 6.4 0.40 ± 0.25 
6 OS 1 Milupa 0.0 0.0 5.7 0.50 ± 0.53 
18 XMTV1 
Maxamaid 
SHS 0.0 0.1 4.1 0.63 ± 0.69 
5 Prompimex 2 Ross 0.0 0.2 2.8 0.55 ± 0.20 
16 MMA/PA 
Anamix Infant 
Nutricia 0.0 0.0 2.1 0.65 ± 0.66 
1 IMTV AM Infant SHS 0.0 0.1 2.1 1.10 
3 XMTVI Nutricia 0.0 0.3 2.0 0.60 ± 0.19 
1 XPTM 
Maxamaid 
Nutricia 1.2 1.1 1.9 0.38 
1 MMA/PA cooler Vitaflo 0.0 0.0 1.8 0.50 
1 Emsogen Nutricia 0.9 0.9 1.5 0.70 
4 Propimex 1 Ross 0.0 0.1 1.4 0.86 ± 0.47 
6 IMTV SHS NA 0.0 NA 0.65 ± 0.30 
1 IMTV AM SHS NA NA NA 0.80 
1 MT 1 SHS NA NA NA 0.70 
1 Anamix Nutricia NA NA NA 0.31 
1 IMTV AM Nutricia NA NA NA 0.22 
1 Maxamaid Nutricia NA NA NA 2.00 
1 OS pur Milupa NA NA NA 0.30 
UCD 2 E-AM3 SHS 13.0 10.6 17.0 0.20 ± 0.04 
9 E-AM2 Nutricia 13.0 10.6 17.0 0.20 ± 0.15 
2 E-AM1 Nutricia 10.3 8.8 16.3 0.45 ± 0.25 
7 E-AA-mix Nutricia 14.6 10.4 16.1 0.38 ± 0.19 
28 UCD 2 Milupa 10.7 8.9 15.0 0.25 ± 0.42 
11 UCD 1 Milupa 9.0 7.6 12.8 0.33 ± 0.26 
1 E-AA-mix Vitaflo 7.2 5.7 9.8 0.35 
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 23 Dialamine SHS 4.6 3.3 5.1 0.20 ± 0.51 
2 E-AM Anamix Nutricia 2.5 2.1 3.4 0.25 ± 0.08 
1 UCD Anamix 
Infant 
Nutricia 2.3 2.3 3.8 0.17 
1 WND1 Mead 
Johnson 
1.2 2.0 2.4 0.20 
1 WND2 Mead 
Johnson 
1.0 1.0 1.9 0.26  
1 UrC-A  Comidamed 1.1 0.9 1.5 1.00  
1 Neocate 
Advance 
Nutricia 0.7 0.6 1.1 1.17 
1 Nutrini Multi 
Fibres 
Nutricia 0.2 0.2 0.3 1.31 
1 Nutrini 
Peptisorb 
Nutricia 0.2 0.2 0.3 0.90 
1 Anamix Milupa NA NA NA 0.20 
3 UCD Milupa NA NA NA 0.49 ± 0.20 
1 URC1 Milupa NA NA NA 0.31 
7 E-AM SHS NA NA NA 0.41 ± 0.17 
1 SHS SHS NA NA NA 0.30 
Ranged based on L-leucine content in AAM products. 
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HOW TO IMPROVE GROWTH IN UCD 
AND CLASSICAL OAD PATIENTS 
Decreased plasma L-arginine levels in organic acidurias 
(MMA and PA) and decreased plasma branched-chain amino 
acid levels in urea cycle disorders as a potential cause of 
growth retardation: options for treatment.
Abstract 
Background and aim: Patients with methylmalonic acidemia (MMA) and propionic acidemia 
(PA) and urea cycle disorders (UCD), treated with a protein restricted diet, are prone to 
growth failure. To obtain optimal growth and thereby efficacious protein incorporation, a 
diet containing the essential and functional amino acids for growth is necessary. Optimal 
growth will result in improved protein tolerance and possibly a decrease in the number of 
decompensations. It thus needs to be determined if amino acid deficiencies are associated 
with the growth retardation in these patient groups. We studied the correlations between 
plasma L-arginine levels, plasma branched chain amino acids (BCAA: L-isoleucine, L-leucine 
and L-valine) levels (amino acids known to influence growth), and height in MMA/PA and 
UCD patients. 
Methods: We analyzed data from longitudinal visits made in stable metabolic periods by 
patients registered at the European Registry and Network for Intoxication Type Metabolic 
Diseases (E-IMD, Chafea no. 2010 12 01).  
Results: In total, 263 MMA/PA and 311 UCD patients were included, all aged below 18 years 
of age. In patients with MMA and PA, height z-score was positively associated with patients’ 
natural-protein-to-energy prescription ratio and their plasma L-valine and L-arginine levels, 
while negatively associated with the amount of synthetic protein prescription and their age 
at visit. In all UCDs combined, height z-score was positively associated with the natural-
protein-to-energy prescription ratio. In those with carbamylphosphate synthetase 1 
deficiency (CPS1-D), those with male ornithine transcarbamylase deficiency (OTC-D), and 
those in the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome 
subgroup, height z-score was positively associated with patients’ plasma L-leucine levels. In 
those with argininosuccinate synthetase deficiency (ASS-D) and argininosuccinate lyase 
deficiency (ASL-D), height was positively associated with patients’ plasma L-valine levels.  
Conclusion: Plasma L-arginine and L-valine levels in MMA/PA patients and plasma L-leucine 
and L-valine levels in UCD patients, as well as the protein-to-energy prescription ratio in 
both groups were positively associated with height. Optimization of these plasma amino acid 
levels is essential to support normal growth and increase protein tolerance in these 
disorders. Consequently this could improve the protein-to-energy intake ratio.   
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1| Introduction 
Failure to thrive with respect to height in patients with organic acidurias (OAD) and urea 
cycle disorders (UCD) has been well described [1-6]. Environmental and genetic factors, 
nutritional factors (essential and functional amino acids), and endocrine factors [7] influence 
children’s growth. Appropriate protein incorporation and protein tolerance is essential for 
normal growth in children [8, 9]. Dietary protein intake stimulates growth through the 
production of insulin-like growth factor 1 [10, 11]. Additionally, the dietary protein itself 
regulates protein turnover via mammalian target of rapamycin (mTOR) signaling by amino 
acids in skeletal muscle, especially (but not exclusively) by L-leucine and L-arginine [12-14]. 
One of the most likely underlying cause of the growth retardation in OAD and UCD patients 
is an installed protein restricted diet [15, 16], with a compensatory high energy intake in 
order to promote anabolism. Protein and energy requirements are interdependent: as Evans 
et al. showed recently [17]. In OAD and UCD patients, optimal growth is essential to 
obtaining sufficient protein incorporation and protein tolerance. In addition, a higher protein 
tolerance is likely to be associated with less frequent decompensations. 
Sufficient intake of essential and functional amino acids is essential to stimulate growth [7]. 
The most important essential amino acids involved in growth are L-leucine, L-isoleucine, L-
valine, L-histidine and L-lysine [18]. Insufficiency of these essential amino acids is associated 
with growth failure in children [19]. Functional amino acids are defined as “those amino acids 
that regulate key metabolic pathways to improve health, survival, growth, development, 
lactation, and reproduction of organisms”; they include L-arginine, L-glutamine, L-proline, 
glycine and L-taurine [20]. L-arginine is a well-known stimulator of the somatotrophic axis 
that supports physiological growth by inducing growth hormone excretion [21-29]. As L-
arginine was shown in a group of ornithine transcarbamylase deficiency (OTC-D) males to 
improve physiological growth, it may be a therapeutic agent [22]. As indicated previously, 
branched-chain amino acids (BCAAs) are essential for normal growth, and levels are known 
to be decreased in MMA/PA and UCD patients alike [15, 16, 30-32].  
As functional amino acids (such as L-arginine) and BCAAs play important roles in growth, we 
aimed to establish any correlations between plasma L-arginine levels, plasma BCAAs levels 
and height in MMA/PA and UCD patients. To do so, we analyzed data on plasma BCAAs and 
3
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L-arginine levels during longitudinal visits in stable disease period of MMA/PA and UCD 
patients registered in the European Registry and Network for Intoxication Type Metabolic 
Diseases (E-IMD).  
 
2 | Methods 
2.1 | Patient registry and inclusion/exclusion criteria 
The E-IMD (URLs: http://www.e-imd.org (website); https://www.eimd-registry.org (registry)) is 
a European network project that was initiated in 2011 and now includes a web-based patient 
registry containing comprehensive follow-up data on more than 1,200 individuals with OAD 
and UCD. A detailed overview of the E-IMD has been published previously (Kölker et al 
2015). The data in the E-IMD registry are entered by clinicians and the dietary information in 
this registry is the diet prescribed by these clinicians/dieticians. Plasma amino acids levels are 
determined by various methods in the different centers. 
The study was approved by the local ethics committee at the coordinating center (University 
Hospital Heidelberg) and then was approved by all clinical partners. The current publication 
project was evaluated by the scientific board and approved by the executive board of the E-
IMD. In this longitudinal study, we included all first visits registered in the E-IMD registry and 
all (other) follow-up visits, during stable metabolic periods. We included methylmalonic 
aciduria (mut-, mut0, cblA and cblB) (MMA; OMIM #251000, CblA OMIM #251100, CblB 
#251110) and propionic aciduria (PA; OMIM #606054), carbamylphosphate synthetase 1 
deficiency (CPS1-D; EC 6.3.4.16; OMIM #237300), ornithine transcarbamylase deficiency 
(males and females) (OTC-D; EC 2.1.3.3; OMIM #311250), hyperammonemia-
hyperornithinemia-homocitrullinuria (HHH; OMIM #238970) syndrome, argininosuccinate 
synthetase deficiency (ASS-D; EC 6.3.4.5; OMIM #215700) and argininosuccinate lyase 
deficiency (ASL-D; EC 4.3.2.1; OMIM #207900) patients. We excluded patients with other 
inherited metabolic diseases, those with an unconfirmed suspicion of an OAD or UCD, those 
with MMA CblC and CblD subtypes and unclassified type. Other exclusion criteria were 
kidney and/or liver transplantation, treatment with growth hormone (n=6) and age over 18 
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years. Clinically symptomatic patients were defined as presenting with a metabolic crisis or 
long-term complications. 
 
2.2 | Data analysis 
Protein prescription was compared with the recommended daily allowance (RDA) as defined 
in the Protein and amino acid requirements in human nutrition (WHO Technical Report 
Series 935, 2007), and caloric prescription was compared with the RDA as defined in The 
National Research Council Washington DC, 2005 [33]. Total protein prescription was 
calculated by adding the prescription of natural and synthetic protein equivalents in the form 
of specialized amino acid mixtures and single amino acids (L-isoleucine, L-valine and/or L-
leucine) (SAA).  
Standard deviation scores (SDS) of height were calculated according to the LMS method [34], 
which provides a way of obtaining normalized growth centiles. The calculation of SDS for 
height was based on published reference data [35, 36]. We used the reference data of Cole 
et al, as they provide complete data for the whole age range examined. The reference data 
seemed applicable to our study cohort, as reference data were obtained from the UK, and 
most of the patients in our study are Caucasian Europeans. Plasma amino acid levels were 
compared with the amino acid reference values provided in table 2.1.5 of the Laboratory 
Guide to the Methods in Biochemical Genetics by Duran et al [37]. The protein-to-energy 
ratio (P:E ratio) is calculated on the basis of the amount of protein prescription (grams) per 
prescription of 100 kilocalories (kcal) per day. The values for natural P:E ratio were compared 
with values associated with optimal growth described by Evans et al, i.e., a P:E ratio ranging 
between 1.5 and 2.9 grams protein/100 kcal per day. 
On the basis of their metabolic amino acid disturbances and long-term treatment, patients 
with the following disorders were combined for analysis in four subgroups. The first 
subgroup consisted of patients with MMA/PA. These OADs are caused by defective enzyme 
activity in the breakdown in L-valine and L-isoleucine. These patients are generally treated 
with a protein-restricted diet supplemented either or not in combination with additional 
amino acid mixtures (AAM) (which lack L-isoleucine and L-valine (AAM-OAD)) and/or SAA. 
3
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The second subgroup consisted of patients with CPS-D, male OTC-D and HHH-syndrome 
and the third subgroup consisted of female patients with OTC-D, which were analyzed 
separately. Patients within both of these two subgroups are generally treated with a protein-
restricted diet supplemented with L-citrulline and/or L-arginine and when necessary with the 
essential amino acid mixtures for urea cycle disorders (contain essential amino acids) (AAM-
UCD). The fourth subgroup consisted of patients with ASS-D and ASL-D. Both disorders show 
high plasma L-citrulline levels, and are generally treated with a protein- restriction 
supplemented with L-arginine and when necessary with AAM-UCD.  
 
2.3 | Statistical analysis 
SPSS (IBM SPSS Statistics 24.0, IBM Corp., Armonk, NY, USA) was used for descriptive 
statistics (percentages, mean, standard deviation, median and range). Normality was 
examined using the Kolmogorov-Smirnov test and quantile-quantile (Q-Q) plots. Student’s t-
test was performed to compare means if distribution was Gaussian, and the Wilcoxon rank 
sum test (Ws) was performed if distribution was non-normal. Pearson’s correlation coefficient 
was used to evaluate the correlation between two Gaussian-distributed continuous variables, 
and Kendall’s tau rank correlation was used in the event of non-normal distributions. For the 
outcomes that were measured longitudinally, we used linear mixed effects models (multilevel 
analysis) to account for the correlations in the repeated measurements per patient. In 
particular, we used these models first to study the longitudinal evolutions of the height z-
score, and then to investigate the effect of dietary treatment and of plasma amino acid levels 
on normal growth.  
In our analysis of the effect of dietary treatment on height z-scores in MMA, PA the four 
fixed effects were 1) the natural P:E ratio; 2) prescription of synthetic protein as % RDA; 3) 
age at visit and 4) clinical symptomatic or not. In our analysis of the effect of dietary 
treatment on height z-scores in the UCD subgroups two other effects were added, namely 
whether L-arginine/L-citrulline therapy was applied or not and whether sodium 
phenylbutyrate was applied or not.  We also analyzed interactions in the ratio of fixed effects 
(age vs. prescription of natural-protein (g/kg/d) to total energy prescription (kcal/d), and age 
vs. synthetic protein as % RDA).  
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In our analysis of the effect of plasma amino acid levels on height z-scores in the MMA/PA 
patients, the six fixed effects were 1) age at visit, and levels of plasma 2) L-arginine, 3) L-
lysine, 4) L-leucine, 5) L-isoleucine and 6) L-valine. In our analysis of the effect of plasma 
amino acid levels on height z-scores in the UCD subgroups, the eight fixed effects were 1) 
age at visit, and levels of plasma 2) L-arginine, 3) L-lysine, 4) L-ornithine, 5) L-citrulline and 
plasma 6) L-leucine, 7) L-isoleucine and 8) L-valine. We also analyzed interactions in the fixed 
effects: age vs. plasma amino acid levels; L-arginine vs. L-lysine levels; L- isoleucine vs. L-
leucine levels; L-isoleucine vs. L-valine levels; and L-leucine vs. L-valine levels.  
For the random-effects structure we used a build-up approach, starting from random 
intercepts, and including random slopes with age and higher-order terms. The appropriate 
random-effects structure was chosen using the Akaike Information Criterion. SPSS (IBM SPSS 
Statistics 24.0, IBM Corp., Armonk, NY, USA) was used.  
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3 | Results  
3.1 | Description of the study population 
Two hundred and sixty-three MMA/PA patients and 311 UCD patients had been registered in 
the E-IMD registry between 1 February 2011 and 20 May 2016 (table 1, supplementary table 
1). At first visit registered, 196 patients with MMA/PA were symptomatic, as were 177 
patients with UCD, excluding female individuals with OTC-D. Fifty-six of the females patients 
with OTC-D—the only X-chromosomal UCD—were symptomatic. Close to fourteen percent 
of all MMA/PA and UCD patients combined had been diagnosed by newborn screening, 10% 
by high-risk family/population screening, 2% by prenatal screening, and the remaining 75% 
by selective metabolic testing. The majority of patients included were Caucasian (80%); the 
remainders were Asian (10%), African (3%), of mixed ethnicity (4%), and not stated (3%). 
Most patients were from Europe (95%), with the remainder from Taiwan (2%), the USA (2%), 
India (0.9%) and Japan (0.1%). In a cumulative number of follow-up visits of 969, a total of 
341 patients had been followed-up (161 MMA/PA patients and 180 UCD patients). Per 
patient, the mean follow-up time was 1.83 years (SD: 1.19). Median time from diagnosis till 
first visit was 5.10 year, ranging from a follow-up of 0.01 year up to 17.80 years. 
 
3.2 | MMA/PA 
3.2.1 | Body length at birth and height z-scores at  first visit registered 
Birth body-length z-score was close to normal in the MMA/PA patients (median: -0.52, 
range: -5.53-3.48) (supplementary figure 1). At first visit registered height z-score was below 
-2SD in 33% of the patients (table 1, supplementary figure 1). The lowest height z-scores 
were those of MMA patients with the MUT0 subtype (mean ± SD: -1.70 ±1.56) and cblB 
subtype (mean ± SD: -1.72 ±1.38) (supplementary table 2), and non-cobalamin responsive 
patients had lower height z-scores (mean ±SD: -1.69 ±1.59) than the cobalamin responsive 
patients (mean ±SD: -0.97 ±1.40) (F(117)=-2.479, p=0.015).  
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3.2.2 | Dietary treatment and height z-scores 
At first visit registered height z-scores did not differ between asymptomatic and 
symptomatic patients, neither between those with and without a protein restriction. Height 
z-score was lower in patients receiving AAM-OAD than in those who were not (Ws=13674.5, 
Z=-2.699, p=0.07). At first visit registered protein restriction (i.e., natural-protein % RDA) was 
more severe in symptomatic patients than in asymptomatic patients (Ws =17339.5, Z= -
2.379, p=0.017) and in patients receiving AAM-OAD than in those who were not receiving 
AAM-OAD (Ws=14339.0, Z=-2.087, p=0.037). Those patients receiving AAM-OAD had a 
median natural protein % RDA prescription of 110% RDA, ranging from 18-278% RDA. At 
first visit registered the mean caloric prescription in all patients was 105% RDA (± SD: 28). At 
first visit registered the median natural P:E ratio was 1.23, with a range of 0.37-3.33; and the 
median total P:E ratio was 1.83 (range: 0.63-4.56) (P:E ratio range of >1.5 to < 2.9 gram 
protein/100 kcal per day is associated with optimal growth [17]). The natural P:E ratio 
increased with age (rt(199)=0.146, p=0.003). Multilevel analysis showed that height z-score 
was positively associated with the natural P:E ratio (β-coefficient = 0.305, F(496.865)= 3.419, 
p=0.001) and negatively associated with the amount of synthetic protein as % RDA (β-
coefficient= -0.002, F(451.802)= -3.102, p=0.002) and with patient’s age at visit (β-
coefficient= -0.052, F(481.130)= -3.466, p=0.001).  
 
3.2.3 | Plasma amino acids: the association with dietary treatment and height z-scores 
In MMA/PA patients, plasma L-isoleucine and mainly plasma L-valine were decreased at first 
visit registered (figure 1A, B), with the lowest levels in MUT0 and cblB patients 
(supplementary table 2). Plasma L-arginine levels lay within reference values (figure 1D). At 
first visit registered patients receiving a protein-restricted diet had lower L-valine levels 
(F(151)=3.620, p<0.001) than those without protein restriction. Compared to those who were 
not receiving AAM-OAD, patients receiving AAM-OAD had lower L-valine (Ws=6302.0, Z=-
4.415, p<0.001) and L-isoleucine plasma levels (Ws=6697.5, Z=-3.245, p=0.001) at first visit 
registered. Multilevel analysis showed that height z-score was positively associated with 
patients’ plasma L-valine level (β-coefficient=0.005, t(350.759)=4.157, p<0.001) and L-
arginine level (β-coefficient=0.004, t(298.425)=3.203, p=0.002), and negatively associated 
3
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with their age at visit (β-coefficient= -0.033, t(144.698)=-2.064, p=0.041). At first visit 
registered MMA/PA patients with a height z-score <-2 had a median plasma L-arginine level 
of 43 µmol/L (range: 12-114) vs. a level of 59 µmol/L (range: 22-143) in those with a height z-
score >-2 (Ws=2502.0, Z=-3.546, p<0.001). In those patients with a height z-score <-2, the 
median plasma L-valine level 76 µmol/L (range: 24-290) at first visit registered vs. a level of 
94 µmol/L (range: 22-247) in those with height z-score >-2 (Ws=2996.5, Z=-2.822, p=0.005).  
 
Table 1. Overview of the included patients. 
Disease group Disease 
name 
Subtype Patients 
(n=) 
Age at 
baseline 
(years) 
(median; 
range) 
Symptomatic 
(n=/n total) 
OAD MMA Mut0 
Mut- 
cblA 
cblB 
86 
12 
24 
15 
4.1; 17.7 
5.1; 17.7 
5.2; 15.3 
6.1; 13.6 
66/81 
8/12 
15/23 
11/12 
 Total (MMA)  137 4.7; 17.7 100/128 
 PA Alfa  
Beta 
not classified 
27 
39 
60 
5.9; 17.0 
5.8; 16.4 
9.3; 17.8 
21/25 
31/38 
44/50 
 Total (PA)  126 6.3; 17.8 96/113 
 Total (OAD)  263 5.7; 17.8 196/241 
UCD CPS1-D  15 8.2; 17.2 14/15 
 OTC-D (m)  80 7.9; 17.9 57/71 
 OTC-D (f)  74 7.2; 17.9 56/69 
 ASS-D  77 4.7; 16.8 59/70 
 ASL-D  55 7.8; 17.8 39/49 
 HHH syndr.  10 4.6; 14.1 8/9 
 Total (UCD)  311 7.3; 17.9 233/283 
OAD + UCD Total  574 6.4; 17.9 429/524 
 Cross-sectional data, one measurement per patient at first visit registered 
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3.3 | Urea-cycle disorders 
3.3.1 | Body length at birth and height z-scores at first visit registered 
Birth body-length z-score was close to normal in all UCD patients combined (median: -0.12, 
range: -4.03-4.49) (supplementary figure 1). Birth length z-score did not differ significantly 
between OTC-D females and OTC-D males (supplementary table 3). In patients with UCD, 
height z-scores was lower in patients with cytosolic forms of UCD, i.e., ASS-D, ASL-D patients 
(mean z-score ± SD: -0.96 ±1.24) at first visit registered than in those with a mitochondrial 
form of UCD (mean z-score ± SD: -0.39 ± 1.28), i.e., CPS1-D and OTC-D patients, 
(F(264)=3.602, p<0.001). At first visit registered body height z-score in those with UCD did 
not differ between OTC-D females (mean ±SD: -0.36 ± 1.16) and OTC-D males (mean ±SD: -
0.20±1.43) (supplementary table 3).  
 
3.3.2 |  Dietary treatment and height z-scores 
At first visit registered height z-score did not differ between asymptomatic and symptomatic 
patients, those with and without a protein restriction, or those receiving AAM-UCD and those 
not receiving AAM-UCD in the following patients: those with CPS1-D, OTC-D males and 
those with HHH syndrome (subgroup 1); those with ASS-D and ASL-D (subgroup 2); and in 
OTC-D females (subgroup 3). In subgroup 1 (mean 118 ± SD: 41 vs. mean 149 ± SD: 57 
(F(73)=2.334, p=0.022)) and subgroup 2 (median 100, range: 38-261 vs. median 139, range: 
33-261 (Ws 3325, Z= -2.511, p=0.012)), the natural-protein prescription % RDA was lower in 
symptomatic patients than in asymptomatic patients at first visit registered. In subgroup 1, 
the mean energy prescription % RDA was 109.4 (± SD: 28.6); in subgroup 2 it was 109.5 (± 
SD: 35.5); and in OTC-D females it was 103.5 (± SD: 29.7). At first visit registered the median 
natural P:E ratio in all UCDs combined was 1.19 (range: 0.47-2.71); and the median total P:E 
ratio was 1.42 (range: 0.53-3.53) (P:E ratio range of >1.5 to < 2.9 gram protein/100 kcal per 
day is associated with optimal growth [17]). The natural P:E ratio increased with age 
(rt(191)=0.134, p=0.006). 
Multilevel analysis in subgroup 2 showed that height z-score was positively associated with 
the natural P:E ratio (β-coefficient=0.413, F(159.693)=2.066, p=0.040) and with the use of L-
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arginine (β-coefficient=0.624, F(132.042)=2.144, p=0.034). In all UCDs combined, multilevel 
analysis showed that height z-score was positively associated with the natural P:E ratio (β-
coefficient=0.224, F(336.091)=2.100, p=0.036).   
 
3.3.3 |  Plasma amino acids: the association with dietary treatment and height z-
scores 
In the CPS1-D, OTC-D male and HHH-syndrome subgroup, patients’ plasma L-leucine levels 
(F(72)=-3.290, p=0.002) and L-isoleucine levels (F(14.748)=-5.420, p <0.001) were lower in 
those receiving protein restriction at first visit registered than in those who were not. In OTC-
D females, plasma L-valine levels (F(52)= 4.726, p<0.001), L-isoleucine levels (F (53)= 4.700, 
p<0.001) and L-leucine levels (F(53)= 5.675, p<0.001) were lower in those with a protein-
restricted diet than in those without. In all UCD subgroups, patients receiving sodium 
phenylbutyrate had lower plasma L-valine, L-isoleucine and L-leucine levels at first visit 
registered than those who were not receiving it, except for L-isoleucine levels in the CPS1-D, 
OTC-D male and HHH syndrome subgroup (supplementary table 4). 
 
Multilevel analysis in the CPS1-D, OTC-D male, and HHH-syndrome subgroup showed that 
height z-score was positively associated with patients’ plasma L-leucine levels (β-
coefficient=0.012, t(84.130)= 3.107, p=0.003). In the CPS1-D, OTC-D male, and HHH-
syndrome subgroup patients with a height z-score <-2 at first visit registered had a mean 
plasma L-leucine level of 62 µmol/L (SD: 37) vs. a level of 93 µmol/L (SD: 36) in those with a 
height z-score >-2 (F(72)=-2.314, p=0.024). 
Multilevel analysis in the ASS-D, ASL-D subgroup showed that height z-score was positively 
associated with patients’ plasma L-valine levels (β-coefficient=0.006, t(144.875)= 2.367, 
p=0.019). In the ASS-D, ASL-D subgroup patients with a height z-score <-2 at first visit 
registered had a mean plasma L-valine level of 104 µmol/L (SD: 367) vs. a level of 139 µmol/L 
(SD: 45) in those with a height z-score >-2 (F(85)=-2.879, p=0.005). 
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4 | Discussion 
Patients with MMA/PA and UCD, treated with a protein restricted diet, are prone to growth 
failure. To obtain optimal growth and thereby efficacious protein incorporation a diet 
containing the essential and functional amino acids for growth is necessary. Optimal growth 
will result in improved protein tolerance and possibly a decrease in the number of 
decompensations. As essential and functional amino acids are important to growth and 
amino acid deficiencies are described in MMA/PA and UCD, the purpose of this longitudinal 
study was to establish how dietary treatment and plasma L-arginine, L-lysine and plasma 
BCAA levels are associated with height z-scores. 
There were four main findings. First, a higher natural P:E ratio was positively associated with 
height z-score in MMA/PA patients and in all UCD patients combined. Second, height z-
scores at first visit registered in MMA/PA as well as in the UCD subgroups did not differ 
significantly between those with a protein restricted diet and those without. Third, height z-
score in MMA/PA patients was positively associated with their plasma L-valine and L-arginine 
levels. Fourth, while height z-score was positively associated with patients’ plasma L-leucine 
levels in patients in the CPS1-D, OTC-D male and HHH- syndrome subgroup, it was positively 
associated with patients’ plasma L-valine levels in those in the ASS-D, ASL-D subgroup. 
 
The results show that a higher natural P:E ratio is associated with improved height z-score. 
Although this is in line with a study published by Evans et al [17], we found that the natural 
P:E ratio in the patients in this study lay below the ratios associated with optimal growth 
described by Evans et al,  implying room for improvement. Natural protein prescription is 
often close to and/or according to the recommended daily allowances by the World Health 
Organisations (WHO) [32, 33]. However, the proteins commonly used by MMA/PA and UCD 
patients are of low biological value and poorly digestible [38]. Whether or not the natural 
protein prescription could be further increased is currently unknown. It is possible that 
patients are over-restricted in their natural protein prescription and/or they receive protein 
of too low biological value. We did not find a significant difference in height z-scores 
between those with and without a protein restricted diet. Other factors could be important, 
such as the P:E ratio. Severely affected patients could be prescribed a higher energy diet, in 
order to compensate for the decreased natural protein prescription and/or protein aversion, 
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to avoid catabolism and thereby resulting in an inappropriate P:E ratio [38]. The high caloric 
prescription can also be harmful by causing long-term complications such as obesity and 
liver steatosis.  
As stated above, BCAAs are essential to optimal growth [19, 39]. MMA/PA patients show that 
a protein-restricted diet was associated with lower plasma levels of BCAA. In MMA/PA 
patients, we observed a mean plasma L-valine level of 94 µmol/L in those whose height was 
> -2SD. This suggests that even a small increase in plasma L-valine towards lower levels of 
normal could help improve growth. MMA/PA patients receiving AAM-UCD had a lower 
natural-protein prescription and lower plasma BCAA levels than those who were not [32]. 
Our data also show that height z-score was lower in MMA/PA patients receiving AAM-OAD 
than in those who were not, underlying the importance of BCAA for optimal growth. Use of 
AAM-OAD products could also be harmful due to disturbed plasma BCAA ratios [32, 40]. 
Close monitoring of plasma BCAA and ratio levels and growth and development is extremely 
important.  
 
In UCD patients our results show that a protein-restricted diet was associated with lower 
plasma levels of BCAA in the following: in the CPS1-D, OTC-D male and HHH-syndrome 
subgroup and in OTC-D females. Insufficient protein prescription/intake can cause growth 
restriction due to low BCAA plasma levels. In UCD patients sodium phenylbutyrate is known 
to be associated with lower plasma BCAA levels and specific attention and monitoring of 
plasma BCAA levels [30, 32] and growth in these patient group is highly important. In UCD 
patients, plasma L-valine and L-leucine levels in low/below normal range were associated 
with height z-score <-2SD and levels in higher normal ranges with height z-score >-2SD. In 
UCD patients, AAM-UCD products contain BCAAs and can be beneficial to those with low 
BCAA levels [32]  and growth restriction.  
As well as being associated with height z-score, low plasma BCAA levels can cause metabolic 
decompensations [41], seem essential for optimal functioning of the central nervous system 
[42-44] and may be important to mitochondrial function in young people [45]—a 
characteristic that may play a role in disease progression, since mitochondrial dysfunction is 
a presumable cause of long-term complications in OAD and UCD [46-51].  
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In view of the metabolic defect, it may not always be possible to optimize MMA/PA patients’ 
plasma L-valine levels. Our data showed that plasma L-arginine levels in MMA/PA patients 
were associated with height z-scores. To date, there have been no evidence-based 
recommendations for plasma L-arginine levels in MMA/PA patients, and our current data do 
not make it easy to give advice on 1) plasma levels that will stimulate growth efficiently and 
2) treatment recommendations on L-arginine supplementation in MMA/PA patients. In the 
study by van Vught, patients who consumed a dose of L-arginine between 2.8 and 3.2 g/day 
grew faster than those who consumed less than 2.2 g/day [21]. However, the study in 
question was performed in healthy children, and its data do not provide a reliable basis for 
recommendations on L-arginine intake in MMA/PA patients. On the basis of the plasma L-
arginine levels in those patients with a height z-score < -2SD compared to those with a 
height z-score > -2SD, we suggest that it could be beneficial to achieve plasma L-arginine 
levels within high normal range in order to stimulate growth. Second, since the consumption 
of functional amino acids such as L-arginine is greater than their production during 
pathologic conditions and growth [52], adequate intake is essential in these circumstances 
[18, 53].  
As well as stimulating the production of growth hormone [21, 22, 54], L-arginine has several 
other characteristics, such as being a precursor for the production of nitric oxide—an 
important signaling molecule—, and of creatine [54] and improving anti-oxidant defenses 
[55, 56]—a characteristic that, in view of the presumed mitochondrial dysfunction in the 
development of long-term complications, may ameliorate the hazardous progression of the 
disease [47, 51, 57-59]. Importantly, L-arginine supplementation can have adverse effects 
[52], such as the induction of hypoglycemia and excessive production of nitric oxide, which 
can lead to the formation of peroxynitrite [60].  
It seems essential to monitor plasma L-arginine levels and verify its possible effect on 
growth. Further research should then be performed to define recommendations on plasma 
L-arginine levels and investigate whether increasing natural protein intake is feasible or 
supplementation of L-arginine is a safe method. Thereafter it is necessary to delineate 
whether chronic L-arginine supplementation is required or should be restricted to sick-day 
management. Careful dosing of L-arginine is essential in order to avoid side effects. 
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Our study and the E-IMD registry had seven main limitations. First, while the E-IMD registry 
provides an option for mentioning the use of growth hormone therapy, in relatively few 
patients (n=6) growth hormone was prescribed, which may represent an underestimation of 
the true number of patients using growth hormone. Second, while the E-IMD registry 
contains detailed information on dietary prescriptions, it does not describe the patients’ real 
daily intake and consequently there was no information on the quality of the natural protein 
consumed. Furthermore, between the different centers practice in dietary treatment can vary 
broadly. Third, the first entry does not reflect the amount of time since diagnosis or dietary 
treatment and consequently dietary treatment could have been inadequate or different prior 
to the first assessment. Fourth, the E-IMD registry does not include time between the last 
meal and the measurement of amino acids. Fifth, due to the high number of participating 
centers, plasma amino acids levels are determined by various methods, and different 
reference values are used. There was no documentation or standardization of the process for 
collection of these amino acids and we did not assess the correctness of measurements and 
the differences between contributing laboratories. However, most laboratories participate 
regularly in external quality assessment (ERNDIM). Sixth, due to the use of the E-IMD registry 
rather than a prospective cohort data are missing. The cross-sectional analysis was done on 
the available data and is only valid under the missing completely at random assumption. 
Finally, the follow-up period for some patients was relatively short and furthermore the 
registry it does not include target height, which would have enabled us to obtain more 
patient specific height z-scores and the follow-up of patients was relatively short.  
Our results are not only important to the MMA/PA and UCD patients but could be of 
importance for intrauterine growth and for children with other chronic diseases with 
(resulting) growth restriction. Amino acid deficiencies, and especially arginine, have proven 
to play an important role in intrauterine growth restriction [61, 62] and plasma L-arginine 
plays an important role in renal disease and short bowel syndrome [63, 64]. 
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5 | Conclusion 
Plasma L-arginine and L-valine levels in MMA/PA patients and plasma L-valine and L-leucine 
levels in UCD patients were positively associated with height z-scores. To make it possible to 
formulate recommendations on plasma L-arginine levels, plasma BCAAs levels and optimal 
natural protein intake (and P:E intake ratio) and to determine whether supplementation of L-
arginine and BCAA in MMA/PA and UCD patients could be an important and safe method, 
further research should be performed. 
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Supplemental tables and figures 
 
Supplementary Figure 1. Body length (z-score) at birth (light grey) vs. height at first visit 
registered (dark gray) in UCDs and MMA/PA. 
 
Circles, outliers; horizontal line, median; whiskers: 5-95 percentile; * p<0.05.  
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HOW TO MONITOR DISEASE 
SEVERITY IN MMA AND PA PATIENTS 
Fibroblast growth factor 21 as a biomarker for  
long-term complications in organic acidemias. 
5
Abstract                 
Background: There is increasing evidence that long-term complications in organic acidemias 
are caused by impaired mitochondrial metabolism. Currently, there is no specific biomarker 
to monitor mitochondrial dysfunction in organic acidemias. Serum fibroblast growth factor 
21 (FGF-21) is a biomarker for mitochondrial disease and could be a candidate to monitor 
mitochondrial function in the deleterious course of disease.  
 
Methods: Data of 17 patients with classical organic acidemias (11 propionic acidemia (PA), 4 
methylmalonic acidemia (MMA) and 2 isovaleric acidemia (IVA) patients) were included. The 
clinical course was evaluated; metabolic decompensations and long-term complications were 
correlated with plasma FGF-21 levels. Cardiomyopathy, prolonged QT interval, renal failure 
and optic neuropathy were defined as long-term complications.  
 
Results: Patients ages ranged from 16 months up to 32 years. Serious long-term 
complications occurred in 8 patients (5 PA and 3 MMA patients). In MMA and PA patients 
plasma FGF-21 levels during stable metabolic periods were significantly higher in patients 
with long-term complications (Mdn = 2556.0 pg/ml) compared to patients without (Mdn = 
287.0 pg/ml). A median plasma FGF-21 level above 1500 pg/ml during stable metabolic 
period, measured before the occurrence of long-term complications, had a positive 
predictive value of 0.83 and a negative predictive value of 1.00 on long-term complications 
in MMA and PA patients. 
 
Conclusion: This study demonstrates the potential role of FGF-21 as a biomarker for long-
term complications in classical organic acidemias, attributed to mitochondrial dysfunction.  
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Chapter 5
1 | Introduction 
The branched chain amino acids isoleucine, valine and leucine are essential nutrients for 
human growth and development [1]. The enzymes methylmalonyl-CoA mutase, propionyl-
CoA carboxylase and isovaleryl-CoA dehydrogenase play pivotal roles in the metabolism of 
these amino acids. Deficiencies of these enzymes result in three classic organic acidemias, 
methylmalonic acidemia (MMA; OMIM #251000, #251100, #251110, #277400, #277410), 
propionic acidemia (PA; OMIM #606054) and isovaleric acidemia (IVA; OMIM #243500). 
MMA and PA are characterized by the potentially lethal accumulation of toxic metabolites, 
mainly 2-methylcitric acid, malonic acid and propionyl-CoA [2, 3].  
The treatment mainly consists of protein reduction as well as avoidance of catabolism, and 
survival has greatly improved beyond childhood [4, 5]. However the prognosis is still 
unsatisfactory with a high rate of severe long-term complications such as renal failure, 
cardiac arrhythmias, cardiomyopathy, optic nerve atrophy with vision loss, pancreatitis and 
mental retardation [6-9]. The protein restricted diet may also cause complications, such as 
failure to thrive [10, 11]. Mitochondrial dysfunction has been established in the 
pathophysiology of all long-term complications [2, 12-22]. Occurrence of mental retardation 
is most likely multifactorial, for example cerebral damage during decompensations with 
metabolic encephalopathy [23], cerebral accumulation of toxic metabolites [24, 25] and 
presumably mitochondrial dysfunction [12, 13] .   
The demonstration of mitochondrial dysfunction is essential to improve the understanding 
of long-term complications and could be of major importance to develop and potentially 
evaluate (preventive) treatment strategies by identifying risk groups. The most reliable 
available evaluation of mitochondrial dysfunction is histological and biochemical assessment 
of a muscle biopsy. However, muscle biopsies are considered invasive and not acceptable for 
follow up of mitochondrial dysfunction over the years. Current plasma biomarkers, such as 
creatine kinase, lactate, pyruvate, alanine and proline levels, and the lactate to pyruvate ratio, 
have a low sensitivity and specificity [26-28]. Serum fibroblast growth factor 21 (FGF-21) has 
been suggested as a biomarker for mitochondrial disease. Serum FGF-21 is stable with 
respect to processing and storage, has a higher specificity and sensitivity compared to other 
biomarkers and is fast and inexpensive to determine [26, 29-35]. We studied the potential of 
serum FGF-21 measured in stable metabolic period as a biomarker for long-term 
complications, attributed to mitochondrial failure, in patients with organic acidemias.   
5
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2 | Methods  
2.1 | Study design 
A total of 17 patients (adults and children) attending the outpatient clinic of the metabolic 
center of the Erasmus University Medical Center, were selected. Thereafter FGF-21 
measurements were done in leftover plasma samples previously collected and stored in the 
laboratory biobank for research purposes. Of the 17 patients included: 11 were known with 
PA (case 1-11), 4 with MMA (case 12-15) and 2 with IVA (case 16 and 17). The clinical courses 
and other laboratory findings were obtained from the medical files. The study was assigned 
as non-Medical Research Involving Human Subjects Act (WMO) by the Medical Ethical 
Committee (METC) of the Erasmus University Medical Center. Patients and/or parents of the 
patients gave permission for publication of their anonymous clinical and laboratory data. 
Patients and/or parents were informed and aware of the use of left over material for research 
to which none objected. Cardiomyopathy, prolonged QT interval, renal failure and optic 
neuropathy were defined as long-term complications. Severe mental retardation and growth 
failure were not defined as long-term complications. A severe decompensation was defined 
as a blood pH level below 7.1 and/or ammonia levels above 400 µmol/L [8]. Total protein 
intake was defined as natural plus synthetic protein intake.  
 
2.2 | Data and statistical analysis 
For diagnostic purposes, propionyl-CoA carboxylase activities were measured in fibroblasts 
at the Section Genetic Metabolic Diseases of the Erasmus University Medical Center, 
Rotterdam, The Netherlands. The propionyl-CoA carboxylase activity measurement is based 
upon the incorporation of  14C-labeled CO2 (given in the form of 14C-labeled sodium 
carbonate) within the substrate propionyl-CoA. The excess CO2 that was not incorporated 
was removed by acidification. At the same time, the incorporation of CO2 was also measured 
with pyruvate and with methylcrotonoyl as the substrate.  The isovaleryl-CoA dehydrogenase 
activities were measured in lymphocytes based upon the anaerobic electron transfer 
flavoprotein fluorescence reduction assay at the Laboratory for Genetic Metabolic Diseases, 
Academic Medical Center, Amsterdam, The Netherlands. Serum levels of FGF-21 were 
determined in duplicate using a commercial ELISA kit (Millipore) which is also applied in our 
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diagnostic process. To establish reference ranges two hundred control subjects were studied, 
covering all ages, including newborns. Positive controls were 50 patients with a 
mitochondrial disorder known with an increased plasma FGF-21 level. We established a 
reference range of 0-200 pg/ml for healthy subjects, which coincides with that of 
Suomalainen et al [29]. The samples were measured in duplicate and no significant 
differences between samples (inter-sample variability) were found. Plasma FGF-21 levels up 
to 3000 pg/ml were linear and measurements were reproducible up to 4000 pg/ml. Higher 
plasma FGF-21 level than 4000 pg/ml were therefore cut off to a value of 4000 pg/ml. Total 
protein intake estimated at several time points was based on dietary prescription by a 
trained metabolic dietitian during standard care, results were compared to the WHO 
recommended daily allowance (RDA) [36]). Plasma amino acid levels measured during the 
standard of care were obtained from the medical records to determine nutritional status, and 
based on reference levels expressed as low (below normal reference level), normal (within 
reference level) or elevated levels (above reference level). The patients with MMA and PA 
were selected to assess the association of plasma amino acid levels and plasma FGF-21 
levels. Data were summarized by frequencies, median and means with standard deviation 
(SD). Normal distribution was examined by Kolmogorov-Smirnov tests and quantile-quantile 
(Q-Q) plots.  Student’s t-tests were performed to compare means in case of Gaussian and 
Wilcoxon rank sum tests (Ws) in case of non-normal distributions. Pearson’s correlation 
coefficient was used to evaluate the correlation between two Gaussian distributed 
continuous variables and Kendall’s tau rank correlation (rτ) in case of non-normal 
distributions. Paired sample t-tests were performed to compare plasma FGF-21 levels in 
stable metabolic periods to levels in decompensations within each patient. In analyzing 
positive predictive value, negative predictive value and odds ratios on the occurrence of 
long-term complications, we included plasma FGF-21 measurements during stable metabolic 
periods prior to the development of long-term complications in MMA and PA patients. In 
defining an optimal cut off point value for FGF-21 we used a receiver operating characteristic 
(ROC) curve (defining the plasma FGF-21 level with optimal sensitivity and specificity). Since 
protein restriction may infer FGF-21 increases and since especially leucine and methionine 
restriction are associated with FGF-21 increase [37],  Kendall’s tau rank correlation was 
calculated to test the correlation of total protein intake and methionine or leucine 
concentrations with plasma FGF-21 levels for each patient individually. Furthermore, we 
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tested the association of other nutritional parameters, namely valine, isoleucine, alanine, 
phenylalanine, proline and threonine, with plasma FGF-21 levels. P-values smaller than 0.05 
were considered to indicate statistical significances. SPSS data manager (version 24) was 
used for statistical analyses.  
 
3 | Results 
3.1 | Description of the study population 
Patient characteristics of all 17 patients with organic acidemia are presented in table 1. Four 
patients were diagnosed by family or selective newborn screening and one patient was 
diagnosed prenatally. Eight patients (six with PA and two with MMA) presented in the 
neonatal period. Two of these patients were initially on mechanical ventilation and one was 
dialyzed. A total of four patients presented in childhood. These patients presented either 
with complaints of vomiting, malaise and weight loss; with gastro-esophageal reflux, with 
encephalopathy or coma.  
Sixteen patients showed a mild clinical course with no severe decompensations after the 
initial presentation (table 1). One patient (case 10) died in the neonatal period during the 
first severe decompensation due to a refractory hemodynamic shock and hyperammonemia. 
Despite good metabolic control, 8 of the remaining 16 patients developed long-term 
complications (table 2). The mean age at the first long-term complication was 8.0 years (± 
SD: 3.4). Five PA patients developed cardiac complications, four of them (case 1, 2, 4 and 8) 
developed cardiomyopathy between 8 and 13 years of age. In one patient (case 2) this was 
unexpected as she was diagnosed prenatally by selective screening and she always showed 
good metabolic control. A rapidly progressive dilated cardiomyopathy lead to cardiac failure 
and death at eight years of age, four months after the diagnosis of cardiomyopathy. Case 8 
had mild cardiomyopathy, but died during a severe metabolic decompensation at the age of 
twelve years. One patient had prolonged QT interval without signs of cardiomyopathy. Four 
patients developed renal failure between the age of 11 months and 12 years of age. Two 
patients developed optic neuropathy, both at the age of 16 years. One of them was also 
known with reduced left ventricular function, and the other patient was already known with 
renal failure.  
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3.2 | Overview of FGF-21 levels and long-term complications 
A total of 62 FGF-21 measurements were performed in the 17 patients. Plasma FGF-21 levels 
were determined before the onset of long-term complications in 7 of the 8 patients with 
long-term complications (figure 1a). In the remaining patient, FGF-21 measurements were 
performed in samples obtained after long-term complications had occurred (figure 1a). All 
FGF-21 levels from samples retrieved before long-term complications developed, were 
elevated (figure 1a). In two patients (case 1 and 2) plasma FGF-21 levels were already 
elevated, up to 10 times the upper level of normal, from the neonatal period onwards and 
remained at the same level with older age. In one patient (case 3) plasma FGF-21 levels 
increased rapidly from the neonatal period up to eight months of age and remained high 
thereafter. In another patient (case 8), plasma FGF-21 levels were extremely high before 
complications and decreased thereafter, as previously mentioned, she eventually died of 
dilated cardiomyopathy. One patient (case 11) demonstrated high plasma FGF-21 levels 
during stable disease, at that time point without long-term complications. In an IVA patient 
without long-term complications (case 16) the highly elevated plasma FGF-21 levels taken 
during a metabolic decompensation normalized thereafter (figure 1b).  
In MMA and PA patients median plasma FGF-21 levels (of each patient) during stable 
metabolic periods were significantly higher in patients with long-term complications during 
follow up (median FGF-21= 2556.0 pg/ml) compared to those who did not develop 
complications (median FGF-21 = 287.0 pg/ml) (Ws=29.00, Z=-2.066, p =0.039) (figure 2a). In 
MMA and PA patients the individual mean plasma FGF-21 levels during stable metabolic 
periods (M=2600, SD=843) did not differ from the individual median plasma FGF-21 levels 
during decompensations (M=2309, SD=619) (t(6)=0.566, p=0.592). None of the patients with 
a median plasma FGF-21 below 1500 pg/ml during stable metabolic period (n=5) developed 
long term complications. All, but one patient, developed long-term complications in those 
with a median plasma FGF-21 above 1500 pg/ml (n=5) (samples taking during stable 
metabolic period prior to the occurrence of long-term complications) in MMA and PA 
patients (supplemental figure 1). A median plasma FGF-21 level above 1500  pg/ml during 
stable metabolic period, measured before the occurrence of long-term complications, has a 
positive predictive value of 0.83 on long-term complications and a negative predictive value 
of 1.00 in MMA and PA patients. 
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FIGURE 1. FGF-21 levels during disease progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dots represent patients with long-term complications (a) and squares those without (b). Colors of the 
lines define the different patients. Vertical gapped line indicates the occurrence first complication 
(figure 1a). 
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3.3 | Renal function and FGF-21  
Plasma creatinine levels did not correlate with plasma FGF-21 levels within the individual 
patient. Nor did the median plasma FGF-21 level of each patient correlate with the median 
plasma creatinine level of each patient. 
 
3.4 | Protein restriction and FGF-21 
Total protein intake (g/kg/day) did not correlate with plasma FGF-21 levels in any patient nor 
did median total protein intake (of each patient) correlate with median plasma FGF-21 levels 
(of each patient). Furthermore, total protein intake as %RDA was not associated with plasma 
FGF-21 levels, except in one patient (case 3) (rτ(9)=0.957, p<0.001) (supplemental figure 2). 
In MMA and PA plasma valine levels were low in the majority of the patients (supplemental 
figure 3). In MMA and PA, plasma FGF-21 levels were not lower in patients with low plasma 
amino acids levels; valine, isoleucine, leucine, methionine, threonine, alanine, phenylalanine 
and proline, respectively (supplemental figure 3). Individual plasma amino acid levels were 
not associated with plasma FGF-21 levels, except for one patient (case 16). In this patient, all 
three branched chain amino acids (BCAA) were associated with plasma FGF-21 levels (valine 
(r(8)=-0.643, p=0.026), isoleucine (r(8)=-0.618, p=0.034), leucine (r(8)=-0.618, p=0.034)).  
 
3.5 | Age, height and FGF-21 
There is no clear association of plasma FGF-21 levels and age of the patient, in patients with 
long-term complications (data not shown) as well as in patients without long-term 
complications (figure 1b). In 16 of 17 patients growth charts were available. Six out of these 
sixteen patients had moderate to severe growth retardation (table 2). In all of the patients 
height z-score did not correlate with plasma FGF-21 levels. The median plasma FGF-21 levels 
did not differ significantly in patients with growth retardation (z-score <-2SD) compared to 
patients without growth retardation (data not shown).  
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4 | Discussion 
This study demonstrates that FGF-21 can be a biomarker for long-term complications, 
attributed to mitochondrial dysfunction, in classic organic acidemia patients. Plasma FGF-21 
levels were high in stable metabolic periods in patients with long-term complications, this 
was well before the onset of these complications. A median plasma FGF-21 level above 1500  
pg/ml during stable metabolic period, measured before the occurrence of long-term 
complications, had a positive predictive value of 0.83 on long-term complications and a 
negative predictive value of 1.00 and an odds ratio of 5.0. Plasma FGF-21 levels were not 
associated with growth, nutritional status or renal function.   
Our results give additional proof to the hypothesis that mitochondrial dysfunction plays a 
role in long-term complications in classical organic acidemia patients [2, 12-21, 38-40]. 
Plasma FGF-21 levels were high in PA patients before they developed long-term 
complications, both before severe complications (such as lethal cardiomyopathy) and before 
milder complications (prolonged QT interval and slight left ventricular hypertrophy). Our 
observation of high plasma FGF-21 levels in a patient with QT prolongation, suggesting a 
role of mitochondrial dysfunction, is in line with Baumgartner et al. [41]. In MMA, the renal 
complications and the high plasma FGF-21 levels could point forward a role of mitochondrial 
dysfunction in renal failure, which was also proposed by others [15]. Kölker et al. have 
suggested that mitochondrial dysfunction is not caused by a direct toxicity of methylmalonic 
acid but by inhibition of the respiratory chain by 2-methylcitric acid, malonic acid and 
propionyl-CoA, which are increased in MMA as well [3]. Furthermore, plasma FGF-21 levels 
can be elevated in chronic as well as acute kidney disease and an association between 
plasma FGF-21 levels and estimated glomerular filtration rate has been found in non OAD 
patients [42]. In our patient population we did not observe an association between plasma 
FGF-21 levels and renal function plasma (creatinine levels). Furthermore, plasma FGF-21 
levels were already elevated before the occurrence of kidney failure and nor was there an 
increase in plasma FGF-21 levels when renal function deteriorated.    
In stable metabolic periods there is a clear difference in plasma FGF-21 levels in patients with 
long-term complications compared to those without. Importantly, in this patient cohort the 
majority of long-term complications occurred between 7 and 9 years of age. This suggests 
that by determination of plasma FGF-21 levels in stable metabolic period in early childhood 
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we can potentially identify risk groups for long-term complications. In stable metabolic 
period only one patient (case 11) had high plasma FGF-21 levels without long-term 
complications. This patient had his latest visit at the age of 4 years and based on our results 
and the occurrence of long-term complications mainly between 7 and 9 years of age, this 
patient can be identified as a potential risk patient for long-term complications. During 
decompensation, one patient (case 16) had a severe increase in plasma FGF-21 levels, which 
normalized thereafter. The high plasma FGF-21 levels in this case, could be due to either the 
decompensation itself or the increased rigorousness of protein restriction; the last was also 
reflected by the decreased plasma BCAA levels observed during this decompensation. Based 
on our results, we recommend to measure plasma FGF-21 levels in stable metabolic periods. 
A median plasma FGF-21 level above 1500 pg/ml measured during stable metabolic period, 
before the occurrence of long-term complications, seems to predict long-term 
complications. The negative predictive value of 1.00 observed in this patient cohort should 
be interpreted with respect to the follow-up time and the fact that long-term complications 
can occur at later disease stage. 
A total of three patients had died, one during the neonatal period (case 10), the others at the 
age of 8 (case 2) and 12 years (case 8) respectively. Case 8 had initially highly elevated 
plasma FGF-21 levels in stable conditions, which decreased over the years until the patient 
died due to lethal cardiomyopathy. This decrease in plasma FGF-21 plasma levels might be 
the consequence of the potentially lethal mitochondrial dysfunction.  
In none of the MMA and PA patients, an association between plasma FGF-21 levels and 
nutritional status, with respect to protein intake and plasma levels of BCAA, alanine, 
phenylalanine, methionine, threonine and proline, was found.  
There are some potential limitations of this study. Firstly, a retrospective study design cannot 
make causal inferences and therefore a prospective study is required to confirm our 
observations. Secondly, this retrospective design could lead to a selection bias and the 
relatively small number of patients studied could lead to low internal validity.  
This study provides a first insight into a potential biomarker for long-term complications in 
organic acidemias. Long-term complications occur despite good metabolic control [16, 43]. 
We suggest that mitochondrial dysfunction is an ongoing process independent of metabolic 
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control. It is important to focus on the role of preventive treatment strategies. A potential 
preventive therapy is anti-oxidants administration. To date, the beneficial efficacy of anti-
oxidant therapies varies, ranging from improvement of long-term complications to no 
beneficial effect [18, 39, 40, 44]. Absence of therapy efficacy can be due to the relative late 
initiation of anti-oxidants in disease progression. First, the results observed in this study, 
namely the association between plasma FGF-21 levels and the occurrence of long-term 
complications as well as the high positive and negative predictive value of a median plasma 
FGF-21 level above 1500 pg/ml, should be replicated in another cohort of classical organic 
acidemia patients. Other biomarkers for mitochondrial dysfunction, like growth 
differentiation factor 15 (GDF-15), should be included in order to identify their role and 
relation with the occurrence of long-term complications in these disorders and compare it to 
plasma FGF-21. Once the FGF-21 results are confirmed and role of GDF-15 established, 
further research should determine if FGF-21 or other mitochondrial markers could play a role 
in the evaluation of preventive strategies concerning the consequences of mitochondrial 
impairment, and if FGF-21 plays a pathogenic role in the development of mitochondrial 
impairment.   
 
5 | Conclusion 
This study provides new insights into the potential role of FGF-21 as a biomarker for 
predicting long-term complications in organic acidemias. Increased plasma FGF-21 levels 
and long-term complications are attributable to mitochondrial dysfunction. Further research 
should be performed in another cohort of patients to verify our observations and to 
investigate the potential role of FGF-21 as a biomarker of (preventive) treatment efficacy. 
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Supplemental tables and figures 
 
Supplemental figure 1. Survival curve (percentage of non-occurrence of long-term 
complications). 
 
Percentage at x-axis defines the total percentage of those without long-term complications. The 
occurrence of long-term complications in patients with a median FGF-21 level above 1500 pg/ml (= 
high), measured during stable metabolic period before the onset of long-term complications, versus 
patients with a median FGF-21 below 1500 pg/ml (= low) measured during stable metabolic period.  
 
Supplemental figure 2. Plasma FGF-21 levels compared to total protein intake %RDA in case 3.   
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NEWBORN SCREENING IN MMA 
AND PA PATIENTS
Retrospective evaluation of the Dutch pre-newborn 
screening cohort for propionic acidemia and isolated 
methylmalonic acidemia: what to aim, expect and evaluate 
from newborn screening? 
6J Inherit Metab Dis. 2019 Dec 11. 
Abstract 
 
Background: Evidence for effectiveness of newborn screening (NBS) for propionic acidemia 
(PA) and isolated methylmalonic acidemia (MMA) is scarce. Prior to implementation in the 
Netherlands, we aim to estimate the expected health gain of NBS for PA and MMA. 
 
Methods: In this national retrospective cohort study, the clinical course of 76/83 Dutch PA 
and MMA patients, diagnosed between January 1979 and July 2019, was evaluated. Five 
clinical outcome parameters were defined: adverse outcome of the first symptomatic phase, 
frequency of acute metabolic decompensations (AMD), cognitive function, mitochondrial 
complications and treatment-related complications. Outcomes of patients identified by 
family testing were compared with the outcomes of their index siblings. 
 
Results: An adverse outcome due to the first symptomatic phase was recorded in 46% of the 
clinically diagnosed patients. Outcome of the first symptomatic phase was similar in 5/9 
sibling pairs and better in 4/9 pairs. Based on the day of diagnosis of the clinically diagnosed 
patients and sibling pair analysis, a preliminary estimated reduction of adverse outcome due 
to the first symptomatic phase from 46% to 36-38% was calculated. Among the sibling pairs, 
AMD frequency, cognitive function, mitochondrial and treatment-related complications were 
comparable. 
 
Discussion: These results suggest that the health gain of NBS for PA and MMA in overall 
outcome may be limited, as only a modest decrease of adverse outcomes due to the first 
symptomatic phase is expected. With current clinical practice, no reduced AMD frequency, 
improved cognitive function or reduced frequency of mitochondrial or treatment-related 
complications can be expected.  
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1 | Introduction 
Propionic acidemia (PA, OMIM #6060054) and isolated methylmalonic acidemia (MMA, 
OMIM #251000, #251100, #251110, #277400 and #277410) are caused by enzyme and 
cofactor deficiencies involved in propionyl-CoA breakdown. The clinical course usually starts 
with an acute metabolic decompensation (AMD) in the neonatal period (early onset, EO) or 
thereafter (late onset, LO) [1]. The first symptomatic phase frequently causes irreversible 
neurological damage, manifesting as movement disorders in varying severity and/or 
psychomotor retardation. This neurological damage is often reflected by white matter lesions 
and/or basal ganglia hyperintensities on brain imaging. In addition, the clinical course is 
characterized by frequent AMD, cognitive deficits and long-term complications [2]. 
A diagnosis before the first symptomatic phase, feasible through newborn screening (NBS), 
could theoretically prevent the neurological damage [3]. However, the majority of patients is 
symptomatic well before NBS results can be available, limiting the potential gain [4, 5]. Four 
studies described the potential additional value of NBS, but each with limited sample sizes 
and follow-up time [6-9], resulting in controversy about the potential effectiveness of NBS 
for PA and MMA. 
Many efforts have been made to achieve consensus on which diseases are suitable for 
screening, both on a global level by the World Health Organization (WHO) [10, 11] 
(Supplementary Notes 1), and on European level [12-14]. Despite these efforts, it is still 
debatable which diseases to screen for and it is not clear on what criteria decisions should be 
based, resulting in divergent conclusions. Regarding PA and MMA, NBS implementation has 
been recommended in the United States of America[15], but PA and MMA were not included 
in the European list of 26 disorders to be considered for NBS expansion [13]. Nevertheless, 
several European countries implemented NBS for PA and MMA [5].  
In the Netherlands, the Health Council decided based on the expected health gain for LO 
patients that NBS for PA and MMA met the screening criteria and will start in October 
2019[16]. NBS will be performed based on increased C3-carnitine and increased C3/C2 
carnitine ratio, complemented with a second-tier test on increased 2-methylcitric acid and 
methylmalonic acid. As the heel prick is performed within 3-7 days after birth, the aim is to 
report a positive second-tier test within 11-21 days after birth.  
For the addition of new diseases to NBS, three WHO criteria seem of particular importance: 
clearly defined objectives (WHO#2), evidence for effectiveness (WHO#4) and careful 
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evaluation (WHO#9) [11] (Supplementary Notes 1). To date, for PA and MMA these three 
criteria are not sufficiently met. Also, despite statements that good long-term outcome is the 
ultimate goal and that monitoring is necessary to evaluate NBS programmes, long-term 
outcome is rarely monitored in a standardized manner [13]. 
We performed a national retrospective cohort study including 76/83 Dutch PA and MMA 
patients. We aim to define which objectives could be attained with NBS implementation. 
Hereto, we estimate the expected health gain in the Netherlands by comparing siblings 
diagnosed via family testing with their older index sibling. In addition, we explore how 
evaluation of NBS implementation can be performed by assessing newly defined clinical 
outcome parameters. Lastly, we use insights obtained from studying this pre-NBS cohort to 
guide counseling and surveillance of NBS cohorts.  
 
 
2 | Methods 
2.1 | Patient inclusion 
In this nationwide retrospective cohort study, patients clinical records from all six Dutch 
metabolic centers were analyzed. Patients were eligible for inclusion if PA or MMA was 
confirmed by enzymatic activity analysis or mutation analysis of PCCA, PCCB, MUT, MMAA, 
MMAB, MCEE or MMADHC. Patients or their legal guardians signed an informed consent 
form, approving analysis of their clinical records and publication of the anonymous data, in 
agreement with institutional and national legislation. The study was approved by the Ethical 
Committees of the University Medical Centers Utrecht (17-490/C) and Rotterdam (MEC-
2018-1312), on behalf of all Ethical Committees of involved University Medical Centers.  
 
2.2 | Data collection 
Data collection was performed by two investigators (HH, FM). Data was extracted from both 
paper and electronic patient files. Data was collected from the first symptomatic phase until 
the last follow-up visit. Data collection was focused on patient and family characteristics, 
outcome of the first symptomatic phase, AMD, hospital admissions, cognitive and 
psychomotor development and long-term complications. All data was entered in 
OpenClinica open source software, version 3.12.2.  
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EO was defined as an episode of severely reduced clinical condition starting in the first 28 
days of life, and LO as symptoms starting after 28 days of life [1]. Patients identified through 
family testing based on an affected older (index) sibling were regarded a separate category.  
 
2.3 | Outcome parameters 
To evaluate clinical outcomes, five grouped outcome parameters were defined 
(Supplementary Notes 2). “Adverse outcome (AO) of the first symptomatic phase” was 
categorized based on the presence of movement disorders that developed during or right 
after the first symptomatic phase, objectified during follow-up examinations by pediatric 
neurologists and physiotherapists shortly after the first symptomatic phase, and/or the 
presence of basal ganglia hyperintensities or white matter abnormalities detected at the first 
time of brain imaging after the first symptomatic phase (Supplementary Notes 2). “AMD 
frequency” was defined based on the frequency of (impending) AMD requiring hospital 
admission per patient year (PY) in the first four years of life, other than the first symptomatic 
phase (Supplementary Notes 2). “Cognitive function” was distinguished in three categories 
based on neuropsychological test results, or in the absence of neuropsychological test 
results on educational level or professional employment[17] (Supplementary Notes 2). Long-
term complications were divided into mitochondrial, treatment-related and miscellaneous 
complications. Patients were categorized into six categories based on the number of 
mitochondrial complications present at a certain age. These mitochondrial complications 
included 21 complications likely to be caused by mitochondrial failure[2] (Supplementary 
Notes 2). Complications with potential treatment-related etiology included decreased bone 
mineral density (BMD), growth retardation and obesity[2] (Supplementary Notes 2). Growth 
retardation was defined present when height to weight was < -2 SD at any moment during 
follow-up. Other complications, with no evidence for a sole mitochondrial or treatment-
related etiology, were regarded miscellaneous complications. These complications included 
pes planovalgus, port-a-cath infections, teeth enamel defects, urolithiasis and gout [2]. 
 
2.4 | Data-analysis 
Each outcome parameter was evaluated in the complete cohort, separate for both PA and 
MMA patients and separate for both EO and LO patients. In addition, for all AMDs age at 
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decompensation, admission duration, need for intensive care unit (ICU) admission and AMD 
triggers were evaluated. For each complication assessed, prevalence was calculated. 
As a proxy for the potential health gain of NBS, all five clinical outcome parameters were 
compared between patients identified by family testing and their index siblings. The 
expected health gain was calculated by extrapolating findings of the sibling comparison on 
AO of the first symptomatic phase to the entire cohort, if NBS would have been 
implemented. Calculations were performed for six possible days that definitive NBS results 
could become available: day 0, 3, 7, 11, 15 and 21 after birth. 
Assessment of risk factors for each outcome parameter was performed by comparing disease 
types, for both PA and MMA presentation types and for MMA vitamin B12 responsiveness. 
All statistical analyses were performed in R programming language. Results are expressed as 
either means or medians with standard deviations and ranges for quantitative data and as 
number and percentage for qualitative data. Student’s t-tests were performed for 
quantitative data and Fisher’s exact tests for qualitative data. P-values were adjusted 
according to the Bonferroni method when multiple testing was performed, adjusted p-values 
< 0.05 were considered statistically significant. P-values solely reported in the text for the 
assessment of risk factors of clinical outcome parameters were calculated using Fisher’s exact 
tests and were not adjusted, as no multiple testing was performed.  
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3 | Results 
3.1 | Patient characteristics 
Of all 83 PA and MMA patients in the Netherlands diagnosed between January 1979 and July 
2019, 76 patients were included. Five patients refused to participate and clinical records of 2 
deceased MMA patients could not be retrieved. For nearly all patients, data was available 
from the first symptomatic phase to the last moment of follow-up. The cohort included 31 
PA patients from 24 families and 45 MMA patients from 40 families. Between 01-01-1998 
and 31-12-2017, 46/76 patients (PA: n = 19, MMA: n = 27) were diagnosed, with a median of 
2 patients per birth year (range: 1 – 5). In this period 3.729.128 live births were registered, 
providing an estimated incidence in the Netherlands of 1:81.000 for PA and MMA combined, 
1:196.000 for PA and 1:138.000 for MMA. Presentation type was EO in 29, LO in 34, family 
testing in 12 and unknown in one patient (Table 1). Clinical data of 5 PA sibling pairs and 1 
trio, and 3 MMA sibling pairs (n = 9) was available for sibling comparison (Table S1). Two 
MMA patients identified through family testing could not be compared with their index 
siblings, because medical records of the index sibling were not available. 
Mutation analysis was available in 52/76 patients and revealed 25 previously unreported 
mutations, including 7 mutations in PCCA, 5 in PCCB, 8 in MUT, 2 in MMAA and 3 in MMAB 
(Table S2). Pregnancy and delivery were uncomplicated in the majority of the patients’ 
mothers. Birth weight of MMA patients was significantly lower compared to PA patients, in 
line with previous reports1 (Table S3). In most patients, the first symptomatic phase was 
characterized by lethargy and anorexia. Significantly more LO patients presented with 
vomiting. Plasma ammonia at presentation was significantly higher in EO patients, resulting 
in significantly more EO patients requiring dialysis (Table S4).  
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3.2 | Adverse outcome of the first symptomatic phase 
An AO of the first symptomatic phase was recorded in 36/76 (47%) of all patients and in 
30/64 (47%) of the clinically diagnosed patients (Figure 1). Movement disorders were 
recorded in 24/36 patients. Basal ganglia hyperintensities were observed in 18, white matter 
abnormalities in 14 and both in 6 patients. In 19/26 patients in whom white matter 
abnormalities and/or basal ganglia hyperintensities were observed, brain imaging was 
performed within 3 days to 6 months after the first symptomatic phase and in 7/26 patients 
later in life (range: 9 months to 23 years). In 3 of these patients also a movement disorder 
was recorded, and in all 7 patients the observed abnormalities were considered to be long-
existent based on unchanged clinical symptoms and imaging characteristics. 
In EO patients an AO due to the first symptomatic phase was either absent or, more often, 
mild, whereas in LO patients most often no AO due to the first symptomatic phase was 
recorded. If an AO was recorded in LO patients it was either mild or severe, which is 
represented by a significant difference in mild AO due to the first symptomatic phase in EO 
versus LO patients (Table 2, Figure S1). AO due to the first symptomatic phase tended to be 
less frequent in patients identified through family testing than in their siblings (better 
outcome of the first symptomatic phase in 4/9 sibling pairs, similar in 5/9) (Table S1). 
Symptoms or signs present during the first symptomatic phase, nor presentation type in PA 
or MMA, nor vitamin B12 responsiveness in MMA, was associated with an increased risk for 
an AO (Table S5). 
The expected health gain of NBS for PA and MMA in the Netherlands was estimated based 
on the moment of presentation of all EO and LO patients in this cohort and based on 
analysis of sibling pairs (Figure 1, Table S1, Table 3). Theoretically, the earlier NBS results are 
available, the more patients could be protected from an AO due to the first symptomatic 
phase (Figure 1, Table 3). In this cohort, NBS results available at day 0 of life could have 
prevented an AO in 14 patients, reducing the percentage of an AO during the first 
symptomatic phase from 46% to 23%. NBS results available between day 11 and 21 could 
have prevented an AO in 6 or 5 patients, reducing the percentage from 46% to 36-38% 
(Table 3). 
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FIGURE 1. Age at onset and age at diagnosis for PA and MMA patients. 
 
 
The y-axis depicts the patients, ordered on type of adverse outcome and age at diagnosis. The x-axis 
depicts the patient age in days, with a maximum of 28 days (early onset). Light gray circles depict age 
at presentation, dark gray circles depict age at diagnosis, open circles depict in which patients the 
exact age at diagnosis is unknown. For all ages at presentation and ages at diagnosis > 28 days of age 
(late onset), the circles have been placed at 28 days. The vertical red solid lines depict the potential 
moments NBS results could become available, in line with Table 3. On the left the severity of adverse 
outcomes (AO) due to the first symptomatic phase are listed: no adverse outcome, mild, severe or 
death due to the first symptomatic phase. 
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3.3 | AMD frequency 
In total, 962 AMD requiring hospital admission were reported. Hospitalization duration was 
significantly shorter in MMA than in PA patients. AMD triggers were similar, with the 
exception of significantly more frequent feeding problems in MMA patients and constipation 
in PA patients (Table S6).  
Among the sibling pairs, AMD frequency was similar in 4/9 pairs. The index patients of 4/9 
sibling pairs died following an AMD, whereas all but one of the siblings identified through 
family testing are still alive, although currently only P6.3 survived his sibling in age (Table S1). 
AMD frequency tended to be shifted towards a more severe frequency in EO patients 
compared to LO patients (Table 2, Figure S1). Between PA and MMA patients no difference in 
AMD frequency was recorded. (Table S6). Among PA patients, EO patients experienced 
significantly more AMD/PY (p = 0.002) and among MMA patients, vitamin B12 unresponsive 
patients experienced significantly more AMD/PY (Table S6). 
 
3.4 | Cognitive function 
A total of 139 neuropsychological test results were recorded in 46/76 patients, with a median 
of 3 tests per patient (range: 1 – 10). In 17 patients, cognitive function was based on the 
patients’ educational level and in 13 patients, cognitive function was not assessed (yet). An 
IQ >90 was noted in 24/63 patients, an IQ between 60 and 90 in 20/63 patients and an IQ 
<60 in 19/63 patients (Table S7).  
Cognitive function was comparable among the sibling pairs (similar in 3, better in 2, worse in 
1, not assessed in 3) (Table S1), as well as between EO and LO patients (Table 2, Figure S1). 
An IQ <60 was significantly more prevalent in PA patients (Table S7). Among PA patients, EO 
was significantly associated with cognitive function (IQ >90: EO 0%, LO 63%, p = 0.002). 
Among MMA patients, presentation type nor vitamin B12 responsiveness were associated 
with cognitive function.  
 
3.5 | Complications with potential mitochondrial etiology 
Mitochondrial complications were present in 70/76 patients, and were mild in 30, moderate 
in 13, severe in 12 and very severe in 14 patients. One PA patient with very severe 
mitochondrial complications died due to cardiomyopathy. Prevalence of mitochondrial 
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complications was compared with the literature and was fairly comparable for most 
complications [2] (Table S7). For quite some complications, especially for MMA, prevalence 
was here assessed for the first time in a cohort study (Table S7). Renal failure was 
significantly more prevalent among MMA patients than among PA patients (Table S7).  
For mitochondrial complications with acute onset, age at onset was assessed (Table S7, 
Figure 2). The earliest manifestation of renal failure was already reported at the age of 1.2 
years in an MMAB patient and in 5/20 patients age of onset was < 6 years (2 MUT, 2 MMAB, 
one unclassified). The first manifestation of prolonged QTc interval was shortly after birth in 
PA, and at 3.6 years in MMA. Cardiomyopathy in PA was noted at 7.5 years, optic atrophy at 
11.8 years in PA and at 12.6 years in MMA (Table S7). Age at onset of hepatomegaly, 
epilepsy and sensorineural hearing loss ranged from birth to ten years, while most other 
complications typically arose from late infancy to adolescence (Table S7, Figure 2). 
Mitochondrial complications were comparable among sibling pairs (similar in 1, better in 4, 
worse in 4) (Table S1). LO patients were significantly more frequently recorded to have only 
mild mitochondrial complications than EO patients (Table 2, Figure S1). PA patients had more 
very severe mitochondrial complications than MMA patients (Table S7), and all of these PA 
patients were EO patients (EO 53%, LO 0%, p = 0.019). Among MMA patients, mitochondrial 
complications were comparable between EO and LO patients but the prevalence of 
moderate to very severe mitochondrial complications was significantly higher in vitamin B12 
unresponsive patients (unresponsive 63%, responsive 24%, p = 0.016).  
EO for PA and vitamin B12 unresponsiveness for MMA were also found to be significantly 
associated with a higher risk for mitochondrial complications with acute onset (Figure 3). In 
addition, EO in PA tended to be associated with the occurrence of hepatomegaly, prolonged 
QTc interval, psychoses and sensorineural hearing loss (Figure S2). Vitamin B12 
unresponsiveness tended to be associated with the occurrence of optic atrophy, pancreatitis 
and prolonged QTc interval in MMA, and was significantly associated with the occurrence of 
renal failure (Figure S3). One of the first occurring mitochondrial complications with acute 
onset was hepatomegaly (Figure 2). Intriguingly, hepatomegaly was significantly associated 
with the onset of other mitochondrial complications with acute onset later in life, for PA and 
MMA as a group and for both PA and MMA separately (Figure 3).  
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3.6 | Complications with potential treatment-related etiology 
Reduced BMD was noted in 27, growth retardation in 21 and obesity in 16 patients. 
Treatment-related complications were absent in 33, mild in 28, severe in 9 and very severe in 
6 patients (Table S8).  
Treatment-related complications were comparable among sibling pairs (similar in 2, better in 
5, worse in 2) (Table S1), as well as among EO and LO patients (Table 2, Figure S1), nor were 
there any differences between PA and MMA, or among PA patients between EO and LO 
patients (Table S8). Among MMA patients, the rate of mild, severe and very severe 
treatment-related complications was significantly higher in vitamin B12 unresponsive 
patients (unresponsive 71%, unresponsive 33%, p = 0.017).  
 
3.7 | Complications with miscellaneous etiology 
A prevalence of 29% pes planovalgus, a feature so far only described in MMA18, was noted in 
PA. In one MMA and one PA patient urolithiasis was recorded. In both patients, calculi 
developed due to hypercalciuria, although dehydration, chronic acidotic state and a low-
protein diet might have contributed. Two MMA patients (MUT and MMAA) were found to 
have juvenile gout (Table S8). The MMAA patient had chronic renal failure when exhibiting 
gout, whereas the MUT patient did not. 
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4 | Discussion 
4.1 | Expected health gain of NBS for PA and MMA in the Netherlands (WHO#4) 
Here we present an extensive, nationwide cohort study, describing the clinical course of 
76/83 Dutch PA and MMA patients. We demonstrated that the expected health gain of 
introducing NBS for PA and MMA in the Netherlands in overall outcome may be limited. 
Patients can already present shortly after birth and even if patients are diagnosed pre-
symptomatically, they can still develop an adverse outcome. We calculated an expected 
reduction from 46% to 36-38% AO due to the first symptomatic phase and we consider it 
unlikely that NBS could result in reduced AMD frequency, improved cognitive function or a 
reduced frequency of mitochondrial and therapy-related complications. 
These findings are in line with previous reports. Although time to diagnosis is reduced in 
patients identified by NBS [9], NBS is unlikely to identify more than 59-72% of PA and MMA 
patients before the first symptomatic phase [8, 9]. One study described no decreased AMD 
frequency, no better neurological outcome and no reduced frequency of long-term 
complications in PA patients [8], although another study found that PA patients identified by 
NBS had lower cardiac manifestations [9], but follow-up time in these patients was limited. In 
MMA patients, besides improved attainment of motor milestones and reduced 
manifestations of movement disorders in vitamin B12 unresponsive patients, NBS 
implementation did not result in other improved outcome parameters [9].  
Thus, as evidence supporting improved outcomes if treatment can be initiated in the 
asymptomatic phase is limited, despite reasonable consensus on therapeutic strategies for 
PA and MMA [18, 19], it is questionable whether the criterion regarding an accepted 
(effective) treatment for patients with recognized disease is met (W&J#2). As a consequence, 
it remains debatable whether the criteria requesting effectiveness (WHO#4) and benefits 
outweigh harm (WHO#10), are met (Supplementary Notes 1). We advocate that the (now 
limited) health gain of NBS can only be improved if treatment strategies are identified that 
can effectively prevent AMD, cognitive impairment and mitochondrial complications, such as 
innovative therapies aiming to increase enzyme activity [19]. 
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4.2 | Evaluation of the implementation of NBS for PA and MMA (WHO #9) 
Insight in NBS efficacy is still limited, due to factors complicating proper evaluation, such as 
timing of evaluation. Follow-up time of the four studies describing the potential additional 
value of NBS for PA and MMA was relatively short, resulting in uncertainty when drawing 
conclusions [6-9]. We propose that these countries reassess their NBS cohorts when a longer 
follow-up time is available. For the Netherlands, assuming a similar incidence in the NBS 
cohort as in the here presented cohort, but taking into account the slightly decreasing birth 
rate, it will take at least till 2050 before an NBS cohort similar in size and follow-up time as 
the pre-NBS cohort is available for evaluation. More timely evaluation can only be achieved 
by composing larger NBS cohorts through data sharing initiatives, within Europe or 
worldwide.  
Even if timing of evaluation is adequate, proper evaluation of the presumed effect of NBS 
remains challenging given the many factors that can influence the clinical course of PA and 
MMA. This includes genotypic factors as mutation type, residual enzyme activity and vitamin 
B12 responsiveness (MMA). Also, a high variability in clinical management existed between 
the different metabolic centers and metabolic physicians (data not shown). Next, compliance 
of parents and patients to clinical management, and disease insight could influence clinical 
outcomes. Moreover, pre-NBS cohorts are diagnosed and treated in the era before NBS 
cohorts, with NBS cohorts taking advantage of general advances in clinical care, and possibly 
increased insights and improved therapies for PA and MMA patients.  
To aid evaluation of NBS efficacy, we suggest the five clinical outcome parameters here 
presented and we advocate the introduction of continuation and stop criteria. We propose 
that NBS for PA and MMA should be continued when it results in a statistically significant 
and clinically relevant reduction of AO due to the first symptomatic phase, and that it should 
be stopped otherwise. While based on our results, NBS may be unlikely to result in reduced 
AMD frequency, improved cognitive function and reduced mitochondrial complications, 
these outcome parameters should be assessed to gain insight in the effects of improved 
treatment strategies. If NBS would unexpectedly result in improvement of these parameters, 
this would be a supportive argument to continue NBS. NBS evaluation should also include 
assessment of treatment-related complications, to gain knowledge regarding risks and harm 
of screening. 
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In NBS cohorts, patients in whom the disease is mild and who would not become 
symptomatic during infancy, could be detected as has been reported in Japan, where a ten 
times higher incidence of PA was found during preparatory studies for NBS implementation 
[20]. These mildly affected patients will probably be treated according to the current 
treatment guidelines [18], inducing a risk for developing treatment-related complications. 
One could advocate that these patients should not be treated in order to prevent treatment-
related complications. However, in our cohort, two PA patients presented at 48 and 56 years 
of age with cardiomyopathy as first presenting symptom [21], indicating that even in very 
mild, untreated patients, mitochondrial complications can still occur. It is presently unknown 
whether earlier initiation of adequate treatment could have prevented this complication. 
Even if this would alter the clinical course, it is questionable whether these patients should be 
exposed to life-long protein restriction, to prevent complications occurring well into 
adulthood. We consider overtreatment of mildly affected patients, that might or might not 
develop late complications [20, 21], a serious risk of NBS. 
 
4.3 | Lessons learned from the pre-NBS cohort, to guide follow-up of post-NBS 
cohorts 
We demonstrated that mitochondrial complications with acute onset can already develop 
before monitoring should be initiated according to recent guidelines [18] and we thus 
propose to adapt these guidelines. Specifically, we suggest to assess renal function in MUT 
and MMAB patients from one year of age, to regularly check QTc intervals in PA and MMA 
patients starting at birth, and to maintain yearly cardiac ultrasounds and ophthalmologic 
assessments from six years onwards. Importantly, as we demonstrate that hepatomegaly is 
associated with the occurrence of other acute onset mitochondrial complications later in life, 
we advise to perform physical examination to check for hepatomegaly during every 
outpatient visit starting at birth, to be able to study the relevance of this finding. Lastly, we 
advocate awareness of all complications assessed in this cohort, including rarely described 
complications as exercise intolerance, acute psychosis, premature ovarian failure, pes 
planovalgus, gout and urolithiasis. 
For surveillance and counseling of patients in NBS cohorts, we stress the importance to take 
into account disease severity. For MMA patients we demonstrated that vitamin B12 
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unresponsiveness increases the risk of AMD frequency, mitochondrial complications and 
treatment-related complications. This is in line with previous reports, that demonstrate that 
vitamin B12 unresponsiveness is associated with a decreased survival rate in EO patients, a 
higher frequency of AMD, an increased rate of developmental delay in EO patients and an 
increased rate of disability [22]. In addition, a tendency towards an increased rate of chronic 
renal failure has been reported [23]. For PA patients, EO is associated with a higher risk for an 
AO of the first symptomatic phase, AMD frequency, cognitive impairment and mitochondrial 
complications. While this still holds true for patients that are symptomatic before NBS results 
are available, presentation type will be unknown for PA patients diagnosed via NBS, 
complicating surveillance and counseling of these patients. This augments the need for 
systematic determination of PCC activity in PA patients and illustrates the imminent need for 
a metabolic marker that can predict the risks for AMD frequency, cognitive function and 
mitochondrial complications [24, 25]. 
We could not identify specific genotype-phenotype correlations due to the variation of the 
identified mutations. However, we did note that whereas patients with MMAB type MMA are 
generally reported to be vitamin B12 unresponsive [18], 6/7 of our MMAB patients were 
responsive. In 5 of these, we identified the previously unreported MMAB c.556C>T missense 
mutation in either homozygous or heterozygous fashion (Table S2). We speculate that this 
mutation might be related to the observed vitamin B12 responsiveness of MMAB patients, 
but we cannot prove this hypothesis.  
 
4.4 | Limitations and strengths 
We note a few limitations. First, due to the retrospective nature of this study and variable 
follow-up schedules, missing data could have affected the reliability of the analyses. We 
expect missing data to be random and consider it unlikely to have resulted in confounding. 
Nevertheless, to facilitate reliable analyses and conclusions on NBS effectivity, we advocate 
precise and structured prospective follow-up of NBS cohorts. Minimum requirements for 
evaluation are listed in Table S9. Centers participating in data-sharing initiatives should agree 
on the items to be recorded and on the timing of diagnostics studies (Table S9). Second, 
sample size of the sibling comparison is limited, hampering solid conclusions on the 
expected health gain of NBS for PA and MMA, but consolidating the urge for thorough 
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assessment of NBS cohorts. The potential health gain might have been overestimated 1) due 
to the unknown number of EO patients that died undiagnosed, 2) since families with an 
index child are prepared for the diagnosis, and can minimize the risk for AMD more 
efficiently than families from individuals identified by NBS, 3) since calculations were 
performed with a potential overestimation of AO due to the first symptomatic phase, as we 
assumed that all observed brain imaging abnormalities were caused by the first symptomatic 
phase instead of being caused by AMD occurring later in life (and thus under treatment). 
Conversely, the potential health gain of NBS might have been underestimated as the clinical 
course between siblings may vary and it is not known whether the sibling diagnosed through 
family testing would have stayed in the same condition if diagnosed later in life. 
Important strengths of our study are that we provide a comprehensive overview of a 
nationwide cohort spanning over four decades, by systematically assessing nearly all PA and 
MMA patients in the Netherlands in great detail. We designed five clinical outcome 
parameters to guide evaluation of implementation NBS and we provide an extensive 
description of a pre-NBS cohort to compare NBS cohorts with. Moreover, due to the 
systematic assessment of AMD, complications and risk factor analysis, we were able to 
establish recommendations regarding surveillance and counseling of NBS cohorts. Lastly, 
continuation and stopping criteria for NBS were provided, as well as minimum requirements 
for follow-up of NBS cohorts to facilitate data sharing initiatives. 
 
5 | Conclusion 
The objective of NBS for PA and MMA in the Netherlands is to protect LO patients from 
irreversible neurological damage due to the first symptomatic phase. Implementation in the 
Netherlands may result in a reduction of AO due to the first symptomatic phase from 46% to 
36-38%, if NBS results become available between day 11 and 21. We consider reduced AMD 
frequency, improved cognitive function and reduced mitochondrial and treatment-related 
complications unlikely given the currently available therapies. 
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Supplemental tables and figures 
 
Supplementary Notes 1 – Screening criteria and recommendations 
 
1968, Wilson and Jungner, ten criteria to guide selection of conditions suitable for screening 
(1) The condition sought should be an important health problem. 
(2) There should be an accepted treatment for patients with recognized disease. 
(3) Facilities for diagnosis and treatment should be available. 
(4) There should be a recognizable latent or early symptomatic stage. 
(5) There should be a suitable test or examination. 
(6) The test should be acceptable to the population. 
(7) The natural history of the condition, including development from latent to declared disease, 
should be adequately understood. 
(8) There should be an agreed policy on whom to treat as patients. 
(9) The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
economically balanced in relation to possible expenditure on medical care as a whole. 
(10)Case-finding should be a continuing process and not a “once and for all” project. 
 
2008, World Health Organization, ten criteria additional to the Wilson and Jungner criteria 
(1) The screening programme should respond to a recognized need. 
(2) The objectives of screening should be defined at the outset.  
(3) There should be a defined target population.  
(4) There should be scientific evidence of screening programme effectiveness.  
(5) The programme should integrate education, testing, clinical services and programme 
management.  
(6) There should be quality assurance, with mechanisms to minimize potential risks of screening.  
(7) The programme should ensure informed choice, confidentiality and respect for autonomy.  
(8) The programme should promote equity and access to screening for the entire target 
population.  
(9) Programme evaluation should be planned from the outset.  
(10)The overall benefits of screening should outweigh the harm. 
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Supplementary Notes 2 – Definition of grouped outcome parameters 
 
Definition of “Adverse outcome (AO) of the first symptomatic phase” as clinical outcome 
parameter 
No AO:  No basal ganglia hyperintensities, or white matter abnormalities or movement 
disorder 
Mild AO: Basal ganglia hyperintensities or white matter abnormalities or movement disorder 
that can be most likely attributed to the first symptomatic phase, but not wheelchair-
bound 
Severe AO: Basal ganglia hyperintensities or white matter abnormalities or movement disorder, 
wheelchair-bound due to movement disorders that most likely arose due to the first 
symptomatic phase 
Death:  Death during or due to the first symptomatic phase 
 
Definition of “AMD frequency” as clinical outcome parameter 
None:  No episode of AMD during first four years of life 
Mild:  >0.0 < 0.5 AMD/PY during first four years of life 
Moderate: >0.5 < 1.0 AMD/PY during first four years of life 
Severe:  >1.0 < 2.0 AMD/PY during first four years of life 
Very severe: >2.0          AMD/PY during first four years of life 
Death:  Death during or due to AMD, at any moment in life 
Not assessed (NA): if death during or due to first presentation 
 
Definition of “Cognitive function” as clinical outcome parameter 
Group 1: IQ >90 or regular education 
Group 2: IQ 60-90 or special education 
Group 3: IQ <60 or no education 
Not assessed (NA): Last moment of follow-up <4 years of age 
 
Definition of “Mitochondrial complications” as clinical outcome parameter 
Twenty-one complications considered to be potentially caused by mitochondrial failure based on an 
extensive literature review2 were included: hepatomegaly, epilepsy, cardiomyopathy, optic atrophy, 
pancreatitis, renal failure, sensorineural hearing loss, acute psychosis, stroke-like episodes, prolonged 
QTc interval, premature ovarian insufficiency, exercise intolerance, autism, feeding disorders, muscular 
hypotonia, constipation, attention deficit hyperactive disorder, anemia, leukopenia, thrombocytopenia 
and pancytopenia. 
 
Severity is based on the number of complications recorded at the last moment of follow-up, as 
follows: 
 
  0-12 year 13-18 year  19-24 year  >25 years 
None:  0  0   0   0  
Mild:  1-2  1-4   1-6   1-8  
Moderate: 3-4  5-6   7-8   9-10  
Severe:  5-6  7-8   9-10   11-12 
Very severe: >7  >9   >11   >13 
Death:  Death due to mitochondrial complication 
Not assessed (NA): If death during or due to first presentation 
 
Definition of “Treatment-related  complications” as clinical outcome parameter 
None:  No decreased BMD, no growth retardation, no obesity 
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Mild:  1 of the following: decreased BMD, growth retardation, obesity 
Severe:  2 of the following: decreased BMD, growth retardation, obesity 
Very severe: Decreased BMD and growth retardation and obesity  
Not assessed (NA): If death during or due to first presentation 
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Supplementary table 6. Acute metabolic decompensations. 
 
 Propionic acidemia 
(n = 31) 
n = ; median + SD /PY [range] 
Methylmalonic acidemia 
(n = 45) 
n = ; median + SD /PY [range] 
P-value Bonferroni 
correction 
Total 394; 0.7 + 1.6 [0.0 – 7.3] 568; 0.4 + 1.1 [0.0 – 4.7] 0.257 NS 
Early onset 
Late onset 
Family testing 
293; 1.2 + 1.3 [0.0 – 4.2] 
  22; 0.2 + 0.2 [0.0 – 0.7] 
  79; 0.8 + 2.7 [0.0 – 7.3] 
254; 0.9 + 1.4 [0.0 – 4.7] 
242; 0.2 + 0.9 [0.0 – 3.5] 
  72; 0.6 +  1.1 [0.0 – 2.8] 
0.604 
0.032 
0.327 
NS 
NS 
NS 
Vitamin B12 unresponsive 
Vitamin B12 responsive 
 504; 1.0 + 1.1 [0.0 – 4.7] 
  64; 0.1 + 0.8 [0.0 – 3.5] 
 
0.001 
 
0.001 
Age: 
     <1 years 
     1-3 years 
     4-11 years 
     12-17 years 
     >18 years 
 
  55; 1.0 + 2.0 [0.0 – 7.0] 
136; 1.0 + 2.0 [0.0 – 8.3] 
146; 0.3 + 0.9 [0.0 – 3.5] 
  40; 0.0 + 0.5 [0.0 – 2.0] 
  17; 0.0 + 0.4 [0.0 – 1.8] 
 
  38; 0.0 + 1.4 [0.0 – 5.0] 
156; 0.3 + 1.7 [0.0 – 6.7] 
206; 0.1 + 1.0 [0.0 – 5.0] 
  85; 0.0 + 0.8 [0.0 – 4.0] 
  73; 0.0 + 1.2 [0.0 – 9.9] 
 
0.032 
0.485 
0.940 
0.483 
0.145 
 
NS 
NS 
NS 
NS 
NS 
Admission duration: 
     1 –   3 days 
     4 –   7 days 
     8 – 14 days 
     > 15 days 
 
110; 28% 
143; 36% 
  80; 20% 
  51; 13% 
 
207; 36% 
164; 29% 
  96; 17% 
  45;   8% 
 
0.006 
0.017 
0.203 
0.012 
 
0.026 
NS 
NS 
0.047 
     NA   10;   3%   56; 10%   
ICU admission    23; 5.8%    18; 3.1% 0.051 NS 
Triggers: 
     Upper RTI 
     Unknown 
     Gastro-enteritis 
     Feeding problems 
     Bacterial infection 
     Constipation 
     Chronic instability 
     Protein overload 
     Other 
     NA 
 
114; 29% 
  77; 20% 
  75; 19% 
  16;   4% 
  24;   6% 
  39; 10% 
  13;   3% 
    4;   1% 
  16;   4% 
  16;   4%  
 
154; 27% 
141; 25% 
111; 20% 
  50;   9% 
  32;   6% 
    4;   1% 
    9;   2% 
    4;   1% 
  11;   2% 
  52;   9% 
 
0.559 
0.060 
0.868 
0.004 
0.781 
<0.001 
0.123 
0.723 
0.072 
 
NS 
NS 
NS 
0.033 
NS 
<0.001 
NS 
NS 
NS 
     
AMD frequency     
     None 
     Mild 
     Moderate 
     Severe 
     Very severe 
     Death 
     NA 
    7; 23% 
    2;   6% 
    1;   3% 
    6; 19% 
    8; 26% 
    5; 16% 
    2;   6% 
  14; 31% 
    2;   4% 
    3;   7% 
    6; 13% 
  10; 22% 
    1;   2% 
    9; 20% 
0.448 
1.000 
0.641 
0.532 
0.787 
0.038 
 
NS 
NS 
NS 
NS 
NS 
NS 
 
AMD: Acute metabolic decompensation; early onset: presentation <28 days of life; late onset: 
presentation >28 days of life; RTI: respiratory tract infection; PY: patient year; NS: not significant; NA: 
not assessed. Student’s t-tests were performed for quantitative data and Fisher’s exact tests were 
performed for qualitative data. All p-values were adjusted according to the Bonferroni method. 
Adjusted p-values < 0.05 were considered statistically significant and are depicted in bold.   
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Supplementary table 7. Complications with potential mitochondrial etiology. 
 
Mitochondrial     Pathophysiologya Propionic acidemia 
(n = 31) 
Methylmalonic 
acidemia 
(n = 45) 
P-
value 
Bonferroni 
correction 
 This cohort Lit. This cohort Lit.   
Mitochondrial complications during 
first pres. 
      
Basal ganglia 
hyperintensities 
Probably n = 10; 32% 22% n =   8; 18% 28% 0.175 NS 
White matter lesions  n =   6; 19% 39% n =   8; 18% 32% 1.000 NS 
        
Complications related to first 
presentation 
      
Cerebral atrophy  n = 13; 42%  n = 11; 24%  0.135 NS 
Movement disorders  n = 10; 32% 16% n = 14; 31% 32% 1.000 NS 
Psychomotor retardation  n = 19; 61% 49% n = 24; 53% 53% 0.638 NS 
Cognitive dysfunction  n = 20; 65% 69% n = 19; 42% 58% 0.066 NS 
     Group 1: IQ >90 or regular education n =   7; 23%  n = 17; 38%  0.212 NS 
     Group 2: IQ 60-90 or special 
education 
n =   7; 23%  n = 13; 29%  0.604 NS 
     Group 3: IQ <60 or no 
education 
     NA 
 
n = 13; 42% 
n =   4; 13% 
 n =   6; 13% 
n =   9; 20% 
 0.007 0.021 
        
Mitochondrial complications with 
acute onset 
      
Hepatomegaly and/or 
hyperechogenic liver 
Probably n = 11; 35% 
3.3 y (0.1 – 
57.1) 
78% n = 14; 31% 
0.4 y (0.0 – 9.9) 
33% 0.805 NS 
Epilepsy Probably n =   7; 23% 
0.0 y (0.0 – 6.3) 
23% n =   2;   4% 
2.1 y (0.0 – 4.2) 
13% 0.027 NS 
Cardiomyopathy Probably n =   7; 23% 
8.5 y (7.5 – 
56.3) 
14% n =   1;   2% 
23.3 y 
5% 0.007 NS 
Optic atrophy Probably n =   4; 13% 
15.9 y (11.8 – 
16.7) 
5% n =   4;   9% 
20.8 y (12.6 – 
26.9) 
6% 0.709 NS 
Pancreatitis Probably n =   1;   3% 
20.8 y 
5% n =   2;   4% 
19.1 y (9.5 – 
28.7) 
4% 1.000 NS 
Renal failure Possibly n =   1;   3% 
21.4 y 
1% n = 20; 44% 
8.9 y (1.2 – 
31.3) 
29% <0.001 <0.001 
Sensorineural hearing loss Possibly n =   6; 19% 
6.6 y (2.0 – 8.5) 
4% n =   3;   7% 
4.8 y (2.5 – 9.8) 
2% 0.434 NS 
Acute psychosis Possibly n =   3; 10% 
17.2 y (16.8 – 
23.5) 
 n =   0;   0%  0.064 NS 
Stroke-like episodes Possibly n =   2;   7% 
13.4 y (9.0 – 
17.9) 
14% n =   0;   0% 17% 0.163 NS 
Prolonged QTc interval Unknown n =   7; 23% 
8.5 y (0.0 – 
38.3) 
31% n =   4;   9% 
14.0 y (3.6 – 
28.4) 
2% 0.300 NS 
Premature ovarian 
insufficiency 
Unknown n =   0;   0% 
 
 n =   1;   2% 
19.1 y 
 1.000 NS 
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Mitochondrial complications with 
chronic onset     
  
Exercise intolerance Probably n = 15; 48%  n = 10; 22%  0.025 NS 
Autism Probably n =   2;   6% 9% n =   4;   9%  1.000 NS 
Feeding problems Possibly n = 18; 58%  n = 22; 49%  0.488 NS 
Muscular hypotonia Possibly n = 13; 42% 45% n = 21; 47%  0.815 NS 
Constipation Unknown n = 14; 45%  n =   9; 20%  0.024 NS 
Attention deficit 
hyperactive disorder  
n =   1;   3% 15% n =   1;   2%  1.000 NS 
        
Mitochondrial complications, 
intermittent occurr.     
  
Anemia Possibly n = 21; 68% 51% n = 28; 62%  0.807 NS 
Leukopenia Possibly n = 19; 61% 31% n = 16; 36%  0.036 NS 
Thrombocytopenia Possibly n = 19; 61% 28% n = 23; 51%  0.483 NS 
Pancytopenia Possibly n = 13; 42% 19% n =   9; 20% 0% 0.044 NS 
        
Mitochondrial complications       
     None  n =   3; 10%  n =   3;   7%  0.683 NS 
     Mild  n =   8; 26%  n = 22; 49%  0.057 NS 
     Moderate  n =   3;   9%  n = 10; 22%  0.219 NS 
     Severe  n =   5; 16%  n =   7; 16%  1.000 NS 
     Very severe  n = 11; 35%  n =   3;   7%  0.002 0.013 
     Death  n =   1;   3%   n =   0;   0%  0.408 NS 
 
a: Likelihood of mitochondrial pathophysiology2; Lit: percentage reported in literature2; NS: not 
significant; NA: not assessed. Statistical significance was determined by performing Fisher’s exact tests. 
All p-values were adjusted according to the Bonferroni method. Adjusted p-values < 0.05 were 
considered statistically significant and are depicted in bold.  
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Supplementary table 9. Minimum requirements for follow-up of the post-NBS cohort. 
 
 Items to record Diagnostics to perform 
Patient characteristics   
Patient Day of birth  
 Sex  
Family Ancestry  
 Consanguinity  
Mutation  g. / c. / p. coding sequence Genetic testing 
Vitamin B12 responsiveness Type enzymatic assay Enzymatic assay B12 responsiveness 
 Results enzymatic assay  
PCC activity Type enzymatic assay Enzymatic assay PCC activity 
 Results enzymatic assay  
Death Day of death  
 Cause of death  
Follow-up Age at last follow-up  
   
Adverse outcome of first sympt.  
phase 
  
First presentation Symptomatic/asymptomatic  
 Day of first symptoms  
 Day of diagnosis  
Adverse outcome first presentation Day of brain MRI Brain MRI at set times 
 Brain MRI results  
 Movement disorder Consult neurologist 
   
AMD frequency   
Number of AMD  Day of admission  
 Day of release  
 Reason of admission  
   
Cognitive function   
Cognition Day of neuropsychological tests Neuropsychological tests at set 
times 
 Neuropsychological test type  
 Neuropsychological test results; IQ  
Education School career  
 Type of employment  
   
Mitochondrial complications   
Hepatomegaly  Day of diagnostic study Liver ultrasound at set times 
Epilepsy Results of diagnostic study EEG at set times 
Cardiomyopathy Presence complication yes/no Cardiac ultrasound at set times 
Prolonged QTc interval  ECG at set times 
Optic atrophy  Consult ophthalmologist at set 
times 
Renal failure  Urine kidney function biochemistry 
at set times 
Pancreatitis  Complete blood count at set times 
Sensorineural hearing loss   
Acute psychosis  On indication: consult ENT doctor, 
gastro-enterologist, neurologist, 
gynecologist, psychiatrist, physical 
therapist 
Stroke-like episodes  
Premature ovarian insufficiency  
Exercise intolerance  
Muscular hypotonia  
Feeding problems  
Constipation  
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Autism  
Attention deficit hyperactive 
disorder 
 
Anemia   
Leukopenia   
Thrombocytopenia   
Pancytopenia   
   
Treatment-related complications   
Bone mineral density Day of diagnostic study DEXA-scan at set times 
Growth retardation Results of diagnostic study  
Obesity Presence complication yes/no  
 Visit date each visit  
 Weight and length each visit  
 
g./c./p. coding sequence: genetic change in the DNA coding sequence and resulting change in the 
protein coding sequence. Adverse outcome of first sympt. phase: Adverse outcome of the first 
symptomatic phase. DEXA: dual-energy X-ray absorptiometry; ECG: electrocardiogram; EEG: 
electroencephalogram; ENT: ear-nose-throat; MRI: magnetic resonance imaging; PCC: propionyl-CoA 
carboxylase; IQ: intelligence quotient. 
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LIVER AND/OR KIDNEY 
TRANSPLANTATION IN 
AOA PATIENTS 
Neurotoxicity including PRES after initiation of calcineurin 
inhibitors in transplanted methylmalonic acidemia patients: 
two case reports and review of the literature.  
Abstract 
Introduction: New neurological symptoms in methylmalonic acidemia (MMA) patients after 
liver and/or kidney transplantation (LKT) are often described as metabolic stroke-like-events. 
Since calcineurin inhibitors (CNIs) are a well-known cause of new neurological symptoms in 
non-MMA transplanted patients, we investigated the incidence of CNI-induced neurotoxicity 
including posterior reversible encephalopathy syndrome (PRES) in post-transplanted MMA 
patients. 
Methods: We report the 2 MMA patients treated with LKT in our center. Additionally, we 
performed a systematic review of case reports/series of post-transplanted MMA patients and 
determined if CNI-induced neurotoxicity/PRES was a likely cause of new neurological 
symptoms. Definite CNI-induced neurotoxicity was defined as new neurological symptoms 
during CNI treatment with symptom improvement after CNI dose reduction/discontinuation. 
PRES was defined as CNI-induced neurotoxicity with signs of vasogenic edema on brain MRI-
scan post-transplantation.  
Results: Our 2 MMA patients both developed CNI-induced neurotoxicity, 1 had PRES. In 
literature 230 transplanted MMA patients were identified. Neurological follow-up was 
reported in 54 of them, of which 24 were excluded from analysis since no anti-rejection 
medication was reported. Thirty patients, all using CNI, were included. Sixteen patients (53%) 
had no new neurological symptoms post-transplantation and five patients (17%) had definite 
CNI neurotoxicity of whom 2 had PRES. Including our cases this results in a pooled incidence 
of 22% (7/32) definite CNI neurotoxicity and 9% PRES (3/32) in post-transplanted MMA 
patients on CNI.  
Conclusion: In MMA post-transplanted patients with new neurological symptoms CNI-
induced neurotoxicity/PRES should be considered. Early recognition of CNI-induced 
neurotoxicity is essential to initiate dose reduction/discontinuation of CNI in order to minimize 
persistent neurologic damage and improve outcome. 
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1 | Introduction 
Methylmalonic acidemia (MMA) is a severe rare inborn error of metabolism, belonging to the 
organic acidemias. MMA leads to increased levels of methylmalonic acid (mma). Isolated MMA 
is caused by complete (mut0) or partial (mut-) deficiency of the mitochondrial enzyme 
methylmalonyl-CoA mutase (MUT) (OMIM #251000) or by deficient synthesis of the MUT-
cofactor adenosylcobalamin (CblA (OMIM #251100) or CblB (OMIM #251110)) [1]. While 
survival of MMA patients has greatly improved over the past decades with conventional 
treatment strategies [2, 3], patients continue to develop serious long-term complications [4], 
including renal insufficiency and  neurological complications such as developmental delay, 
seizures and metabolic stroke [5]. Furthermore patients have an impaired quality of life [6]. 
Since the prognosis of MMA patients is often poor, liver and/or kidney transplantation is 
performed with increased frequency [7, 8]. Although the liver is the main site of MUT enzyme 
expression the enzyme is expressed in other tissues as well [9], including the kidneys and in 
lesser extent the muscles and brain [10]. Hence liver and/or kidney transplantation does not 
fully restore MUT enzyme activity. The outcome of transplantations in MMA patients varies 
and there are multiple reports of patients who developed new neurological complications after 
transplantation [11, 12]. Concerns about new neurological complications after transplantation 
is well described and it is mentioned  in a recent guideline on organic acidurias ([5]). The new 
neurological complications after transplantation can be due to deficient MUT activity in non-
transplanted tissues leading to high mma levels in cerebrospinal fluid [13, 14] and cerebral 
tissues or to metabolic encephalopathy during decompensations.  
However, new neurological complications are also a disturbing and relatively common 
phenomena in non-MMA patients after organ transplantation (occurring in 15%-40% of 
patients) [15-17]. These neurological complications can be caused by a variety of factors 
including immunosuppressive medication (especially calcineurin inhibitors (CNI), such as 
tacrolimus and cyclosporine) [16]. CNI-induced neurotoxicity in non-MMA organ transplanted 
patients can present with a variety of symptoms such as confusion, tremor, seizures, cerebral 
hemorrhage, ischemic stroke and posterior reversible encephalopathy syndrome (PRES) [17-
20]. In CNI-induced PRES, the brain magnetic resonance imaging (MRI)-scan typically shows 
bilateral areas of vasogenic edema, which may be located in the cortex and/or subcortical 
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white matter of brain areas; supplied by posterior circulation. However an atypical distribution 
pattern is not infrequently observed, e.g. involving the basal ganglia and/or the brain stem 
[18], with or without  atypical imaging findings (contrast enhancement, hemorrhage or 
restricted diffusion) [20].   
Recently, two adult MMA patients received combined liver/kidney transplantation in our 
center. They were the first transplanted MMA patients in our center, and both patients had 
new neurological symptoms within months post transplantation, which we attributed to CNI-
induced neurotoxicity. The aim of this study was to investigate the occurrence of CNI-induced 
neurotoxicity in liver and/or kidney transplanted MMA patients. Therefore we describe the two 
transplanted MMA patients in our center and performed a systematic review of previously 
published case reports and case series of MMA patients following liver and/or kidney 
transplantation. We retrospectively reviewed if neurological symptoms could be attributed to 
CNI-induced neurotoxicity. Furthermore, we calculated the pooled incidence of CNI-induced 
neurotoxicity, including PRES, in MMA patients in our center and from literature. 
 
2 | Methods 
To identify all published case reports and case series of transplanted MMA patients, we 
performed a systematic search of MEDLINE and EMBASE databases on the 11th of September 
2018. Search terms were  ‘mma OR (methylmalonic AND acidemia) OR (methylmalonic AND 
aciduria) OR (methylmalonic AND acidaemia) OR mcm OR (methylmalonyl AND coa AND 
mutase) OR mut OR (mcm AND deficiency) OR (acidemia AND methylmalonic) OR (cblb AND 
type) OR (cblb AND disease) OR (cblb AND disorder) OR (cbla AND type) OR (cbla AND 
disease) OR (cbla AND disorders) OR mut- OR mut0 OR mmaa OR mmab AND transplantation 
OR transplant OR grafting OR graft OR implantation OR implant AND liver OR hepatic OR 
kidney OR renal OR combined OR  (liver AND kidney) OR clkt’ in Embase and Pubmed. 
Exclusion criteria were another disease than MMA and in vitro or animal studies. Duplicate 
patients identified by the same author(s) and same age at transplantation (when reported) 
and/or mutation (when reported) were excluded. Informed consent of the two Erasmus MC 
patients was obtained.  
226
Chapter 7.2
2.1 | Definitions 
We defined the condition of ‘definite CNI-induced neurotoxicity’ as new neurological 
symptoms that started while the patient was using CNI, as anti-rejection medication, within 
the first year after transplantation and improvement following dose reduction or 
discontinuation. We attributed new neurological symptoms after transplantation to ‘probable 
CNI induced neurotoxicity’ as 1) patients with new seizures, unlikely due to another cause than 
CNI, within one year after transplantation (in case time period was mentioned) without 
reported anti-rejection medication or 2) newly acquired symptoms, unlikely due to another 
cause than CNI, within one year after transplantation while on CNI with unclear outcome 
reported of neurological symptoms. We attributed ‘CNI-induced PRES’ to ‘definite CNI-
induced neurotoxicity’ in combination with 1) brain MRI-scan abnormalities, with typical 
imaging findings (signs of vasogenic edema) with a typical (in parieto-occipital and/or 
posterior frontal cortex and/or subcortical white matter) or an atypical distribution (in other 
brain areas such as brain stem, basal ganglia, subcortical or cortical frontal regions without a 
posterior predominance), with or without atypical imaging findings (such as contrast 
enhancement, hemorrhage and or restricted diffusion on brain MRI-scan) and either 2a) 
improvement of brain MRI-scan findings on follow-up or, in case of unavailability of follow-up 
MRI 2b) return to baseline neurological status after dose reduction or discontinuation of CNI 
[15, 20, 21]. 
 
2.2 | Data analysis from the literature  
Characteristics of all described outcome parameters of each reported case were derived from 
the   reports that were found via the literature search. Three reviewers (F.M., Ma.Wa. and 
Mo.Wi.) independently judged whether or not the cases were described in enough detail to 
conclude that they had 1) generally reported follow-up after solid organ transplantation, 2) 
reported neurological follow-up. Subsequently, the same reviewers independently decided in 
which group the patients with new neurological symptoms should be included, i.e. 1) patients 
without reported post-transplantation anti-rejection medication, 2) patients with reported 
anti-rejection medication, either with or without neurological symptoms. Finally the reviewers 
retrospectivity attributed new neurological symptoms to 1) ‘definite CNI-induced 
7.2
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neurotoxicity’, subdividing them into patients with and without PRES 2) ‘probable CNI-induced 
neurotoxicity, 3) neurological symptoms due to another cause (such as stroke-like event). 
Thereafter consensus was made on those cases that were non-conclusive.  
 
2.3 | Analysis of FGF-21 concentrations in the two cases from the Erasmus MC 
We measured serum levels of FGF-21 levels in the two patients transplanted in our center on 
several time points before and after transplantation and during neurological events. All were 
measured using a commercial ELISA kit (Millipore) according to local protocol, as reported in 
Molema et al [22].  
 
2.4 | Analysis of MRI findings in the two cases from our center 
The MRI-scans, existing of T1-weighted, T2-weighted and diffusion weighted imaging (DWI) 
before, and T1-weighted and 3D FLAIR imaging after gadolinium injection, were performed in 
a clinical setting. The initial scan of case 1 additionally included susceptibility weighted imaging 
and contrast enhanced MR angiography. The neuroradiologist (AE) from the Erasmus MC 
performed a second reading of the MRI-scans, taking into account the original radiological 
reports. 
 
2.5 | Statistical analysis 
Descriptive parameters (frequencies, median and range) were used as outcome measurements 
in this study. The pooled incidence of CNI-induced neurotoxicity, including PRES, was 
calculated by combining the patients from literature and the patients from our center. 
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3 | Results 
3.1 | Case reports from our center 
Case 1:  
A 29 year old female patient was diagnosed with MMA at the age of 4.5 months while 
presenting with coma, vomiting and hepatomegaly. The patient was non-vitamin b12 
responsive and the MMA was caused by a homozygous frameshift mutation in the MUT gene 
(c.1311_1312insA) (table 1). At the age of 28 years she had been admitted to the hospital 58 
times for metabolic derangements. She had a mild intellectual disability; she worked as a shop-
assistant. She had developed visual loss at 12 years of age and progressive renal insufficiency. 
At age 28 years she required hemodialysis and she opted for a combined LKT. There were no 
peri-operative complications. She was placed on an immunosuppressive regime of tacrolimus, 
prednisone and mycophenolate mofetil (MMF) and her diet was liberated to a non-restricted 
diet. Of the previous medication only carnitine and vitamin b12 supplementation were 
continued. She recovered well without any metabolic disturbance.  
Approximately 2.5 months after the transplantation, she started feeling unwell without 
objective abnormalities during physical and laboratory examination. After two weeks 
(postoperative day (POD) 83) she presented with headache, ataxia and bradyphrenia. An MMA 
related metabolic stroke was initially considered, although no metabolic decompensation was 
present (according to laboratory characteristics), and a strict emergency regime was 
prescribed. Her brain MRI-scan (POD83) showed abnormalities: 1) symmetrical T2 
hyperintense laesions in basal ganglia (figure 1a1), mammillary bodies (figure 1a2), pons and 
cerebellum (figure 1a3), 2)  swelling and faint contrast enhancement in basal ganglia (figure 
1a1), swelling and avid contrast enhancement in the mammillary bodies (figure 1a2) and 3) 
high signal on DWI with intermediate ADC of the basal ganglia (figure 1a1), no diffusion 
restriction in the mammillary bodies (figure 1a2), and diffusion restriction of some of the 
cerebellar lesions (figure 1a3) (supplementary table 1). Due to movement artefacts, no reliable 
assessment of contrast enhancement of the cerebellar abnormalities was possible (figure 1a3). 
These findings can be caused by a metabolic (MMA induced) stroke-like episode but also by 
PRES. The involvement of the mammillary bodies is atypical for both etiologies. Furthermore, 
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a lentiform fork sign was observed, suggestive of metabolic acidosis, which was biochemically 
not confirmed. Also calcifications in anterior limb of internal capsule (figure 1a4) were 
observed. At POD85 mma was still very low and tacrolimus levels were within the normal non-
toxic range (table 1). The patient did not improve with the emergency regime and a tacrolimus 
induced PRES was suggested. The tacrolimus was discontinued at POD86 and replaced by 
everolimus. Within a week the clinical picture of the patient clearly improved, apart from a 
severe depression (POD 93), which was successfully treated with medication and 
psychotherapy.  
Three months later a new brain MRI-scan (POD193) showed decreased signal abnormalities, 
however with tissue loss in basal ganglia, mammilary bodies and diffuse atrophy in SCA 
territory and focal loss of tissue at the locations of the lesions in the –PICA and AICA territories 
of the cerebellum. At 14 months follow up the ataxia has greatly improved but mild 
bradyphrenia, orophacial dyskinesia (which is thought to be caused by citolapram) and a mild 
left sided hemiparesis is still present. In conclusion: because the time of onset of the new 
neurological symptoms after transplantation, the abnormalities on MRI scan and the evident 
improvement of symptoms after discontinuation of tacrolimus this patient was diagnosed with 
a CNI-induced PRES. 
 
Laboratory characteristics: mma and FGF-21. 
Plasma mma values before transplantation ranged between 3000 -11700 µmol/L and after 
transplantation rapidly declined to 200-300 µmol/L on day 4 after transplantation (figure 2). 
Although FGF-21 values, measured retrospectively before transplantation, were very high 
(>4000 pmol/ml), they rapidly decreased after transplantation (<700pmol/ml). At POD85 when 
presenting with new neurological symptoms mma was still very low, but there was a significant 
rise in FGF-21 plasma levels (retrospectively) (figure 2). Cerebrospinal fluid (CSF) mma levels 
(728 µmol/l), measured once during the work-up of the neurological symptoms, were higher 
than in plasma with a CSF/plasma mma ratio of 2.7, conform reported in literature [13, 14]. 
FGF-21 normalized when she clinically recovered. 
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Case 2 (previously reported in Molema et al [22] as case 12):  
A 19 year old female was diagnosed with early onset MMA (at the age of 12 days) presenting 
with vomiting, weight loss and an ammonia level of 172 µmol/L. The MMA was caused by a 
homozygous frameshift mutation in the MUT gene (c.2078delG), and was non vitb12 response 
(table 1). At the age of 19 years the patient had been hospitalized a total of 22 times because 
of metabolic decompensations. At 16 years of age she developed rapid visual loss due to 
optical atrophy and a progressive renal insufficiency, stage 4 and had to leave school (higher 
secondary education). Because her clinical condition rapidly deteriorated she received a 
combined LKT at the age of 19 years and 2 months. Conform case 1; she was placed on an 
immunosuppressive regime of tacrolimus, prednisone and MMF. Whilst the transplantation 
itself was uncomplicated the direct postoperative period was complicated by primary kidney 
graft dysfunction caused by an arterial thrombosis in the anastomosis, which despite a 
thrombectomy resulted in graft kidney loss, which was removed at POD 2. At POD 7 the patient 
developed a life threatening hemorrhagic shock caused by acute gastrointestinal bleeding (Hb 
of 2.5 mmol/L) a complication of reflux esophagitis, LA grade C. She recovered well with proton 
pump inhibitors without neurological complications and the patient received 1 g/kg natural 
protein per day. On POD 31 she presented with a tonic clonic seizure, without signs of 
metabolic decompensation (according to laboratory characteristics). Triggered by the 
experience with case 1, CNI-induced neurotoxicity was immediately suspected even though 
tacrolimus levels were within normal non-toxic range and tacrolimus was switched to 
everolimus on POD31. The brain MRI-scan performed at POD 32 (supplementary figure 2) 
showed no signs of PRES nor other signal abnormalities. Coincidentally, a hypoplasia of the 
vermis cerebelli was found with enlarged fourth ventricle and mildly enlarged supratentorial 
ventricles. Because of recurrent seizures in the first week after her initial seizure, treatment with 
levetiracetam was started with good result and no persisting neurological symptoms. However 
the patient developed a status epilepticus on POD49, shortly after the everolimus dose was 
increased, thought to be caused by supra-therapeutically levetiracetam levels (42 mg/L) (in 
combination with use of everolimus). She was treated with Diphantoine and midazolam, 
levetiracetam dose was reduced and since everolimus could also be causative everolimus was 
temporary discontinued. One more episode of three seizures on occurred on POD 68, 
everolimus was again briefly discontinued. Currently the patient has a follow-up of 8 months 
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and she is functioning better than before transplantation (more energy and less nausea) with 
no lasting new neurological symptoms. She is now treated with everolimus, prednisolone, 
MMF, levetiracetam (which we plan to discontinue soon), levocarnitine and idebenon. In 
conclusion: because the time of onset of the new severe epilepsy after transplantation, which 
resolved after discontinuation of tacrolimus this patient was diagnosed with a CNI induced 
neurotoxicity. 
Laboratory characteristics: mma and FGF-21. 
A significant drop in plasma mma and FGF-21 after transplantation was seen in both 
parameters (figure 2). However within a week after transplantation the patient had a life 
threatening hemorrhagic shock, in which FGF-21 increased severely. At her second and third 
admission with epilepsy a relatively mild rise in FGF-21 was seen.             
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FIGURE 1. Brain MRI images of the two patients from our center. POD 83= initial MRI or CT-scan 
and POD 193 = follow-up MRI. T2= T2 weighted images. FLAIR = Fluid attenuated inversion recovery 
images, acquired after intravenous administration of contrast medium. T1 gado = T1-weighted image 
after gadolinium administration. 1a = case 1 and 1b = case 2.  
 
1a1 Initial MRI: swelling and T2 hyperintensity of basal ganglia (blue); lentiform fork (red); faint 
contrast enhancement (green); high intensity on DWI and low/normal ADC in basal ganglia (yellow). 
Follow-up MRI: decreased signal abnormalities of basal ganglia, with tissue loss. 
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1a2 Initial MRI: swelling and T2 hyperintensity of mammillary bodies (blue); avid contrast enhancement 
(red) and no diffusion restriction. Follow-up MRI: decreased signal abnormalities, tissue loss.  
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1a3 Pons: central T2 hyperintensity (blue). Upper cerebellum, SCA territory:  diffuse T2 hyperintensity 
and swelling (red). PICA and AICA territory: asymmetrical focal T2 hyperintensities (green). Pons and 
SCA territory: no diffusion restriction (not shown). Focal lesions in PICA and AICA territory: diffusion 
restriction (yellow). Follow-up MRI: Pons: central T2 hyperintensity (blue); SCA territory decreased signal 
abnormalities (orange), diffuse atrophy; PICA and AICA territory: focal tissue loss (purple ). 
 
 
 
 
1a4 Calcifications in anterior limb of internal 
capsule (blue).   
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FIGURE 2. FGF-21 and mma plasma level before and after transplantation in case 1 (a) and case 
2 (b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blue vertical lines indicate timing of first neurological symptoms due to the CNI.  
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3.2 | Literature review 
A total of 399 unique articles were retrieved and screened on title and abstract. One hundred 
and twenty-four of these articles reported a total of 230 transplanted MMA patients. Only 23% 
of the cases (54/230) explicitly reported neurological follow-up. Of these 54 patients, 24 were 
excluded from further analysis because of lack of information on the use of post-transplant 
medication (figure 3). However of these 24 cases, who likely all used a CNI, 5 (21%) had 
probable CNI-induced neurotoxicity (supplementary table 2a, dark green boxes figure 3) and 
6 (25%) had acquired new neurological symptoms due to another cause (supplementary table 
3a); the remaining patients did not develop new neurological symptoms after transplantation.   
Of the 30 cases that were included in our analysis all were reported to receive a CNI. Sixteen 
patients (55%) did not develop new neurological symptoms while on CNI, five patients (17%) 
had definite CNI neurotoxicity (table 1, bright green boxed figure 3, (1 patient related to 
cyclosporine [23], and all others to tacrolimus), two patients (7%) had probable CNI-induced 
neurotoxicity and seven patients (23%) developed new neurological symptoms due to another 
cause (supplementary table 2b, 3b). Of the two patients with probable CNI-induced 
neurotoxicity (dark green boxes figure 3), one patients did not improve when tacrolimus was 
switched to cyclosporine (another CNI) and in the other patient no information regarding 
continuation of CNI was available.  
Of the five patients with definite CNI neurotoxicity described in literature three had brain MRI-
scan findings reported [12, 23, 24].  Signs of vasogenic edema were found in 2 patients 
(supplementary table 1); one of these patients had posterior cerebral involvement. Both 
patients were defined as having PRES considering the improvement of MRI findings and return 
of symptoms to baseline neurological status after discontinuing CNI respectively [23, 24].  
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FIGURE 3. Flow-chart of literature review and overview of excluded patients (which are further 
described supplementary table 1, 2a and b and 3a and b)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to another cause 
Probable CNI-induced 
Definite CNI-induced neurotoxicity 
  
 
 
 
240
Chapter 7.2
3.3 | Pooled incidence of CNI-induced neurotoxicity, including PRES  
In total, 5 of 30 patients from the literature, and our two cases have been described in enough 
detail to conclude that they had CNI-induced neuro-toxicity (figure 3, table 1) resulting in 
pooled incidence of 22% (7/32) in MMA patients after solid organ transplantation, and an 
incidence of neurological symptoms due to other etiology than CNI of 22% (7/32) 
(supplementary table 3b). 
Overall, in patients with CNI-induced neurotoxicity median age at transplantation was 20 years 
(range: 5- 28years) and the median follow-up after transplantation was 1.5 years (range 0.33-
11.5year). Symptoms occurred between POD10 to 3 months after transplantation (table 1). 
Symptoms varied widely (table 1), with seizures being the most frequently presenting 
symptom (5/7). The majority of patients had tacrolimus levels within reported therapeutic 
reference ranges (5/6). Overall, 9% (3/32) of the patients likely had a CNI-induced PRES 
identified by brain MRI-scan. 
4 | Discussion 
This is the first systematic review that investigates the frequency of new neurological 
symptoms in MMA patients after liver and/or kidney transplantation and investigates whether 
these symptoms could be related to CNI-induced neurotoxicity, including PRES. Since 
neurological symptoms are likely to resolve when CNI is timely reduced/discontinued it is 
essential that physicians treating transplanted MMA patients are aware of CNI-induced 
neurotoxicity. 
 
4.1 | CNI-induced neurotoxicity, including PRES, in transplanted MMA patients 
4.1.1 | Clinical findings 
According to our findings the risk of developing CNI-induced neurotoxicity in transplanted 
MMA patients seems similar to the risk of neurological symptoms due to other etiologies 
(22%), such a metabolic stroke-like episode. Differentiation between these different etiologies 
is difficult. The time after transplantation of occurrence of new neurological symptoms seems 
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to be indicative. CNI-induced neurological symptoms generally occur shortly after 
transplantation (days up to months [19, 25]. This is confirmed in this study (all within 3 month 
after transplantation), while symptoms occurring more than a year after transplantation seem 
to be more likely metabolically induced, among other probably due to the entrapment of mma 
in the brain [26]. To gain more insight in the effect of transplantation on mma levels in CSF 
and to aid clinical interpretation of new neurological symptoms after transplantation, we 
recommend the measurement of mma CSF levels before/during and after transplantation in 
all to be transplanted MMA patients.  
However, in non-MMA patients CNI induced PRES has also been described years after kidney 
transplantation [27]; and CNI induced neurotoxicity should therefore never be discarded as 
possible cause. CNI induced neurotoxicity frequently presents with seizures, both in 
transplanted MMA patients (5/7 with CNI-induced neurotoxicity and 3/3 with PRES and in the 
majority of non-MMA patients with CNI-induced PRES [17, 19, 28]. We recommend 
considering CNI-induced neurotoxicity in all transplanted MMA patients presenting with new 
onset of seizures after transplantation. In CNI-induced seizures more recently developed 
anticonvulsants should be used and no valproic acid [17].  
 
4.1.2 | Diagnosis and treatment  
There are three steps to diagnose new neurological symptoms as CNI-induced neurotoxicity 
(in which plasma CNI levels do not necessarily have to be above the therapeutic window [25, 
29, 30], including PRES [17]. Firstly, other etiologies should be excluded, such as a metabolic 
stroke-like episode, which is likely to be preceded by a systemic decompensation. Secondly, 
neuro-imaging should be performed. In case T2 hyperintensity is found on MRI, diffusion-
weighted imaging (DWI) can help distinguish between vasogenic edema, which is typically 
found in PRES, and cytotoxic edema (with restricted diffusion) that is typical for acute ischemic 
stroke. However this is not always the case:  restricted diffusion can also be encountered in 
PRES, and vasogenic edema can also occur in acute metabolic ischemic stroke. Brain location 
seemed typical only in one patient involving occipitoparietal region (Giussani). A recent study 
describes a central variant of PRES [31], which seems more in line with case 1. Thirdly, there 
should be improvement of symptoms after reduction /discontinuation of the CNI. There are 
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no clear recommendations on whether to reduce the dose or discontinue the CNI and how 
long discontinuation should last [21].  
 
4.1.3 | Outcome  
With early recognition and treatment of CNI-induced neurotoxicity, including PRES, the 
majority of patients will have no remaining neurological symptoms [28]. However, life-
threatening complications may occur [32] and acquired neurological damage may persist [33, 
34]. In the three MMA patients with PRES some remaining clinical abnormalities were found 
(case 1; [12, 24].  
 
4.2 | FGF-21 and CNI-induced neurotoxicity, including PRES, in transplanted MMA 
patients 
The exact pathophysiology of CNI-induced neurotoxicity, including PRES, is unclear but seems 
multifactorial [35] [36]. Impairment of oxidative phosphorylation by CNIs and thereby 
mitochondrial dysfunction has been reported to be a possible cause [37, 38]. Mitochondrial 
dysfunction plays an important role in the pathophysiology of MMA, and FGF-21 is a 
biomarker for mitochondrial dysfunction.  Clearly increased FGF-21 levels have been described 
in MMA [22, 39-42]. We confirmed the severe initial decrease of FGF-21 after transplantation 
as recently reported by Manoli et al [43]  in our two case reports. However, we also showed an 
increase in FGF-21 plasma levels in case 1 at the time of neurological symptoms due to CNI-
induced PRES with a decrease in FGF-21 with improvement of symptoms and brain MRI-scan 
findings. This is suggestive for the pathogenic role of disturbed mitochondrial function in CNI-
induced PRES. In case 2, a severe increase of FGF-21 was seen during hemorrhagic shock, 
which indicates that other factors such as ischemia impair mitochondrial function as well. 
Importantly, further studies are required on the potential role of FGF-21 in adding evidence to 
the underlying cause of CNI-induced neurotoxicity in transplanted MMA patients with new 
neurological symptoms. We hypothesize that patients with pre-existent mitochondrial 
dysfunction (as present in patients with MMA) are more at risk to develop CNI-induced 
neurotoxicity than the general population because of the cumulative effect of CNI on the 
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mitochondria. However, to date there is no clear evidence to support this and this should be 
prospectively investigated. If MMA patients indeed have a greater risk to develop CNI induced 
neurotoxicity than the general population we should consider to give a none CNI 
immunosuppressant, like Sirolimus, as first line immunosuppression in these patients, even 
though they are less potent as immunosuppressant [44, 45]. 
 
4.3 | Incidence of CNI-induced neurotoxicity, including PRES, in non-MMA transplanted 
patients 
Previous studies in non-MMA transplanted patients reported an incidence of CNI induced 
neurotoxicity in 20% of the transplanted adults [46] and 8% of pediatric patients [47, 48]. The 
incidence of CNI induced PRES has been reported to  range from 0.34 to 1% of the non-MMA 
patients after transplantation [19] [25] [27]. The incidence of CNI-induced neurotoxicity in 
transplanted MMA patients in this study seems comparable to the incidence with non-MMA 
transplanted patients, while the incidence of PRES seems much higher than in non-MMA 
transplanted patients.  
 
4.4 | Study limitations  
Several limitations of this study require attention. The true incidence of CNI-induced 
neurotoxicity is difficult to investigate by means of a systemic review since not all transplanted 
MMA patients have been published, neurological follow-up was described only in a minority 
(20%) of the reported cases and it is uncertain whether the authors/clinicians were aware of 
the possibility of CNI-induced neurotoxicity, including PRES, in MMA. Adding our patients to 
the total of transplanted patients could lead to bias. However since these cases were the only 
two MMA patients transplanted within our center we avoided this bias as much as possible. 
Furthermore, several authors published numerous articles with the likelihood of using the 
same patient case multiple times without explicitly mentioning so. We did therefore look into 
potential duplicates.  
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In order to investigate the true incidence of CNI-induced neurotoxicity, including PRES, and 
neurological complications due to other causes it is essential to establish a thorough 
prospective database with follow-up of all the MMA transplanted patients. Since pre-existent 
MRI abnormalities are frequent in MMA patients a pre-transplant brain MRI-scan would be of 
great value to distinguish between pre-existing and new problems in all (to be) transplanted 
MMA patients. In MMA patients typical MRI findings (with typical as well as atypical brain 
locations) suggest PRES with the added value of DWI and ADC (in first 10 days after new 
neurological symptoms). Furthermore, mma levels and FGF-21 in plasma and cerebrospinal 
fluid should be included in future studies/databases.  
 
5 | Conclusion 
CNI-induced neurotoxicity should be considered in all transplanted MMA patients with CNI 
use and new neurological symptoms. When CNI-induced neurotoxicity cannot be excluded 
brain MRI-scans (including DWI) should be performed and CNI dose must be reduced or 
discontinued, since with timely recognition of CNI-induced neurotoxicity and dose reduction 
or discontinuing CNI, symptoms can resolve.  
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LIVER AND/OR KIDNEY TRANSPLANTATION IN AOA PATIENTS 
  
 GENERAL DISCUSSION AND 
FUTURE PERSPECTIVES
8
In recent years treatment for classical organic acidemia (OAD) and urea-cycle disorders (UCD) 
has not changed dramatically regarding the dietary therapies. It is known that with the 
currently applied treatment, patients have an unsatisfactory outcome characterized by 
recurrent metabolic decompensations, long-term complications (with an increased mortality 
risk), impaired growth, and cognitive developmental delay. The data collected by the E-IMD 
(n=271 OAD and n=361 UCD patients) and the collection of a large retrospective cohort in the 
Netherlands on methylmalonic (MMA) and propionic acidemia (PA) patients (n=76 patients) 
made it possible to analyze current dietary treatment strategies and define how to improve 
these. Furthermore, the effort of all European metabolic clinicians led to the collection of a 
large data set on liver and/or kidney transplantation performed in Europe.  
The hypothesis to be answered was: patient’s outcome can be improved by optimization of 
the currently available treatment. It is essential to evaluate currently applied treatment 
strategies, not only because long-term outcome of classical OAD and UCD patients continues 
to be disappointing, but also because newborn screening for these diseases is implemented 
in an increasing number of countries. 
This thesis had four sub-aims: 
1. To explore the natural history of classical OAD and UCD patients and the treatments 
applied, to provide insight in the outcome/prognosis obtained with the currently 
applied therapies (chapter 2, 3 and 6). 
2. To determine the most optimal dietary treatment advice (chapter 2 and 4). 
3. To improve monitoring of classical OAD and UCD patients (chapter 5 and 6).  
4. To determine the outcome (mortality, complications, quality of life (QOL) and cognitive 
development) of AOA patients who received solid organ transplantations (chapter 7). 
This chapter discusses the main findings of the research performed and described in this thesis 
and their relevance to clinical practice. Firstly, the outcome measures will be argued, and 
thereafter treatment recommendations and tools on how to monitor patients will be provided.  
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MAIN CONCLUSIONS OF THIS THESIS 
Discussed in 1.1 and 1.2:  
1. Despite their relatively high natural protein prescription according to WHO 
recommendations, classical OAD and UCD patients have low levels and disturbed ratios 
of branched chain amino acids (BCAA) (chapter 2 and 4). 
2. In classical OAD patients, and in particular in MMA, amino acid mixtures can be harmful 
and should be prescribed as advised and with care (chapter 2 and 4). 
Discussed in 1.3: 
1. Impaired growth is observed; optimization of L-arginine in MMA and PA and of branched 
chain amino acid levels in UCD is essential to improve growth (chapter 3). Height is 
associated with the natural and total protein energy ratio (chapter 3 and 4).  
Discussed in 1.4:  
1. Newborn screening in MMA and PA can potentially lead to a reduction of an adverse 
neurological outcome from 46% to 36%. The frequency of decompensations, 
mitochondrial complications and treatment related complications are most likely not 
positively affected (chapter 6). 
Discussed in 2.0: 
1. Metabolic decompensations and long-term (mitochondrial) complications are major 
problems in MMA and PA patients. The high protein prescription increases the risk of 
metabolic decompensations (PA) and mitochondrial complications (MMA) and of 
impaired cognitive development (entire MMA and PA cohort) (chapter 4). 
2. In MMA and PA patients, long-term mitochondrial complications can be life threatening; 
FGF-21 is a good biomarker to define risk groups for mitochondrial long-term 
mitochondrial complications (chapter 5).  
3. Liver and/or kidney transplantation in AOA seems a safe treatment option with good 
overall survival (78-100%) and stable or improved cognition and quality of life (chapter 
7.1). However in MMA patients, caution should be taken in using calcineurin inhibitors 
(CNI), since they can induce severe neurotoxicity, likely due to pre-existing mitochondrial 
dysfunction (shown by FGF-21 levels). This neurotoxicity can be reversible when CNI is 
stopped in time (chapter 7.2). 
Discussed in 3.0: 
1. To improve patient care of MMA and PA patients identified by the recently implemented 
newborn screening program, additional recommendations on clinical evaluation for 
long-term complications are given (chapter 4 and 6). 
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1 | Main outcomes regarding dietary treatment  
1.1 | A high protein intake is prescribed and (in MMA and PA) harmful 
Protein prescription in classical OAD 
The guidelines for MMA and PA patients states that: ‘’ The goals of long-term management 
are to achieve normal development and to prevent episodes of metabolic decompensation, 
whilst providing good quality of life and avoiding side effects and complications’’. In the 
European cohort, we observed that several patients had a high natural protein prescription 
and total protein prescription, even above RDA by the FAO/WHO/UNU. In OAD, the guideline 
suggests prescribing AAM-OAD in those patients with a natural protein prescription below the 
RDA. However, we observed that the majority of those who received AAM-OAD, had natural 
protein prescription that was already compliant and even above the recommended daily 
allowances (RDA). In all subgroups of MMA and PA patients, total protein prescription was 
high according to the RDA, even in the severe patients (MMA vitaminB12 unresponsive and 
PA early onset (EO) patients). In the severe patients, the high total protein prescription was 
mainly due to the prescription of AAM-OAD. Why such high amounts of protein are applied 
remains unclear. It could be due to 1) unfamiliarity with RDA, as most often g/kg is used to 
calculate protein prescription, 2) adjustments of protein prescription when impaired growth is 
observed, 3) prescribing more than RDA to compensate for the protein quality patients 
consume, or 4) adjustments of protein prescription based on low BCAA levels. 
Whether or not the natural protein prescription could be further increased was unknown and 
a trend towards prescribing a higher natural protein in the meantime was already taking place.  
In the sub-cohort of the Dutch MMA and PA patients (chapter 4) we clearly showed that an 
increased natural protein prescription increases the risk of 1) metabolic decompensations, 2) 
mitochondrial complications, and 3) impaired cognitive development. This holds in particular 
for the severe disease types (MMA vitaminB12 unresponsive and PA EO patients). Firstly, based 
on the pathophysiology a higher tendency towards metabolic decompensations seems likely 
with higher protein prescription. However, to date it was unclear at which protein prescription 
this risk on decompensation was significantly increased. It is necessary to take patient specific 
characteristics into account, such as physical activity. Secondly, more metabolites that are toxic 
seem to accumulate with high protein prescription resulting in a higher detrimental effect on 
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mitochondrial function. These metabolites can harm the mitochondria and thereby disturb 
their function. The harmful effect on mitochondrial function will be further explained in the 
latter part of this discussion.  Thirdly, regarding cognitive development it is known that certain 
proteins can affect the integrity of the blood brain barrier and thereby induce stress on 
neurological functions [1].  
Regarding protein prescription in MMA and PA patients the statement: ‘first do no harm’, 
seems applicable. Which mean that to date it is recommend to prescribe a lower protein intake, 
to reduce metabolic decompensations, mitochondrial complications and potentially improve 
cognitive development. It should be taken into consideration that one should compensate for 
a low biological value of the protein consumed. For MMA vitB12 responsive patients, it is 
recommended not to prescribe AAM to any of these patients. In MMA vitB12 unresponsive 
patients, outcome needs to be evaluated in patients treated with a natural and total protein 
prescription below RDA. It needs to be answered what will happen with the BCAA plasma levels 
and with growth. This prospective evaluation will take a long time-period and therefore other 
studies are essential. To obtain an answer on the short-term in vitro studies might help to get 
insight in the effect of adjusted dietary therapies on cellular levels and in the potential 
pathophysiological mechanisms that elicit the harmful effects. Furthermore, we advise to 
measure biomarkers (FGF-21 and potentially GDF-15) when dietary therapies are adjusted in 
patients, to monitor the potential harmful effect on mitochondria in patients. Potentially, it 
should be advices that protein in MMA and PA patients need to be of low as well as high 
biological value, as was recommended recently for UCD patients in the newly published UCD 
guideline [2]. 
 
Protein prescription in UCD 
The goal of the dietary treatment in UCD is to acquire metabolic stability with optimized 
growth and development, while preventing chronic complications [2]. The guideline for UCD 
proposed by Häberle et al [2, 3] suggests that the FAO/WHO/UNU requirements should be 
used to determine optimal protein prescription. The protein RDA by the FAO/WHO/UNU is 
based on individuals consuming protein of a high biological value. The protein commonly used 
by UCD is however often of low biological value [4]. The guideline recommends, when 
8
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synthetic protein (AAM-UCD) is used, to prescribe 20-30% of the total protein prescription as 
protein from AAM-UCD [3]. The updated guideline also discusses that the effects of physical 
activity of patients on their protein needs, need to be taken into account [2]. In this thesis it is 
shown that natural protein prescription in UCD patients was compliant with the RDA in several 
patients, but that total protein prescription was above RDA in the majority of patients due to 
the additional amino acid supplementation. There was no clear difference in total protein 
prescription between the UCD subgroups. The differences between countries regarding 
protein prescription, clearly indicates that to date it is unknown what optimal dietary 
prescription in these patients is.  
AAM-UCD should be applied in patients with a low protein tolerance. Accordingly, in this thesis 
it is shown that in numerous symptomatic patients taking additional AAM-UCD, natural 
protein prescription was below the RDA, while total protein prescription was compliant to and 
above the RDA. In UCD, AAM-UCD contain essential amino acids and these products seem 
efficient in acquiring higher plasma amino acid levels. The products should not include 
tryptophan, phenylalanine, and tyrosine. These amino acids can be used to produce serotonin 
and dopamine, which levels can be increased in hyperammonemia and they can be therefore 
harmful for the patients. So far, AAM-UCD products have not been shown to cause any harmful 
effects and the advice is to prescribe these products in patients with low plasma BCAA levels, 
low protein prescription and/or sodium phenylbutyrate use.  
The amount of protein prescribed in UCD seems sufficient according to guidelines, but it is 
questionable if this advice is indeed appropriate and whether optimal patient outcome is 
achieved with this treatment. Overall protein prescription compared to the RDA was relatively 
high. And a high protein prescription can be harmful since it can induce hyperammonemia 
and put the patient at risk for renal disease [5]. It is interesting to observe that mainly 
asymptomatic patients received a high total protein prescription and it is unknown why this is 
done. It could well be that clinicians are fearful to induce deficiencies by a relatively low protein 
diet. A low protein intake can induce mineral and vitamin deficiencies and physicians should 
monitor this and when necessary supply minerals and vitamins to patients. However, to date 
there is no evidence to support that a lower protein presription in these patients will be actually 
harmful. The protein that is consumed should, according to the last insights, contain protein 
of high as well as low biological value to avoid any deficiencies.   
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More in depth studies, such as done in the sub-cohort of Dutch MMA and PA patients, are 
necessary to evaluate the potential harmful consequences of the high total protein 
prescription. To date, we recommend close monitoring of classical OAD and UCD patients, of 
their outcome and of their plasma amino acid levels. A biomarker to monitor disease 
progression is essential to optimize patient outcome.  
 
1.2 | Low plasma BCAA levels are frequently observed  
BCAA (and aromatic neutral amino acids) compete for the cellular uptake by the same L-type 
amino acid transporter (LAT) [6]. Four subtypes of LAT are known, all of them are involved in 
the transport of BCAA and methionine and phenylalanine. LAT1 and LAT2 are also transporting 
other amino acids such as histidine and tyrosine. LAT1 is located at the blood-brain barrier, 
colon, and liver. Interestingly, LAT1 is also expressed at the blood retinal barrier and we should 
look into this transporter (including the BCAA transport) in our patients/mouse models 
regarding the occurrence of optical atrophy in classical OAD patients. LAT2 is expressed in the 
kidney, jejunum, ileum, but also on brain and liver. Not only amino acids are transported by 
the LAT transporter, but thyroid hormones as well (by the LAT1 and LAT2). Interestingly, in 
some MMA and PA patients disturbed thyroid hormone levels have been observed with to 
date no clear pathophysiological explanation. LAT3 is expressed in human pancreas, liver, 
skeletal muscle, and fetal liver, whereas LAT4 is expressed in placenta, kidney, and peripheral 
blood leukocytes.  
Disturbed BCAA ratios can influence the uptake of any of the BCAA by the LAT. High levels of 
leucine can lead to a decreased uptake of the other two branched chain amino acids and 
isoleucine as well as valine can both interfere with leucine uptake. Optimized BCAA ratios will 
most likely improve BCAA uptake.  
In MMA and PA, plasma L-valine and L-isoleucine levels lay below reference ranges in 
respectively 57% and 55% of the patients in the E-IMD cohort. We confirmed these low BCAA 
levels in the Dutch sub-cohort of MMA and PA patients. In MMA and PA patients, AAM-OAD 
products seem to partially cause the disturbed BCAA ratios. AAM-OAD contain high amounts 
of leucine, while no valine or isoleucine. In MMA and PA we showed that L-leucine: L-isoleucine 
8
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as well as L-leucine: L-valine ratios were higher in those who received AAM-OAD versus those 
who did not, which is in line with a study by Myles et al. [7].   
BCAAs are essential to 1) maintain anabolism [8], 2) optimize growth (height) and  bone 
marrow function [9, 10], 3) support normal development [11-13], 4) optimize functioning of 
the central nervous system [14-16], and 5) support normal mitochondrial function [17].  
Towards improving patient care, it thus seems necessary to fine-tune plasma BCAA levels in 
individual patients. The first step towards better monitoring of the classical OAD patient is 
regular measuring of plasma BCAA levels [18].  
In UCD, plasma L-valine, L-isoleucine and L-leucine levels lay below reference ranges in 18%, 
30% and 31% of the total group of UCD patients in the E-IMD cohort. The cause for the low 
plasma BCAA levels could be the protein restricted diet; however, we observed a relative high 
protein prescription in the majority of patients. AAM-UCD products contain BCAA in ratios 
that are closer to the optimal ratio of 1:2:4 (isoleucine: leucine: valine) than the products in 
AAM-OAD. Isoleucine content was a bit higher and valine contents overall a bit lower in AAM-
UCD products. However, plasma BCAA ratio’s observed in UCD patients consuming AAM were 
normal and AAM-UCD do not seem to be explain the low plasma BCAA levels in UCD patients. 
One important cause for low BCAA levels in UCD patients is the use of sodiumphenylbutyrate 
[8, 19] and patients using this medication should be monitored closely.  
In MMA and PA, for optimized dietary treatment it is essential to calculate BCAA ratios, rather 
than to monitor their overall plasma levels only. In the first published study in this thesis on 
dietary prescription in classical OAD and UCD, we stated that since a low natural protein 
prescription can be potentially harmful, i.e. low BCAA levels, one should ensure that each 
patient achieves a higher natural protein prescription in such a way that it does not cause 
metabolic instability. Regarding AAM supplementation in MMA and PA, patients who received 
AAMs-OAD had very low BCAA levels and disturbed plasma BCAA ratios. Considering the likely 
harmful effects of AAM products on these BCAA plasma levels, it could be questioned what 
the effect of increasing natural protein prescription will be if a patient is still on AAM. In 
patients already receiving 100% RDA natural protein or in those with an adequate RDA we 
highly recommend to stop AAM prescription. In UCD patients, it seems that AAM can help to 
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obtain normal BCAA levels. In UCD, we recommend to apply AAM in those patients with low 
BCAA levels. Furthermore, in line with OAD, we must also pay attention to the BCAA ratios.  
 
Pathological mechanisms in other diseases and the knowledge obtained from treatment in 
these diseases can potentially be applicable to the disorder focused upon in this thesis. For 
MMA and PA patients, we hereby examined the treatment of phenylketonuria (PKU) patients. 
PKU patients are treated with indispensable L-amino acids, which decrease plasma 
phenylalanine levels due to interaction on a the LAT1 carrier protein. Furthermore, it is known 
that this transporter present on the mucosal epithelium is the same as the one exposed in the 
brain and it is shown that phenylalanine levels in the brain are decreased by these L-amino 
acids [20-22]. In MMA and PA, the same LAT transporter plays a role on the mucosal epithelium 
and is also present at the blood brain barrier. In PKU, a clear recommendation is given on the 
amount of L-amino acid supplements that should be provided [23]. This principle of treating 
patients with a certain amino acid to counteract the uptake of the ‘toxic’ amino acids could be 
used in MMA and PA patients. Within the early years of discovery of MMA and PA, a study has 
been published on the effect of solely applying L-leucine to a patient [24].  The AAM-OAD 
products have a high level of leucine and considering the interaction it could be that it is 
helpful in decreasing isoleucine and valine uptake. However, according to our data it seems 
that with the current applied dietary treatment there is no appropriate balance in BCAA plasma 
levels, with very low levels of isoleucine and valine in the majority of the patients.  In conclusion, 
it is definitely worth considering leucine supplementation as a treatment strategy, however in 
lower quantities than the high amount currently available in AAM products. Lower amounts 
might be helpful to obtain optimal BCAA ratios and uptake.  
Regarding recommendations on plasma BCAA levels, which to date are not given in MMA and 
PA, the guidelines for MSUD could be of help. These guidelines give clear recommendations 
on plasma BCAA levels at certain ages (in case of leucine). In MSUD: ‘’The goal of dietary BCAA 
restriction for the individual with MSUD is to achieve and maintain plasma BCAA 
concentrations as close to normal as possible while preventing and correcting BCAA 
deficiencies’’. While this has not mentioned to be a goal for MMA and PA patients, it could 
well be that we should achieve and maintain plasma BCAA levels close to normal considering 
8
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the very low BCAA levels in our patients. Hereby we aim to achieve normal BCAA ratios and 
potentially improve growth and decrease metabolic decompensations. Optimization of these 
BCAA levels rather than aiming towards a high total protein prescription could be a future goal 
of treatment. Furthermore this MSUD guideline states: ‘to promote anabolism of LEU, when 
LEU blood concentrations are high, additional supplementation of VAL and ILE is often 
required’. So again, in both the PKU and the MSUD guideline it is recommended to take the 
interaction of BCAA with the same LAT transporter into account in the treatment of patients. 
In the MSUD guideline it is even stated how much of each BCAA has proven to be successful 
and should be taken as part of the daily nutrient prescription [25].  
 
1.3 | Growth (height) is often impaired 
Considering the dietary treatment in classical OAD and UCD patients, we have to be aware of 
the fine scale/balance the patients live on. Growth in children can be used as a ‘marker’ of 
good health. On one side we want to increase protein prescription to optimize growth, and on 
the other side we want to minimize the risk of long-term complications (such as mitochondrial 
complications) and metabolic decompensations. This all while preventing neurological 
damage and maintaining optimal cognitive development. Growth is disturbed in the majority 
of classical OAD and UCD patients [26-31]. While growth is often used as outcome measure 
for appropriate protein intake it is questionable whether this assumption is correct in these 
patients. It is furthermore questionable if normal height needs to be achieved in patients with 
these diseases. In our early studies, we suggested that optimal growth will result in improved 
protein tolerance and possibly a decrease in the number of decompensations. We must 
consider the possibility that in classical OAD and UCD patients not necessarily the total protein 
intake reflects growth, but that rather the deficiency of certain specific amino acids, such as L-
leucine, L-isoleucine, L-valine, L-histidine, L-arginine and L-lysine are the cause of insufficient 
growth [11, 32]. Whether the disturbed growth is an important issue in these patients is 
questionable. Of course, with improved growth protein tolerance it will likely be optimized. If 
a higher protein prescription is necessary to achieve optimized growth, while inducing 
decompensation and mitochondrial complications optimized growth should not be the main 
goal of treatment. 
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In the study on growth in OAD patients, we observed that L-arginine plasma levels are 
associated with growth. While L-arginine supplementation can potentially be beneficial, it can 
also have severe side effects [33], such as the induction of hypoglycemia and excessive 
production of nitric oxide [34]. Further research should be performed with regard to 
recommendations on the most optimal plasma L-arginine levels in these patients and whether 
supplementation of L-arginine is a safe method. In UCD, disturbed growth was mainly 
observed in CPS1-D and ASS-D patients. Plasma L-leucine and L-valine levels in UCD patients 
were associated with growth in UCD subgroups and AAM-UCD can be helpful to improve 
growth.  
 
Regarding protein prescription, the protein: energy ratio is often calculated and used in dietary 
prescription. In our studies we found a positive effect of increased P:E ratio on growth in MMA 
unresponsive patients in the subset of the Dutch MMA patients. Furthermore we observed that 
a higher P:E in PA EO patients was associated with less mitochondrial complications. A 
disturbed ratio can be due to a low protein prescription (although this was not observed in 
any of the published studies) or due to a high kilo caloric intake installed to avoid catabolism. 
While the P:E ratio seems helpful in dietary management it is essential to acknowledge that 
several factors need to be taken into account, which clarify that the use of P:E ratio has some 
drawbacks. Energy intake does not always reflect energy requirements. Energy requirement is 
highly dependent on physical activity. Therefore it is hard to define the optimal P:E needed to 
achieve optimal growth.  
 
1.4 | Impaired cognitive development is regularly seen and associated with protein 
prescription (in MMA and PA) 
Cognitive development is often impaired in classical OAD and UCD. Of the Dutch MMA and 
PA patient group almost one third had an IQ below 60. Cognitive development is more 
frequently impaired in PA patients than in MMA patients [35, 36]. The impaired cognitive 
development can be caused by different factors, of which 1) the timing and severity of the first 
metabolic decompensation, 2) recurrent decompensations and 3) ongoing toxicity are of main 
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importance. To avoid neurotoxicity induced by the first metabolic decompensation early 
recognition of the disease and immediate start of treatment is essential. In this thesis we 
showed that the introduction of newborn screening could potentially be beneficial in 
preventing neurological damage of first symptomatic presentation. However, studies 
performed so far show that newborn screening did not seem to influence the clinical course, 
including the number of metabolic crises, physical and neurocognitive development, and long-
term complications [21,22]. This is in part due to the fact that there is currently no curative 
treatment available. It is essential to be aware that by implementing newborn screening we 
may lose the discrimination between patients with early and late onset of PA. By not knowing 
how the patient would have presented without NBS, it is harder to determine whether a patient 
will be severely affected or milder and thus which treatment will be appropriate. Identification 
of the genetic variants may help to discriminate. In case of an unknown variant functional in 
vitro studies (e.g. in vitro mutagenesis) may be helpful to predict the phenotype. One can 
speculate that biomarkers for disease severity become even more important now newborn 
screening has been implemented. In line with this further studies on FGF-21, in particular in 
patients identified by NBS, are essential to guide patient treatment and care.  
Recurrent decompensations still occur despite current treatment strategies. In our study in 
Dutch MMA and PA patients, we observed that MMA vitaminB12 unresponsive and PA EO 
patients were mainly at risk of metabolic decompensations. Newborn screening in these 
patients did not seem beneficial on the severity/frequency of metabolic decompensations. 
Regarding treatment during and after decompensations several questions are still 
unanswered. For example, it is not clear whether patients need a higher protein prescription 
(than before admission to the hospital) after a metabolic decompensation to compensate for 
the temporarily lower intake (often already before and) during decompensations. It could well 
be that they do need some extra intake to recover from this decompensation [37]. The effect 
of decompensations on patient development, stability and energy balance needs to be taken 
into account.  
Ongoing toxicity occurs due to accumulation of toxic metabolites even when a patient is stable 
and not decompensated. In PA, one of the toxic metabolites that accumulates and have shown 
to be associated with cognitive outcome is 3-hydroxypropionate [35]. Regarding the cognitive 
development, BCAA seem essential for optimal functioning of the central nervous system [11-
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16]. As previously mentioned the LAT is the main transporter for BCAA, also for transport 
across the blood brain barrier. In this thesis we showed that a high protein prescription was 
associated with more severe cognitive developmental delay in MMA and PA patients. Different 
studies have been performed to determine the effect of proteins on brain function in other 
diseases. While it is known that BCAA are essential for cognitive development, it is also shown 
that a high protein intake can disturb the blood brain barrier function. Furthermore the 
oxidative stress/ mitochondrial dysfunction observed in MMA and PA patients can also take 
place in the brain and thereby cause severe damage. Since oxidative stress is also observed in 
stable disease period it could well be that patients experience ongoing neurocognitive damage 
despite the fact that they do not experience metabolic decompensations. A typical MRI 
abnormality in MMA and PA patient is the involvement of the basal ganglia, but abnormalities 
in sulci and fissures as well as delayed myelination are also reported. We recommend to 
perform brain MRI (MRS) studies in classical OAD patients in order to monitor the patient and 
gain knowledge on potential other causative factors (such as mitochondrial failure) for 
disturbed cognitive development.  
Within the different UCD subgroups the frequency of impaired cognitive development differs. 
In 34% to 66% of the patients the cognitive development is impaired [2]. In UCD patients, 
cognitive outcome mainly depends on the severity and duration of the first hyperammonemic 
crisis [38]. Within the different UCD subgroups the frequency of impaired cognitive 
development differs, with 34% to 66% of patients having an impaired cognitive development 
[2]. In UCD, brain MRI (MRS) studies are recommended to monitor patients, even if they have 
a normal cognitive development, to correlate anatomical characteristics on brain MRI to 
cognitive development [2].   
 
1.5 | Conclusions on main outcomes regarding dietary treatment 
From this thesis the following recommendations on dietary treatment are essential: 
1. For the treatment of UCD and classical OAD patients, use the RDA as a guide when 
determining protein prescription.  
2. Be very aware of the potential harmful consequences of high protein prescription on 
patient outcome, even when protein prescription is in line with or close to the RDA. 
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3. In MMA and PA patients be aware of harmful consequences of AAM prescription. 
4. Monitor BCAA plasma levels and ratio’s closely and frequently in UCD (mainly in those 
treated with sodiumphenylbutyrate) and in classical OAD patients. 
5. In classical OAD patients, measure FGF-21 (and other (potentially newly identified) 
markers/ material for metabolomics)  levels in stable period to guide patients disease 
progression/improvement. 
 
 
2 | Long-term (mitochondrial) complications due to improved survival 
In MMA and PA patients several long-term complications may occur. Some are due to 
mitochondrial dysfunction, of which cardiomyopathy, optic atrophy, abnormality of the liver, 
pancreatitis, pancytopenia, seizures and abnormalities of the basal ganglia are of major 
importance [39]. In the Dutch MMA and PA cohort mitochondrial complications were present 
in 70 of the 76 patients, and were mild in 30, moderate in 13, severe in 12 and very severe in 
14 patients. Interestingly renal failure is mainly observed in MMA, while cardiomyopathy is 
mainly observed in PA patients. To date no clear explanations have been found to explain 
why MMA and PA patients differ in these types of complications. It could be due to the 
difference metabolites in PA and MMA. In PA 3-hydroxypropionate, methylcitrate, 
tiglyglycine and propionylgycine as well as glycine are increased, while this is less in MMA. 
Different tissues have different enzyme activity (MUT and PCC) and different vulnerability 
towards mitochondrial stress and it could be that specific tissues are more vulnerable to 
certain metabolites. In UCD, a major complication is liver failure, mainly in OTCD, ASS-D, 
ASL-D, Arg1, and HHH syndrome patients. In ASL-D arterial hypertension can be observed 
and should be monitored. In Arg1 spastic paraplegia and developmental delay are often 
observed. In HHH syndrome spastic paraparesis, and coagulopathy can be observed.  
 
In keeping a balanced scale in the individual patients, energy intake and uptake is important.  
In classical OAD mitochondrial failure and energy disturbance is a major problem. The study 
on FGF-21 presented in this thesis gives additional proof to the hypothesis that 
mitochondrial dysfunction plays a role in long-term complications in classical OAD patients. 
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Levels of FGF-21 were increased even before mitochondrial complications occurred and we 
showed that FGF-21 is a good biomarker for (emerging) mitochondrial complications. Manoli 
et al confirmed our observations on FGF-21[40]. It must be noticed that FGF-21 is influenced 
by several other factors, other than mitochondrial function. Further research on this 
biomarker is therefore essential and its role as a potential treatment efficacy measure needs 
to be established. Mainly with the upcoming newborn screening in these disorders we need 
biomarkers to determine patient´s disease severity, which may help in establishing and a 
more personalized treatment approach. It is essential to provide an adequate therapy as 
early as possible, since mitochondrial failure seems to be an early onset and ongoing 
process. 
The dysfunction of the mitochondria in classical OAD have been assumed to be due to the 
direct toxicity of methylmalonic acid. However, in recent publications it is suggested that 
mitochondrial dysfunction is caused by inhibition of the respiratory chain by 2-methylcitric 
acid, malonic acid and propionyl-CoA [41]. Factors influencing mitochondrial function besides 
toxic metabolites in these patients are plasma BCAA levels and L-arginine[17]. The latter two 
have also been shown in this thesis to play an important role in growth.  L-arginine is a 
precursor for the production of nitric oxide and of creatine [42] and plays a role in improving 
anti-oxidant defenses [43, 44] and thereby potentially improve disease outcome [45-49].  
If we look more in depth into the mitochondria the close interaction between mTORC1, protein 
regulation and mitochondrial function needs to be taken into account (figure 1). mTORC1 is a 
protein that plays an important role in cell growth. Its expression is depended on several 
factors. A higher amino acid availability, mainly by L-leucine and L-arginine,  increases mTORC1 
expression. Increased mTORC1 increases protein synthesis, aging, lipid synthesis, and 
mitochondrial function, and it blocks autophagy and lysosome biogenesis [50-53] (figure 1). 
Furthermore,  increased mTORC1 expression increases FGF-21 levels, the biomarker identified 
in this thesis for disease severity in MMA and PA patients. The positive stimulation of mTORC1 
expression on protein expression can be disturbed due to endoplasmic reticulum stress, 
mitochondrial dysfunction and hypoxia. This will lead to decreased protein synthesis and it will 
stimulate autophagy. Given that in MMA and PA mitochondrial dysfunction is an ongoing 
process in the severely affected patients, it is questionable what the effect of the amino acid 
availability will be on protein synthesis in these patients.  
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Regarding the role of mTORC1 towards aging, it is interesting that in recent publications and 
newspaper articles show that a decreased dietary intake can decrease accelerated aging [54] 
(Volkskrant 21-09-2019). While in UCD and classical OAD patients no direct effect on aging or 
DNA repair dysfunction is known or shown to date, it is stimulating to look into potential 
overlaps. And we should question ourselves do we harm the patients by overfeeding and 
thereby overloading the capacity of the mitochondria. This potential overfeeding has also been 
observed in intensive care unit patients [55]. MTORC1 gene expression is also influenced by 
growth hormone. FGF-21 is stimulated by growth hormone, but FGF-21 can also decrease 
growth hormone production. Growth hormone is applied in a minority of the patients in order 
to stimulate growth. While we now know that in severely affected patients FGF-21 levels are 
highly increased it needs to be further studied what the effect of FGF-21 on growth hormone 
and mTOR plasma levels will be. Interestingly, Sirolimus/rapamicin which can be used as 
immunosuppressive medication after transplantation, is a known inhibitor of mTOR [56]. 
The induced mitochondrial long-term complications can be very severe, leading to blindness 
and even death. While several studies have been performed on the potential efficacy of anti-
oxidant treatment in MMA and PA mouse models and patients, to date no clear advices on 
their use are available [57-60]. Some report beneficial effects, while others report no effects. 
We suggest that mitochondrial dysfunction is an ongoing process independent of metabolic 
control. Liver and/or kidney transplantation can potentially prevent the development of long-
term mitochondrial complications. It could be that a liver transplant is sufficient to lower the 
oxidative stress induced by mitochondrial failure and thereby prevent these complications. 
Liver and/or kidney transplantation seems a safe method in AOA, regarding mortality risk. 
Survival rate ranged 78% to 100% and complications occurred in approximately 5-20%. 
However collaboration between European centers is essential, not only to improve surgical 
techniques, but also to determine how to treat patients after transplantation. Continuation of 
a protein restricted diet is suggested but not evaluated with regard to long term outcome in 
MMA and PA patients after transplantation. To date, we cannot yet advise when to start anti-
oxidant treatment or when to transplant, we can however advise to monitor FGF-21 levels in 
all patients and look into the effects of different treatment strategies on plasma FGF-21 levels.  
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3 | Recommendations 
In the guideline by Baumgartner et al [18] together with information retrieved from our study 
in the Dutch MMA PA patient cohort we hereby provide a table (Table 1) suggesting what to 
monitor and a second table (Table 2) when to screen for the different  complications. A biobank 
collecting patient plasma samples is very useful regarding future research questions. 
Table 1. Guide to monitor OAD patients 
 Items to record Diagnostics to perform 
Patient characteristics   
Patient Day of birth  
 Sex  
Family Ancestry  
 Consanguinity 
Length parents  
Mutation  g. / c. / p. coding sequence Genetic testing 
Vitamin B12 responsiveness Type enzymatic assay and results Enzymatic assay B12 
responsiveness 
PCC activity Type enzymatic assay and results Enzymatic assay PCC activity 
Death Day of death, Cause of death  
Follow-up Age at last follow-up  
   
Adverse outcome of first sympt.  phase   
First presentation Symptomatic/asymptomatic  
 Day of first symptoms  
 Day of diagnosis  
Adverse outcome first presentation Day of brain MRI Brain MRI at set times 
 Brain MRI results  
 Movement disorder Consult neurologist 
Metabolic instability   
Number of AMD  Day of admission  
 Day of release  
 Reason of admission 
BCAA levels 
Protein intake at admission, protein 
prescription after hospital stay 
 
Dietary treatment   
 Each time diet changes: 
Date of change 
Natural protein intake 
Amino acid mixture: name, protein intake 
Single amino acid prescription 
Kcal prescription 
Vitamin/mineral supplementation 
Diet diary 
Calculate P:E ratio 
 
Patient follow-up   
 According to the guideline:  
Physical activity 
BCAA levels at each clinical visit 
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Table 2. When to screen for certain complications in OAD patients 
 Items to record When to screen for Diagnostics to perform 
Cognitive function 
Cognition Day of neuropsychological 
tests 
At set times Neuropsychological tests  
 Neuropsychological test type   
 Neuropsychological test 
results; IQ 
  
Education School career   
 Type of employment   
    
Mitochondrial complications 
Hepatomegaly  Day of diagnostic study From birth onwards, 
each visit by physical 
examination 
Liver ultrasound at set 
times 
Epilepsy Results of diagnostic study At indication EEG at set times 
Cardiomyopathy Presence complication yes/no From six years 
onwards, annually 
Cardiac ultrasound at set 
times 
Prolonged QTc interval  From birth onwards, 
annually 
ECG at set times 
Optic atrophy  From six years 
onwards, annually 
Consult ophthalmologist 
at set times 
Renal failure eGFR, plasma creatinine From one year 
onwards, every 6 
months 
Urine kidney function 
biochemistry at set times 
Pancreatitis, anemia, 
leukopenia, thrombocytopenia, 
pancytopenia 
 From birth, every 6 
months 
Complete blood count at 
set times 
Sensorineural hearing loss  On indication: consult 
ENT doctor, gastro-
enterologist, 
neurologist, 
gynecologist, 
psychiatrist, physical 
therapist 
 
Acute psychosis 
Stroke-like episodes 
Premature ovarian insufficiency 
Exercise intolerance 
Muscular hypotonia 
Feeding problems 
Constipation 
Autism 
Attention deficit hyperactive 
disorder 
Treatment-related complications 
Bone mineral density Day of diagnostic study At set times DEXA-scan at set times 
Growth retardation Results of diagnostic study Each clinical visit  
Obesity Presence complication yes/no   
 Visit date each visit   
 Weight and length each visit   
Other:     
Keep in mind rarely described 
complications as pes 
planovalgus, gout and 
urolithiasis. 
   
 
DEXA: dual-energy X-ray absorptiometry; ECG: electrocardiogram; EEG: electroencephalogram; ENT: 
ear-nose-throat; MRI: magnetic resonance imaging; PCC: propionyl-CoA carboxylase; IQ: intelligence 
quotient.  
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4 | Future perspectives: Sharing data to future research 
In this thesis we evaluated current treatment and presented suggestions for the improvement 
of treatment strategies in classical OAD and UCD.  
In MMA and PA: 1) high protein prescription, above 100%RDA, should be avoided since this 
induces harmful effects, 2) AAM products should be prescribed with care since can induce 
complications and disturbed plasma BCAA levels, 3) leucine can potentially be used as 
treatment strategy, but not in such high amounts as in currently applied AAM, 4) growth 
should not be the main goal of treatment if this necessitates a protein prescription above 
100%RDA, and 5) FGF-21 should be used to monitor patients. 
In classical OAD, more specific advices on the amount of natural protein prescription within 
the different severity groups need to be formed based on new long-term follow-up studies. 
Furthermore, specific indications when to start or stop with AAM products are necessary and 
new AAM products with lower leucine content seem essential.  In future studies the possible 
harmful consequences (i.e., the number of decompensations, growth, long-term complications 
and mortality) of the very low plasma BCAA levels in MMA, PA and UCD patients must be 
evaluated prospectively. Recommendations on adequate BCAA plasma levels in OAD and UCD 
should be formulated and the efficacy of adjusted treatment (including AAM and/or SAA), 
without inducing toxicity, needs to be followed. Even more importantly the effect of dietary 
treatment on the interaction on the LAT transporter needs to be studied. In this also the 
potential effect of leucine, either or not within AAM (not in such high amounts of currently 
available), as a treatment to lower valine and isoleucine uptake and thereby increase the 
possibility to achieve natural protein RDA without complications is essential.  
The role of potential biomarkers, FGF-21 as well as other biomarkers for mitochondrial 
dysfunction, like growth differentiation factor 15 (GDF-15), should be included in order to 
identify their role and relation with the occurrence of long-term complications in these 
disorders. Further research should determine if FGF-21 or other mitochondrial markers such 
as GDF-15, could play a role in the evaluation of preventive strategies concerning the 
consequences of mitochondrial impairment, and if FGF-21 plays a pathogenic role in the 
development of mitochondrial impairment. Other biomarker will be likely to be identified by 
the use of metabolomics.  
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In UCD a relative high protein intake was prescribed, but low BCAA levels were found and 
BCAA plasma levels were associated with growth. In UCD further research is necessary to 
identify the potential harmful effects and shortcomings of the relatively high protein 
prescription and hereafter guidelines needs to come up with more specific advices on the 
amount of natural and total protein intake.  
Further research should desirably be more focused on personalized medicine. This could for 
example be achieved by using patient fibroblast and preferable IPS cells to construct cell 
models (liver, heart and brain) and perform research on these models. Not only the effect of 
certain amino acids could be studied but also certain medications, such as tacrolimus. Another 
method could be to determining protein requirement by amino acid oxidation method or 
nitrogen balance studies in MMA and PA patients [61, 62]. 
Additional guidelines regarding transplantation should be established on MMA and PA after 
evaluation of the transplanted patients. In a European wide registry all data regarding 
transplantation should be studied in detail, including all metabolic data. Regarding 
transplantation as treatment option cooperation between transplantation centers is required 
within Europe. It needs to be discussed if we need to work with specific transplantation centers 
for patients with IMD. Specific transplantation centers can work with more experienced 
transplantation teams with strong collaboration with metabolic specialists.  
The data collected in the Dutch MMA and PA patient cohort can form a good basis for future 
research. The goal for collecting this data was to study the cohort as a historic control before 
the introduction of the newborn screening in the Netherlands. The collaboration with the 
transplantation centers in Europe can be used to perform a more in depth 
research/questionnaire regarding transplantation in classical OAD.     
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Summary 
Inborn errors of metabolism are rare disorders but often with severely impaired patient outcome. 
This thesis focused on the inborn errors in protein metabolism. Within the inborn errors in protein 
metabolism different disorders can be distinguished, one of these are a group of disorders belonging 
to the amino and organic acid related disorders (AOA).  The main diseases discussed in this thesis 
are: classical organic acidemias (OAD) and urea-cycle disorders (UCD). 
In classical OAD and UCD patient outcome is still unsatisfactory despite the fact that patients have 
now been diagnosed for several decades. The main aim of this thesis was therefore to define how to 
improve current available treatment strategies in these disorders. To do so we had four sub-aims:  
1. To describe current practice and natural history in classical OAD and UCD patients (chapter 
2, 3 and 6). 
2. To describe the consequences of current treatment and how to potentially improve dietary 
treatment in MMA and PA patients (chapter 2 and 4). 
3. To describe whether to screen for and how to monitor MMA and PA patients (chapter 5 and 
6).  
4. To define the safety of liver and/or kidney transplantation in AOA patients as an alternative 
treatment (chapter 7). 
We identified the shortcomings of current dietary management by evaluating the E-IMD cohort, 
consisting of 271 OAD and 361 UCD patients, and by long-term retrospective cohort study of 76 
Dutch MMA/PA patients. Importantly, in both classical OAD and UCD a high protein intake was 
prescribed in the majority of the patients. Natural protein prescription exceeded the recommended 
daily allowances by the WHO in 63% of the classical OAD patients and in >50% of the UCD patients 
in the E-IMD cohort. In the Dutch MMA/PA cohort natural protein prescription exceeded RDA in 37% 
and total protein prescription exceeded RDA in 84% of all measured protein prescriptions.  A high 
total protein prescription was often the result of additional amino acid mixtures (AAM) prescription. 
Despite this high protein prescription, plasma branched chain amino acid (BCAA) levels were low in 
approximately 55% of the OAD patients and 30% of the UCD patients. Ratios of these BCAA were 
disturbed, mainly in OAD patients receiving AAM with a L-isoleucine: L-leucine: L-valine ratio of 
1.0:3.0:3.2 (normally 1.0:2.0:4.0). A potential cause for the disturbed BCAA levels, despite an 
appropriate protein prescription in MMA and PA patients, is the high leucine content (due to 
interaction with other BCAA at the large neutral amino acid transporter (LAT)) in amino acid mixtures 
prescribed. In UCD patients sodiumphenylbutyrate causes low plasma BCAA levels. In MMA and PA 
patients, a higher natural protein (mainly when exceeding RDA) as well as a higher AAM prescription 
A
285
ADDENDUM
are associated with more frequent severe complications, namely cognitive development delay, 
mitochondrial complications, and metabolic decompensations. Considering the harmful effects of 
current applied treatment we need to adjust dietary management in MMA and PA patients.  
Growth is disturbed in the majority of OAD and UCD patients. In both OAD and UCD patients (from 
the E-IMD registry), height was positively associated with the natural protein: energy prescription, 
and in OAD also negatively with the synthetic protein prescription (a finding that was confirmed in 
the Dutch MMA/PA cohort). In OAD plasma L-valine and L-arginine levels and in UCD plasma L-
valine and L-isoleucine were positively associated with height. 
Furthermore, we looked into the potential effect of newborn screening (NBS) in MMA and PA 
patients based on the long-term retrospective Dutch cohort study in 76 MMA/PA patients. In MMA 
and PA patients, NBS thus far does not seem to improve outcome regarding metabolic 
decompensations, and mitochondrial complications. It can potentially have a beneficial effect on 
the occurrence of a neurological severe adverse outcome after the first presentation with a 
preliminary estimated reduction of 46% to 36-38% in the occurrence of an adverse outcome. 
Screening results in the Netherlands will frequently be available after the first presentation in 
neonatal onset patients (often presenting within the first week after birth).  
We identified a biomarker (FGF-21) to identify risk groups on mitochondrial complications 
established on a national cohort study consisting of 17 classical OAD patients. In MMA/PA patients 
a median plasma FGF-21 level >1500 Pmol/L, measured during stable disease period, had a 
positive predictive value of 0.83 and a negative predictive value of 1.00 on long-term mitochondrial 
complications. 
Lastly, since with current dietary treatment outcome seem to remain unsatisfactory we looked into 
the safety of liver transplantation. Regarding transplantation in the whole group of AOA, 
transplantation seems save regarding mortality risk with a survival rate at a median of 3.5years 
follow-up of 78-100%. The mortality risk was the highest within 14 days after transplantation and in 
PA patients transplanted before they were 4 years of age.  Risk on neurological complications 
mainly in MMA Mut0 patients needs to be taken into account, since calcineurin inhibitors (CNI) can 
cause neurotoxicity and even a posterior reversible encephalopathy syndrome (PRES) (with an 
estimated incidence of 9% based on a review of the literature). More specified treatment after 
transplantation needs to be established.  
  
286
ADDENDUM
  
Samenvatting 
Aangeboren stofwisselingsziekten zijn zeldzame aandoeningen, en gaan vaak gepaard met 
een ernstig ziektebeloop. In dit proefschrift is er onderzoek gedaan naar aangeboren 
aandoeningen in het eiwitmetabolisme. Binnen deze aandoeningen kunnen verschillende 
ziektegroepen worden onderscheiden, waarvan de groep aminozuur en organische 
acidemieën de groep is waar dit proefschrift over gaat. De belangrijkste ziekte categorieën 
besproken in dit proefschrift zijn: organische acidemieën (OA) en ureumcyclusdefecten 
(UCD). Binnen de OA, hebben de volgende klassieke  OA: methylmalonacidemie (MMA) en 
propionacidemie (PA) de nadruk. 
Patiënten met een klassieke OA of een UCD kunnen al sinds tientallen jaren 
gediagnosticeerd en behandeld worden. Desondanks hebben patiënten een slechte 
prognose. Het doel van dit proefschrift was om te bepalen of en hoe we de huidige 
toegepaste behandeling binnen deze patiëntengroep kunnen verbeteren. Om dit te bepalen 
zijn er vier subdoelen opgesteld, namelijk: 
1. Het beschrijven van de huidig toegepaste behandeling en het natuurlijk beloop van 
patiënten met een klassieke OA en een UCD (hoofdstuk 2, 3 en 6). 
2. Het beschrijven van de gevolgen van de huidig toegepaste behandeling en hoe we 
eventueel de dieet behandeling van de patiënten met MMA en PA kunnen 
verbeteren (hoofdstuk 2 en 4). 
3. Het beschrijven of screenen via de hielprikscreening zinvol is voor MMA en PA en 
hoe we patiënten met deze aandoeningen kunnen monitoren (hoofdstuk 5 en 6).  
4. Het beschrijven van de veiligheid van lever en/of niertransplantatie als alternatieve 
behandeling in patiënten met een aminozuur en/of organische acidemie (hoofdstuk 
7). 
In dit proefschrift hebben we laten zien hoe we in de huidige dieet behandeling van 
patiënten tekortschieten door middel van een evaluatie van 271 OA en 361 UCD patiënten 
uit de E-IMD database en door middel van een retrospectieve cohortstudie van 76 
Nederlandse MMA en PA patiënten. In zowel patiënten met een OA als in patiënten met een 
UCD werd een hoge hoeveelheid eiwit voorgeschreven. Het natuurlijk eiwit voorschrift was 
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hoger dan de aanbevolen dagelijkse hoeveelheid door de WHO in 63% van de klassieke OA 
en >50% van de UCD patiënten uit de E-IMD database. In het Nederlandse MMA/PA cohort 
was het voorschrift van het natuurlijk eiwit hoger dan de aanbevelingen in 37% van alle 
momenten dat er eiwitvoorschrift was beschreven en van het totaal eiwit in 84%. Echter 
ondanks deze hoge inname van eiwit waren de plasma spiegels van de vertakte keten 
aminozuren laag in 55% van de OA en in 30% van de UCD patiënten (E-IMD cohort). De 
verhoudingen van deze vertakte keten aminozuren waren verstoord, met name in OA 
patiënten die aminozuurproducten gebruikten. Deze laatste groep patiënten had een ratio 
van 1.0:3.0: 3.2 van L-isoleucine: L-leucine: L-valine, welke normaal 1.0:2.0:4.0 is.  In MMA en 
PA patiënten kunnen deze lage/verstoorde plasma spiegels het gevolg zijn van een hoge 
hoeveelheid leucine (door interactie met andere vertakte keten aminozuren op het LAT 
transporteiwit) in de aminozuurproducten die vele patiënten gebruiken. In UCD worden de 
lage plasma vertakte keten aminozuren vaak veroorzaakt door het gebruik van sodium 
phenylbutyrate. In MMA en PA patiënten was een hoge inname van natuurlijk eiwit als wel 
een hoge inname van aminozuurmengsels geassocieerd met een slechte prognose, namelijk 
met het optreden van ontwikkelingsbeperking, mitochondriële complicaties (energiewinning 
complicaties) en metabole ontregelingen. Gezien deze schadelijke gevolgen van de huidige 
hoeveelheid voorgeschreven eiwit is het essentieel om de behandeling van MMA en PA aan 
te passen. 
De lengtegroei was in de meerderheid van de OA en UCD patiënten verstoord. In beide 
ziektebeelden was een hoger voorschrift natuurlijk eiwit: energie geassocieerd met een 
positieve lengtegroei. In OA had een hoger voorschrift van aminozuurproducten een 
negatieve associatie met lengtegroei (dit werd ook gevonden in het Nederlandse sub-
cohort). In OA waren de plasma spiegels van L-valine en L-arginine en in UCD de plasma 
spiegels van L-valine en L-isoleucine geassocieerd met positieve lengtegroei. 
Daarnaast hebben we gekeken naar de mogelijke positieve effecten van het toevoegen van 
MMA en PA aan de hielprikscreening in Nederland gebaseerd op een retrospectieve 
cohortstudie van 76 MMA/PA patiënten. Op basis van onze studie is te concluderen dat op 
dit moment er geen positief effect te verwachten valt van deze hielprikscreening op het 
aantal metabole decompensaties en mitochondriële complicaties in MMA en PA patiënten. 
Het is mogelijk dat in enkele patiënten de ziekte ontdekt wordt voordat een ernstige eerste 
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decompensatie optreedt en er kan daarbij een verwachte afname zijn van 48% naar 36-38% 
in het optreden van neurologische schade bij de eerste klinische presentatie. Echter zijn er 
veel patiënten die zich op zeer jonge leeftijd al presenteren (binnen de eerste levensweek), 
voordat er uit de hielprikscreening bekend is of ze MMA of PA hebben. In dit proefschrift 
tonen we een mogelijke biomarker, namelijk FGF-21, die gebruikt kan worden om 
risicogroepen op mitochondriële complicaties te identificeren. Deze studie werd uitgevoerd 
bij 17 klassieke OA patiënten. Een mediane FGF-21 plasma spiegel van >1500 Pmol/L, 
gemeten in stabiele periode, had een positief voorspellende waarde van 0.83 en een 
negatieve voorspellende waarde van 1.00 op het optreden van mitochondriële lange-termijn 
complicaties. 
Omdat de huidige behandeling met een dieet niet afdoende is (en momenteel het enige 
alternatief) om te zorgen voor een mogelijke verbetering van de prognose in patiënten met 
een OA of UCD hebben we gekeken naar de veiligheid van het toepassen van lever en/of 
niertransplantatie. Gezien de relatief lage mortaliteit gevonden in onze studie (78-100% 
overleving bij een gemiddelde follow-up van 3.5 jaar) kunnen we concluderen dat 
transplantatie een veilig alternatief is. Het overlijdens risico was het hoogst binnen 14 dagen 
na de transplantatie en bij PA patiënten die getransplanteerd werden op een leeftijd jonger 
dan 4 jaar. Er zijn veel patiënten met complicaties na transplantatie, waarin we bij de MMA 
mutase negatieve patiënten met name vaak neurologische complicaties zagen. Calcineurine-
remmers zijn immunosuppressiva die neurologische schade en zelfs een posterior reversible 
encephalopathy syndrome (PRES) kunnen veroorzaken. De incidentie van PRES in MMA 
patiënten na transplantatie werd geschat op 9% op basis van een literatuur review van  de 
getransplanteerde MMA patiënten. Het is belangrijk om ook deze uitkomsten mee te nemen 
en goed te definiëren hoe we patiënten na een transplantatie behandelen. 
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presentation) 
- EIMD meeting, Brussels, Belgium (oral 
presentation) 
- Society of Inborn Errors of Metabolism (SSIEM), 
Athens, Greece (poster presentation) 
- Dietistendag (Organische Acidemieen) Nutricia 
(oral presentation) 
- Grand round Sophia Erasmus MC (oral 
presentation) 
- E-IMD meeting 
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- Sophia research day (oral presentation) 
- EMG conference 2019 Lyon 
- SSIEM, Rotterdam  
- AOA subnetwork meeting Frankfurt (oral 
presentation) 
- Erfelijke Stofwisselingsziekten Nederland (ESN ) 
voorjaarssymposium, Doorn, Netherlands (oral 
presentation) 
- Erfelijke Stofwisselingsziekten Nederland (ESN ) 
najaarssymposium, Utrecht, Netherlands (oral 
presentation) 
- AOA meeting Brussels (oral presentation) 
- MMA and PA guideline meeting Brussels  
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- Succesful scientific writing by Janice R Matthews 
and Robert W Matthews 
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Abbreviations 
 
AAM(s)  Amino acid mixture(s) 
AAM(s)-OAD Amino acid mixture(s) for organic acidemias (lack L-isoleucine and L-
valine) 
AAM(s)-UCD Amino acid mixture(s) for urea-cycle disorders (contain essential amino 
acids) 
AMD   Acute metabolic decompensation 
AMPK   AMP-activated protein kinase 
AO   Adverse outcome 
AOA    Amino and organic acid related disorders 
OAD   Organic acidemia 
ASL (-D)   Argininosuccinate lyase (deficiency) 
ASS (-D)  Argininosuccinate synthetase (deficiency) 
Arg1   Arginase deficiency 1 
BCAA   Branched-chain amino acids 
BMD   Bone mineral density 
Cbl   Cobalamin 
CNI   Calcineurin inhibitor 
CPS1 (-D)   Carbamylphosphate synthetase 1 (deficiency) 
CSF   Cerebrospinal fluid 
DWI   Diffusion-weighted imaging  
EO   Early onset 
E-IMD   European registry and network for intoxication type metabolic diseases 
ER   Endoplasmic reticulum 
FGF-21  Fibroblast growth factor 21 
FS   Family screening 
GDF-15  Growth differentiation factor 15 
GH   Growth hormone 
HHH    Hyperornithinemia-hyperammonemia-homocitrullinuria  
ICU   Intensive care unit 
IGF   Insulin-like growth factor 
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IVA   Isovaleric acidemia 
kcal   Kilocalories 
LKT   Liver and/or kidney transplantation 
LO   Late onset 
MMA    Methylmalonic acidemia/aciduria 
mma   Methylmalonic acid 
MELD   Model for end-stage liver disease 
MMF   Mycophenolate mofetil 
MRI   Magnetic resonance imaging 
MSUD   Maple syrup urine disorder 
mTOR   Mammalian target of rapamycin 
MUT   Methylmalonyl-CoA mutase 
NAGS (-D)  N-acetylglutamate synthetase (deficiency) 
NBS   Newborn screening 
OAD    Organic acidurias 
OTC (-D)   Ornithine transcarbamylase (deficiency) 
ORNT   Ornithine transporter 
PA    Propionic acidemia/aciduria 
P:E ratio Protein-to-energy ratio (natural P:E ratio is natural protein-to-energy 
ratio and total P:E ratio is total protein-to-energy ratio) 
PCC Propionyl-CoA carboxylase 
POD   Post-operative day 
PRES   Posterior reversible encephalopathy syndrome  
PY   Patient year 
RDA   Recommended daily allowance 
rτ   Kendall’s tau rank correlation  
SAA Single amino acids (L-valine and/or L-isoleucine supplied as a 
supplement, either independently or in combination) 
SDS   Standard deviation score 
TCA cycle  Tricarboxylic acid cycle (= citric acid cycle) 
TFEB   Transcription factor EB 
Tyr1   Tyrosinemia type 1 
A
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UCD    Urea-cycle disorders 
UNOS   United network for organ sharing 
WHO   World Health Organization 
Ws   Wilcoxon rank sum test 
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